Chimeric antigen receptor (CAR) t cells and related methods for treating autoimmune diseases
By inserting exogenous polynucleotides encoding CD47 and CAR into CAR-T cells, the expression of specific antigens is reduced, and the problem of host anti-graft response is solved, achieving long-term survival of engineered cells in the body and improving the therapeutic effect.
Patent Information
- Application Number
- CN202280092363.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-16
- Filing Date
- 2022-12-23
- Publication Date
- 2024-12-03
AI Technical Summary
Existing CAR-T cell therapy is hindered by host anti-graft response, resulting in difficulties in amplification and persistence of allogeneic CAR-T cells, and lack of effective low immunogenic cell transplantation pathways for the treatment of autoimmune diseases and Inflammatory disease.
An engineered cell was developed to reduce HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DP, HLA-A by inserting exogenous polynucleotides encoding CD47 and chimeric antigen receptor (CAR) into cells Expression of DQ, HLA-DR, B2M, CIITA, TCR-α and/or TCR-β and insert these polynucleotides at specific loci to reduce host immune response.
It significantly reduces the host's immune response to engineered cells, prolongs cell survival in the body, and improves the effectiveness of treating autoimmune and inflammatory diseases.
Smart Images

Figure BDA0005005564980001601 
Figure BDA0005005564980001611 
Figure BDA0005005564980002081
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 293,637, filed December 23, 2021, and U.S. Provisional Application No. 63 / 320,672, filed March 16, 2022, the contents of which are incorporated herein by reference in their entirety. Summary of the Invention
[0003] Off-the-shelf CAR-T cells and other therapeutic cells can offer advantages over autologous cell-based strategies, including ease of manufacturing, quality control, and avoidance of malignant contamination and T-cell dysfunction. However, strong host anti-graft immune responses against histoincompatible T cells prevent the expansion and persistence of allogeneic CAR-T cells and reduce the efficacy of this approach.
[0004] There is ample evidence both in animal models and in human patients that transplantation of hypoimmunogenic cells is a scientifically feasible and clinically promising approach for treating a variety of disorders, conditions and diseases, particularly autoimmune diseases / disorders and / or inflammatory diseases / disorders.
[0005] There remains a need for novel approaches, compositions, and methods for producing cell-based therapies that avoid detection by the recipient's immune system.
[0006] In some embodiments, provided herein is an engineered cell comprising reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β relative to a wild-type cell or a control cell, the engineered cell further comprising a set of exogenous polynucleotides comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a chimeric antigen receptor (CAR), wherein the first and / or second exogenous polynucleotides are inserted into a specific locus of at least one allele of the cell.
[0007] In some embodiments, the specific locus is selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus. In many embodiments, the first exogenous polynucleotide encoding CD47 is inserted into a specific locus selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus. In some embodiments, the second exogenous polynucleotide encoding CAR is inserted into a specific locus selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus.
[0008] In some embodiments, the first exogenous polynucleotide encoding CD47 and the second exogenous polynucleotide encoding CAR are inserted into different loci. In many embodiments, the first exogenous polynucleotide encoding CD47 and the second exogenous polynucleotide encoding CAR are inserted into the same locus. In several embodiments, the first exogenous polynucleotide encoding CD47 and the second exogenous polynucleotide encoding CAR are inserted into the B2M locus. In some embodiments, the first exogenous polynucleotide encoding CD47 and the second exogenous polynucleotide encoding CAR are inserted into the CIITA locus. In many embodiments, the first exogenous polynucleotide encoding CD47 and the second exogenous polynucleotide encoding CAR are inserted into the TRAC locus. In some embodiments, the first exogenous polynucleotide encoding CD47 and the second exogenous polynucleotide encoding CAR are inserted into the TRB locus. In some embodiments, the first exogenous polynucleotide encoding CD47 and the second exogenous polynucleotide encoding CAR are inserted into a safe harbor or target locus. In some embodiments, the safe harbor or target locus is selected from the group consisting of: CCR5 locus, CXCR4 locus, PPP1R12C (also known as AAVS1) locus, albumin locus, SHS231 locus, CLYBL locus, Rosa locus (e.g., ROSA26 locus), F3 locus (also known as CD142), MICA locus, MICB locus, LRP1 locus (also known as CD91 locus), HMGB1 locus, ABO locus, RHD locus, FUT1 locus, and KDM5D locus. In various embodiments, the safe harbor or target locus is selected from the group consisting of: AAVS1 locus, CCR5 locus, and ROSA26 locus.
[0009] In some embodiments, CAR is selected from the group consisting of CD19-specific CAR, CD22-specific CAR, and CD20-specific CAR. In some embodiments, CAR is a bispecific CAR. In some embodiments, CAR is a CD19-specific CAR. In some embodiments, CAR is a CD22-specific CAR. In some embodiments, CAR is a CD20-specific CAR. In some embodiments, CAR is a bispecific CAR. In some embodiments, CAR is a CD19 / CD20 bispecific CAR. In some embodiments, CAR is a CD19 / CD22 bispecific CAR.
[0010] In many embodiments, the engineered cells do not express HLA-A, HLA-B and / or HLA-C antigens. In some embodiments, the engineered cells do not express B2M. In other embodiments, the engineered cells do not express HLA-DP, HLA-DQ and / or HLA-DR antigens. In some embodiments, the engineered cells do not express CIITA. In some embodiments, the engineered cells are selected from the group consisting of: pluripotent stem cells, induced pluripotent stem cells, T cells differentiated from induced pluripotent stem cells, primary T cells, and cells derived from primary T cells, and the engineered cells do not express TCR-α and / or TCR-β.
[0011] In many embodiments, the engineered cells are pluripotent stem cells. In some embodiments, the engineered cells are induced pluripotent stem cells.
[0012] In some embodiments, the engineered cells are differentiated cells derived from induced pluripotent stem cells.In various embodiments, the differentiated cells are selected from the group consisting of NK cells and T cells.
[0013] In some embodiments, the engineered cells are cells derived from primary T cells.In many embodiments, the cells derived from primary T cells are derived from a T cell bank comprising primary T cells from one or more donor subjects different from the recipient subject.
[0014] In some embodiments, the engineered cells are cells derived from primary NK cells.In many embodiments, the cells derived from primary NK cells are derived from a NK cell bank comprising primary NK cells from one or more donor subjects different from the recipient subject.
[0015] In some embodiments, the engineered cells retain pluripotency and / or retain differentiation potential.
[0016] In many embodiments, after being transferred into the first subject, the engineered cells show one or more reactions selected from the group consisting of: (a) T cell reaction, (b) NK cell reaction, and (c) macrophage reaction, which is reduced compared to the wild-type cells after being transferred into the second subject. In some cases, the first subject and the second subject are different subjects. In some cases, the macrophage reaction is phagocytosis. In various embodiments, compared with the wild-type cells after being transferred into the subject, the engineered cells show one or more reactions selected from the group consisting of: (a) TH1 activation of the subject is reduced, (b) NK cell killing of the subject is reduced, and (c) killing of the complete PBMC of the subject is reduced. In many embodiments, compared with the wild-type cells after being transferred into the subject, the engineered cells trigger one or more reactions selected from the group consisting of: (a) donor-specific antibodies of the subject are reduced, (b) IgM or IgG antibodies of the subject are reduced, and (c) complement dependent cytotoxicity (CDC) of the subject is reduced.
[0017] In some embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding a CAR inserted into the TRB locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失In some embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a CAR inserted into the TRB locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 In various embodiments, the engineered cells are selected from the group consisting of pluripotent stem cells, induced pluripotent stem cells, T cells differentiated from induced pluripotent stem cells, primary T cells, and cells derived from primary T cells, and the engineered cells are B2M cells comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 In some embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding a CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 cell.
[0018] In some embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding a CAR inserted into the TRB locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In some embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a CAR inserted into the TRB locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In various embodiments, the engineered cells are selected from the group consisting of pluripotent stem cells, induced pluripotent stem cells, T cells differentiated from induced pluripotent stem cells, primary T cells, and cells derived from primary T cells, and the engineered cells are B2M cells comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In some embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding a CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In many embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 cell.
[0019] In some embodiments, the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In many embodiments, the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In many embodiments, the engineered cell is a B2M cell comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the TRB locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失In some embodiments, the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding CAR inserted into the TRB locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In various embodiments, the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In many embodiments, the engineered cell is a B2M cell comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In some embodiments, the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and / or a second exogenous polynucleotide encoding CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In many embodiments, the engineered cell is a B2M comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 cell.
[0020] In some embodiments, an engineered cell is provided that comprises reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β relative to a wild-type cell or a control cell.
[0021] In some embodiments, the engineered cells do not express HLA-A, HLA-B and / or HLA-C antigens. In many embodiments, the engineered cells do not express CIITA.
[0022] In many embodiments, the engineered cells do not express HLA-DP, HLA-DQ, and / or HLA-DR antigens. In some embodiments, the engineered cells do not express B2M.
[0023] In many embodiments, the engineered cells are selected from the group consisting of: pluripotent stem cells, induced pluripotent stem cells, T cells differentiated from induced pluripotent stem cells, primary T cells, and cells derived from primary T cells, and the engineered cells do not express TCR-α. In many embodiments, the engineered cells are selected from the group consisting of: pluripotent stem cells, induced pluripotent stem cells, T cells differentiated from induced pluripotent stem cells, primary T cells, and cells derived from primary T cells, and the engineered cells do not express TCR-β.
[0024] In various embodiments, the engineered cells overexpress CD47 relative to wild-type or control cells.
[0025] In some embodiments, the engineered cells are pluripotent stem cells. In many embodiments, the engineered cells are induced pluripotent stem cells.
[0026] In many embodiments, the engineered cells are differentiated cells derived from induced pluripotent stem cells. In some embodiments, the differentiated cells are selected from the group consisting of NK cells and T cells.
[0027] In many embodiments, the engineered cells are cells derived from primary T cells. In several embodiments, the cells derived from primary T cells are derived from a T cell bank comprising primary T cells from one or more donor subjects different from the recipient subject.
[0028] In various embodiments, the engineered cells retain pluripotency and / or retain differentiation potential.
[0029] In some embodiments, upon transfer into a subject, the engineered cells elicit one or more responses selected from the group consisting of: (a) a T cell response, (b) a NK cell response, and (c) a macrophage response that is reduced compared to wild-type cells after transfer into a second subject. In some cases, the first subject and the second subject are different subjects. In some cases, the macrophage response is phagocytosis.
[0030] In various embodiments, the engineered cells exhibit one or more of the following combinations after being transferred into a subject, compared to wild-type cells after being transferred into a subject: (a) a reduction in TH1 activation of the subject, (b) a reduction in NK cell killing of the subject, and (c) a reduction in killing of intact PBMCs of the subject. In many embodiments, the engineered cells induce one or more of the following combinations after being transferred into a subject, compared to wild-type cells after being transferred into a subject: (a) a reduction in donor-specific antibodies of the subject, (b) a reduction in IgM or IgG antibodies of the subject, and (c) a reduction in complement dependent cytotoxicity (CDC) of the subject.
[0031] In some embodiments, the engineered cell is a B2M 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In some cases, the engineered cell is a B2M 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 Primary T cells. In some cases, engineered cells are B2M cells differentiated from low immunogenic induced pluripotent stem cells. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In some embodiments, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M cell. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 In some cases, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M cell. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 Primary T cells. In some embodiments, the engineered cells are selected from the group consisting of pluripotent stem cells, induced pluripotent stem cells, T cells differentiated from induced pluripotent stem cells, primary T cells, and cells derived from primary T cells, and the engineered cells are B2M 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRB 插入缺失 / 插入缺失In some cases, the engineered cell is selected from the group consisting of: a pluripotent stem cell, an induced pluripotent stem cell, a T cell differentiated from an induced pluripotent stem cell, a primary T cell, and a cell derived from a primary T cell, and the engineered cell is a B2M cell. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRB 插入缺失 / 插入缺失 Primary T cells. In some cases, engineered cells are B2M cells differentiated from low immunogenic induced pluripotent stem cells. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRAC 插入缺失 / 插入缺失 In some embodiments, the engineered cells are B2M 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 In some cases, the engineered cell is a B2M 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 Primary T cells. In some cases, engineered cells are B2M cells differentiated from low immunogenic induced pluripotent stem cells. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 and / or TRB 插入缺失 / 插入缺失 T cells.
[0032] In some embodiments, the engineered cells are low immunogenic cells.
[0033] In some embodiments, a pharmaceutical composition is provided that comprises any of the engineered cell populations described herein and a pharmaceutically acceptable additive, carrier, diluent, or excipient.
[0034] In some embodiments, pharmaceutically acceptable additives, carriers, diluents, or excipients include one or more selected from the group consisting of: Plasma-Lyte Dextrose, dextran, sodium chloride, human serum albumin (HSA), dimethyl sulfoxide (DMSO) and combinations thereof. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable buffer. In some embodiments, the pharmaceutically acceptable buffer is neutral buffered saline or phosphate buffered saline.
[0035] In some embodiments, a pharmaceutical composition is provided comprising any of the engineered cell populations described herein, at a concentration of about 70-80% weight / weight. A base solution of CSB, and one or more of the following: approximately 20-30% weight / weight PlasmaLyte-A TM, about 0.3-5.3% weight / volume human serum albumin (HSA), about 0-20% volume / volume dimethyl sulfoxide (DMSO), and about 100-400 mM trehalose.
[0036] In some embodiments, a pharmaceutical composition is provided comprising any of the engineered cell populations described herein, PlasmaLyte-A at a concentration of about 20-30% weight / weight. TM A base solution, and one or more of the following: about 70-80% weight / weight CSB, about 0.3-5.3% weight / volume human serum albumin (HSA), about 0-20% volume / volume dimethyl sulfoxide (DMSO), and about 100-400 mM trehalose.
[0037] In some embodiments, a pharmaceutical composition is provided comprising any of the engineered cell populations described herein, about 0.3-5.3% weight / volume human serum albumin (HSA), and one or more of: about 70-80% weight / volume of CSB, about 20-30% w / w PlasmaLyte-A TM , about 0-20% volume / volume dimethyl sulfoxide (DMSO), and about 100-400 mM trehalose.
[0038] In some embodiments, a pharmaceutical composition is provided comprising any of the engineered cell populations described herein, about 0-20% volume / volume dimethyl sulfoxide (DMSO), and one or more of: about 70-80% weight / weight CSB, about 20-30% w / w PlasmaLyte-A TM , about 0.3-5.3% weight / volume human serum albumin (HSA) and about 100-400 mM trehalose.
[0039] In some embodiments, a pharmaceutical composition is provided comprising any of the engineered cell populations described herein, about 100-400 mM trehalose, and one or more of: about 70-80% weight / weight of CSB, about 20-30% w / w PlasmaLyte-A TM , about 0.3-5.3% weight / volume human serum albumin (HSA) and about 0-20% volume / volume dimethyl sulfoxide (DMSO).
[0040] In some embodiments, the pharmaceutical composition comprises about 75% weight / weight of In some embodiments, the pharmaceutical composition comprises about 25% weight / weight PlasmaLyte-A TM In some embodiments, the pharmaceutical composition comprises about 0.3% weight / volume HSA. In some embodiments, the pharmaceutical composition comprises about 7.5% volume / volume DMSO.
[0041] In some embodiments, a pharmaceutical composition is provided comprising any of the engineered cell populations described herein, at a concentration of about 75% weight / weight. CSB base solution, approximately 25% w / w PlasmaLyte-A TM , about 0.3% weight / volume human serum albumin (HSA) and about 7.5% volume / volume dimethyl sulfoxide (DMSO).
[0042] In some embodiments, the engineered cell population is at most about 8.0 x 10 8 In many embodiments, the engineered cell population is at most about 6.0 x 10 8 In other embodiments, the engineered cell population is about 1.0 x 10 6 to about 2.5x10 8 In some embodiments, the engineered cell population is about 2.0 x 10 6 to about 2.0x10 8 cells.
[0043] In various embodiments, the scope of the engineered cell population is about 5 ml to about 80 ml. In many embodiments, the scope of the engineered cell population is about 10 ml to about 70 ml. In some embodiments, the scope of the engineered cell population is about 10 ml to about 50 ml.
[0044] In some embodiments, the composition is formulated for administration in a single dose. In many embodiments, the composition is formulated for administration in up to three doses.
[0045] In some embodiments, the composition is formulated for administration to a subject in a single dose that requires a duration of about 60 minutes or less. In many embodiments, the composition is formulated for administration to a subject in a single dose that requires a duration of about 30 minutes or less.
[0046] In some embodiments, the engineered cell population of the pharmaceutical composition or its progeny exhibits a survival rate of at least 40% in a subject 10 days after administration. In various embodiments, the engineered cell population of the pharmaceutical composition or its progeny exhibits a survival rate of at least 80% in a subject about 2 weeks after administration. In several embodiments, the engineered cell population of the pharmaceutical composition or its progeny exhibits a survival rate of at least 100% in a subject about 3 weeks after administration. In many embodiments, the engineered cell population of the pharmaceutical composition or its progeny exhibits a survival rate of at least 150% in a subject about 4 weeks after administration.
[0047] In another embodiment, a dosage regimen for treating a disease or condition in a subject is provided, comprising administering a pharmaceutical composition comprising any of the engineered cell populations described herein and a pharmaceutically acceptable additive, carrier, diluent, or excipient, wherein the pharmaceutical composition is administered in about 1-3 doses.
[0048] In some embodiments, the pharmaceutical composition administered in about 1-3 doses is at most about 6.0 x 10 8 In some embodiments, the pharmaceutical composition administered in about 1-3 doses is about 0.6 x 10 6 to about 6.0x10 8 In some embodiments, if the subject weighs 50 kg or less, the pharmaceutical composition administered in about 1-3 doses is about 0.2 x 10 6 to about 5.0x10 6 In some embodiments, if the subject weighs more than 50 kg, the pharmaceutical composition administered in about 1-3 doses is about 0.1 x 10 cells / kg of the subject's body weight. 8 to about 2.5x10 8 In some embodiments, the pharmaceutical composition administered in about 1-3 doses is about 2.0 x 10 6 cells / kg subject body weight and up to approximately 2.x10 8 cells.
[0049] In some embodiments, a single dose is administered to a subject for a duration of about 60 minutes or less. In some embodiments, a single dose is administered to a subject for a duration of about 30 minutes or less.
[0050] In some embodiments, pharmaceutically acceptable additives, carriers, diluents, or excipients include one or more selected from the group consisting of: Plasma-Lyte Dextrose, dextran, sodium chloride, human serum albumin (HSA), dimethyl sulfoxide (DMSO), and combinations thereof.
[0051] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable buffer. In some embodiments, the pharmaceutically acceptable buffer is neutral buffered saline or phosphate buffered saline.
[0052] In some embodiments, the cell population or its progeny exists in the subject for up to 9 months after administration of the pharmaceutical composition.In some embodiments, the cell population or its progeny exists in the subject for at least two years or more after administration of the pharmaceutical composition.
[0053] In some embodiments, after administration of the pharmaceutical composition, the engineered cell population or its progeny exhibits a survival rate of at least 40% in the subject after about 10 days after administration. In some embodiments, after administration of the pharmaceutical composition, the engineered cell population or its progeny exhibits a survival rate of at least 80% in the subject after about 2 weeks after administration. In some embodiments, after administration of the pharmaceutical composition, the engineered cell population or its progeny exhibits a survival rate of at least 100% in the subject after about 3 weeks after administration. In some embodiments, after administration of the pharmaceutical composition, the engineered cell population or its progeny exhibits a survival rate of at least 150% in the subject after about 4 weeks after administration.
[0054] In some embodiments, 2-3 doses are administered to a subject such that the interval between administrations of each dose ranges from 1 to 24 hours. In some embodiments, 2-3 doses are administered to a subject such that the interval between administrations of each dose ranges from 1 to 28 days. In some embodiments, 2-3 doses are administered to a subject such that the interval between administrations of each dose ranges from 1 to 6 weeks. In some embodiments, 2-3 doses are administered to a subject such that the interval between administrations of each dose ranges from 1 to 12 months or longer.
[0055] Provided herein is a dosage regimen for treating a disease or condition of a subject, comprising administering a pharmaceutical composition comprising (i) engineered cells comprising reduced HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β expression, the engineered cells further comprising a set of exogenous polynucleotides encoding CD47 and a chimeric antigen receptor (CAR). In some embodiments, viral transduction (e.g., using a vector) is used to insert an exogenous polynucleotide group into at least one allele of a T cell. In some embodiments, the vector is a pseudotyped, self-inactivating lentiviral vector carrying an exogenous polynucleotide group. In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with a vesicular stomatitis virus glycoprotein (VSV-G) envelope, and carries an exogenous polynucleotide group. In some embodiments, an exogenous polynucleotide group is inserted into at least one allele of a T cell using a lentiviral vector based on a lentiviral vector. In some embodiments, the exogenous polynucleotide set is inserted into a safe harbor or target locus of at least one allele of the cell; and (ii) a pharmaceutically acceptable additive, carrier, diluent, or excipient, wherein the pharmaceutical composition comprises at most about 6.0 x 10 8 cells.
[0056] Provided herein is a dosage regimen for treating a disease or condition of a subject, comprising administering a pharmaceutical composition comprising (i) engineered cells comprising reduced HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β expression, the engineered cells further comprising a set of exogenous polynucleotides encoding CD47 and chimeric antigen receptors (CAR). In some embodiments, viral transduction is used to insert exogenous polynucleotide groups into at least one allele of a T cell. In some embodiments, a lentiviral-based viral vector is used to insert exogenous polynucleotide groups into at least one allele of a T cell. In some embodiments, exogenous polynucleotide groups are inserted into a safe harbor or target locus of at least one allele of a cell; and (ii) a pharmaceutically acceptable additive, carrier, diluent or excipient, wherein the pharmaceutical composition is administered in 1-3 doses.
[0057] Provided herein is a dosage regimen for treating a disease or condition in a subject, comprising administering a pharmaceutical composition comprising (i) engineered cells comprising reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β, the engineered cells further comprising a set of exogenous polynucleotides encoding CD47 and a chimeric antigen receptor (CAR), wherein the set of exogenous polynucleotides is inserted into a safe harbor or target locus of at least one allele of the cells; and (ii) a pharmaceutically acceptable additive, carrier, diluent, or excipient, wherein a dose of the pharmaceutical composition is administered for a duration of about 60 minutes or less.
[0058] Provided herein is a dosage regimen for treating a disease or condition in a subject comprising administering a pharmaceutical composition comprising (i) engineered cells comprising reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β; and (ii) a pharmaceutically acceptable additive, carrier, diluent, or excipient, wherein the pharmaceutical composition comprises up to about 6.0 x 10 8 cells.
[0059] Provided herein is a dosage regimen for treating a disease or condition in a subject, comprising administering a pharmaceutical composition comprising (i) engineered cells comprising reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β; and (ii) a pharmaceutically acceptable additive, carrier, diluent, or excipient, wherein the pharmaceutical composition is administered in 1-3 doses.
[0060] Provided herein is a dosage regimen for treating a disease or condition in a subject, comprising administering a pharmaceutical composition comprising (i) engineered cells comprising reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β; and (ii) a pharmaceutically acceptable additive, carrier, diluent, or excipient, wherein a dose of the pharmaceutical composition is administered for a duration of 60 minutes or less.
[0061] In some embodiments, a method for treating an autoimmune disease / disorder and / or inflammatory disease / disorder for a subject is provided, comprising administering to the subject any engineered cell as described herein or any pharmaceutical composition as described herein or any dosage regimen as described herein. In some embodiments, the autoimmune disease / disorder and / or inflammatory disease / disorder is at least in part an autoimmune disease / disorder and / or inflammatory disease / disorder mediated by B cells and / or plasma cells. In some embodiments, the autoimmune disease / disorder and / or inflammatory disease / disorder is an autoimmune disease / disorder and / or inflammatory disease / disorder mediated by B cells and / or plasma cells. In some embodiments, B cells and / or plasma cells express CD19, CD20, or a combination thereof. In some embodiments, autoimmune diseases include but are not limited to Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren's syndrome, Graves' disease, scleroderma, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, and diabetes. Further examples of "autoimmune diseases" or "autoimmune disorders" or "inflammatory diseases" or "inflammatory disorders" can be found in Section Z below.
[0062] In some embodiments, a method for preventing T cell exhaustion in a subject is provided, comprising administering to the subject any engineered cell described herein, wherein CAR is a CD19 / CD20 bispecific CAR. In some embodiments, a method for preventing T cell exhaustion in a subject is provided, comprising administering to the subject any engineered cell described herein, wherein CAR is a CD19 / CD22 bispecific CAR.
[0063] In some embodiments, provided herein is a method of preventing T cell exhaustion or treating a disease in a subject, comprising: (i) administering to the subject a first dosage regimen comprising a first population of any engineered cells described herein at a first time point; and (ii) administering to the subject a second dosage regimen comprising a second population of any engineered cells described herein at a second time point, wherein the first dosage regimen and the second dosage regimen are different.
[0064] In some embodiments, provided herein is a method of preventing T cell exhaustion or treating a disease in a subject, comprising: (i) administering to the subject a first dosage regimen comprising a first population of any engineered cells described herein at a first time point; and (ii) administering to the subject a second dosage regimen comprising a second population of any engineered cells described herein at a second time point, wherein the first population of engineered cells and the second population of engineered cells comprise the same chimeric antigen receptor.
[0065] In some embodiments, provided herein is a method of preventing T cell exhaustion or treating a disease in a subject, comprising: (i) administering to the subject a first dosage regimen comprising a first population of any engineered cells described herein at a first time point; and (ii) administering to the subject a second dosage regimen comprising a second population of any engineered cells described herein at a second time point, wherein the first population of engineered cells and the second population of engineered cells comprise different chimeric antigen receptors.
[0066] In some embodiments, provided herein is a method of preventing T cell exhaustion or treating a disease in a subject, comprising: (i) administering to the subject a first dosage regimen comprising a first population of any engineered cells described herein at a first time point; and (ii) administering to the subject a second dosage regimen comprising a second population of any engineered cells described herein at a second time point, wherein the engineered cells of the first population comprise a first chimeric antigen receptor that binds a first antigen, and the engineered cells of the second population comprise a second chimeric antigen receptor that binds a second antigen, and wherein the first antigen and the second antigen are the same.
[0067] In some embodiments, provided herein is a method of preventing T cell exhaustion or treating a disease in a subject, comprising: (i) administering to the subject a first dosage regimen comprising a first population of any engineered cells described herein at a first time point; and (ii) administering to the subject a second dosage regimen comprising a second population of any engineered cells described herein at a second time point, wherein the first population of engineered cells comprises a first chimeric antigen receptor that binds a first antigen, and the second population of engineered cells comprises a second chimeric antigen receptor that binds a second antigen, and wherein the first antigen and the second antigen are different.
[0068] Provided herein are non-activated T cells comprising reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β relative to wild-type T cells, and a first exogenous polynucleotide encoding a chimeric antigen receptor (CAR).
[0069] In some embodiments, the non-activated T cells are primary T cells. In other embodiments, the non-activated T cells are differentiated from engineered cells of the present technology.
[0070] In some embodiments, the T cells are CD8 + T cells.
[0071] In some embodiments, the non-activated T cells are not treated with anti-CD3 antibodies, anti-CD28 antibodies, T cell activating cytokines, or soluble T cell co-stimulatory molecules.
[0072] In some embodiments, the anti-CD3 antibody is OKT3. In some embodiments, the anti-CD28 antibody is CD28.2. In some embodiments, the T cell activating cytokine is selected from the group of T cell activating cytokines consisting of IL-2, IL-7, IL-15, and IL-21. In some embodiments, the soluble T cell co-stimulatory molecule is selected from the group of soluble T cell co-stimulatory molecules consisting of anti-CD28 antibodies, anti-CD80 antibodies, anti-CD86 antibodies, anti-CD137L antibodies, and anti-ICOS-L antibodies.
[0073] In some embodiments, non-activated T cells do not express activation markers.
[0074] In some embodiments, the non-activated T cells express CD3 and CD28, and wherein CD3 and / or CD28 are inactive.
[0075] In some embodiments, the first exogenous polynucleotide is carried by a lentiviral vector comprising a CD8-binding agent.
[0076] In some embodiments, the non-activated T cells further comprise a second exogenous polynucleotide encoding CD47.
[0077] In some embodiments, the first and / or second exogenous polynucleotides are inserted into a specific locus of at least one allele of a T cell. In some embodiments, viral transduction is used to insert the first and / or second exogenous polynucleotides into at least one allele of a T cell. In some embodiments, a lentiviral-based viral vector is used to insert the first and / or second exogenous polynucleotides into at least one allele of a T cell. In some embodiments, the vector is a pseudotyped, self-inactivating lentiviral vector carrying the first and / or second exogenous polynucleotides. In some embodiments, the vector is a self-inactivating lentiviral vector pseudotyped with a vesicular stomatitis virus glycoprotein (VSV-G) envelope, and carries the first and / or second exogenous polynucleotides. In some embodiments, the specific locus is selected from the group consisting of: safe harbor or target locus, B2M locus, CIITA locus, TRAC locus, and TRB locus. In some embodiments, the second exogenous polynucleotide encoding CD47 is inserted into a specific locus selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus. In some embodiments, the first exogenous polynucleotide encoding CAR is inserted into a specific locus selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into different loci. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into the same locus. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into the B2M locus. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into the CIITA locus. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into the TRAC locus. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into the TRB locus. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into the safe harbor or target locus.In some embodiments, the safe harbor or target locus is selected from the group consisting of: CCR5 locus, CXCR4 locus, PPP1R12C (also known as AAVS1) locus, albumin locus, SHS231 locus, CLYBL locus, Rosa locus (e.g., ROSA26 locus), F3 locus (also known as CD142), MICA locus, MICB locus, LRP1 locus (also known as CD91 locus), HMGB1 locus, ABO locus, RHD locus, FUT1 locus, and KDM5D locus. In some embodiments, the safe harbor or target locus is selected from the group consisting of: AAVS1 locus, CCR5 locus, and ROSA26 locus.
[0078] In some embodiments, CAR is selected from the group consisting of CD19-specific CAR, CD22-specific CAR, and CD20-specific CAR. In some embodiments, CAR is a bispecific CAR. In some embodiments, bispecific CAR is a CD19 / CD20 bispecific CAR. In some embodiments, bispecific CAR is a CD19 / CD22 bispecific CAR.
[0079] In some embodiments, non-activated T cells do not express HLA-A, HLA-B, and / or HLA-C antigens. In some embodiments, non-activated T cells do not express B2M. In some embodiments, non-activated T cells do not express HLA-DP, HLA-DQ, and / or HLA-DR antigens. In some embodiments, non-activated T cells do not express CIITA. In some embodiments, non-activated T cells do not express TCR-α and TCR-β.
[0080] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and / or a first exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0081] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and a first exogenous polynucleotide encoding CAR inserted into the TRAC locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0082] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and / or a first exogenous polynucleotide encoding a CAR inserted into the TRB locus.插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0083] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and a first exogenous polynucleotide encoding a CAR inserted into the TRB locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0084] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and / or a first exogenous polynucleotide encoding a CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0085] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and a first exogenous polynucleotide encoding a CAR inserted into the B2M locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0086] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and / or a first exogenous polynucleotide encoding CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0087] In some embodiments, the non-activated T cells are B2M cells comprising a second exogenous polynucleotide encoding CD47 and a first exogenous polynucleotide encoding a CAR inserted into the CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0088] Provided herein are engineered T cells, comprising reduced HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β expression relative to wild-type T cells, wherein engineered T cells also include the first exogenous polynucleotides encoding chimeric antigen receptor (CAR) carried by a lentiviral vector. Provided herein are engineered T cells, comprising reduced HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-α and / or TCR-β expression relative to wild-type T cells, wherein engineered T cells also include the first exogenous polynucleotides encoding chimeric antigen receptor (CAR) carried by a lentiviral vector comprising CD8 binding agents.
[0089] In some embodiments, the engineered T cells are primary T cells. In other embodiments, the engineered T cells are differentiated from engineered cells of the present technology. In some embodiments, the T cells are CD8 + T cells.
[0090] In some embodiments, the engineered T cells are not treated with anti-CD3 antibodies, anti-CD28 antibodies, T cell activating cytokines, or soluble T cell co-stimulatory molecules. In some embodiments, the anti-CD3 antibody is OKT3, wherein the anti-CD28 antibody is CD28.2, wherein the T cell activating cytokine is selected from the group of T cell activating cytokines consisting of IL-2, IL-7, IL-15, and IL-21, and wherein the soluble T cell co-stimulatory molecule is selected from the group of soluble T cell co-stimulatory molecules consisting of anti-CD28 antibodies, anti-CD80 antibodies, anti-CD86 antibodies, anti-CD137L antibodies, and anti-ICOS-L antibodies.
[0091] In some embodiments, the engineered T cells do not express activation markers. In some embodiments, the engineered T cells express CD3 and CD28, and wherein CD3 and / or CD28 are inactive.
[0092] In some embodiments, the engineered T cells further comprise a second exogenous polynucleotide encoding CD47. In some embodiments, the first and / or second exogenous polynucleotides are inserted into a specific locus of at least one allele of the T cell. In some embodiments, the specific locus is selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus. In some embodiments, the second exogenous polynucleotide encoding CD47 is inserted into a specific locus selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus. In some embodiments, the first exogenous polynucleotide encoding CAR is inserted into a specific locus selected from the group consisting of: a safe harbor or target locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus. In some embodiments, the second exogenous polynucleotide encoding CD47 and the first exogenous polynucleotide encoding CAR are inserted into different loci. In some embodiments, the second exogenous polynucleotides encoding CD47 and the first exogenous polynucleotides encoding CAR are inserted into the same locus.In some embodiments, the second exogenous polynucleotides encoding CD47 and the first exogenous polynucleotides encoding CAR are inserted into B2M locus, CIITA locus, TRAC locus, TRB locus or safe harbor or target locus.In some embodiments, safe harbor or target locus are selected from the group consisting of: CCR5 locus, CXCR4 locus, PPP1R12C (also referred to as AAVS1) locus, albumin locus, SHS231 locus, CLYBL locus, Rosa locus (for example, ROSA26 locus), F3 locus (also referred to as CD142), MICA locus, MICB locus, LRP1 locus (also referred to as CD91 locus), HMGB1 locus, ABO locus, RHD locus, FUT1 locus and KDM5D locus. In some embodiments, the safe harbor or target locus is selected from the group consisting of: the AAVS1 locus, the CCR5 locus, and the ROSA26 locus.
[0093] In some embodiments, the CAR is selected from the group consisting of a CD19-specific CAR, a CD22-specific CAR, and a CD20-specific CAR.
[0094] In some embodiments, the engineered T cells do not express HLA-A, HLA-B and / or HLA-C antigens, wherein the engineered T cells do not express B2M, wherein the engineered T cells do not express HLA-DP, HLA-DQ and / or HLA-DR antigens, wherein the engineered T cells do not express CIITA, and / or wherein the engineered T cells do not express TCR-α and TCR-β.
[0095] In some embodiments, the engineered T cell is a B2M cell comprising a second exogenous polynucleotide encoding CD47 and / or a first exogenous polynucleotide encoding CAR inserted into the TRAC locus, TRB locus, B2M locus, or CIITA locus. 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 cell.
[0096] In some embodiments, the non-activated T cells and / or engineered T cells of the present technology are in a subject. In some embodiments, the non-activated T cells and / or engineered T cells of the present technology are in vitro.
[0097] In some embodiments, the non-activated T cells and / or engineered T cells of the present technology express a CD8 binding agent. In some embodiments, the CD8 binding agent is an anti-CD8 antibody. In some embodiments, the anti-CD8 antibody is selected from the group consisting of: mouse anti-CD8 antibody, rabbit anti-CD8 antibody, human anti-CD8 antibody, humanized anti-CD8 antibody, camelid (e.g., llama, alpaca, camel) anti-CD8 antibody and its fragment. In some embodiments, its fragment is scFV or VHH. In some embodiments, the CD8 binding agent binds to CD8 alpha chain and / or CD8 beta chain.
[0098] In some embodiments, the CD8 binding agent is fused to a transmembrane domain incorporated into the viral envelope. In some embodiments, the lentiviral vector is pseudotyped with a viral fusion protein. In some embodiments, the viral fusion protein comprises one or more modifications to reduce binding to its natural receptor.
[0099] In some embodiments, the viral fusion protein is fused to a CD8 binding agent. In some embodiments, the viral fusion protein comprises Nipah virus F glycoprotein and Nipah virus G glycoprotein fused to a CD8 binding agent. In some embodiments, the lentiviral vector does not comprise a T cell activation molecule or a T cell co-stimulatory molecule. In some embodiments, the lentiviral vector encodes a first exogenous polynucleotide and / or a second exogenous polynucleotide.
[0100] In some embodiments, upon transfer into a first subject, the non-activated T cells or engineered T cells exhibit one or more responses selected from the group consisting of: (a) a T cell response, (b) a NK cell response, and (c) a macrophage response that is reduced compared to wild-type cells after transfer into a second subject. In some embodiments, the first subject and the second subject are different subjects. In some embodiments, the macrophage response is phagocytosis.
[0101] In some embodiments, the non-activated T cells or engineered T cells, when transferred into a subject, exhibit one or more selected from the group consisting of: (a) reduced TH1 activation in the subject, (b) reduced NK cell killing in the subject, and (c) reduced killing of intact PBMCs in the subject, compared to wild-type cells after transfer into the subject.
[0102] In some embodiments, the non-activated T cells or engineered T cells elicit one or more selected from the group consisting of: (a) a decrease in donor-specific antibodies in the subject, (b) a decrease in IgM or IgG antibodies in the subject, and (c) a decrease in complement dependent cytotoxicity (CDC) in the subject, compared to wild-type cells after transfer into the subject.
[0103] In some embodiments, non-activated T cells or engineered T cells are transduced in a subject with a lentiviral vector comprising a CD8 binding agent. In some embodiments, the lentiviral vector carries a gene encoding CAR and / or CD47.
[0104] Provided herein are pharmaceutical compositions comprising a population of non-activated T cells and / or engineered T cells of the present technology and a pharmaceutically acceptable additive, carrier, diluent, or excipient.
[0105] Provided herein are methods comprising administering to a subject a composition comprising a population of non-activated T cells and / or engineered T cells of the present technology, or one or more pharmaceutical compositions of the present technology.
[0106] In some embodiments, the subject is not administered a T cell activation therapy before, after, and / or concurrently with administration of the composition. In some embodiments, the T cell activation therapy comprises lymphodepletion.
[0107] Provided herein are methods for treating subjects suffering from autoimmune diseases / disorders and / or inflammatory diseases / disorders, comprising administering to the subject a composition comprising a non-activated T cell and / or engineered T cell population of the present technology, or one or more pharmaceutical compositions of the present technology, wherein T cell activation therapy is not administered to the subject before, after, and / or concurrently with the administration of the composition. In some embodiments, the T cell activation therapy comprises lymphocyte depletion.
[0108] Provided herein are methods for expanding T cells capable of recognizing and killing tumor cells in a subject in need thereof, comprising administering to the subject a composition comprising a non-activated T cell and / or engineered T cell population of the present technology, or one or more pharmaceutical compositions of the present technology, wherein T cell activation therapy is not administered to the subject before, after, and / or simultaneously with the administration of the composition. In some embodiments, T cell activation therapy comprises lymphocyte depletion.
[0109] Provided herein are dosage regimens for treating a disease or condition in a subject, comprising administering a pharmaceutical composition comprising a population of non-activated T cells and / or engineered T cells of the present technology, or one or more pharmaceutical compositions of the present technology, and a pharmaceutically acceptable additive, carrier, diluent, or excipient, wherein the pharmaceutical composition is administered in about 1-3 doses.
[0110] In some embodiments, provided herein is a method of treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0111] In some embodiments, provided herein is a method of treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0112] In some embodiments, the encoded CD19 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 117, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 117, having the following components: a CD8 alpha signal peptide, an FMC63 scFv (VL-Whitlow linker-VH), a CD8 alpha hinge domain, a CD8 alpha transmembrane domain, a 4-1BB costimulatory domain, and a CD3 zeta signaling domain.
[0113] In some embodiments, the encoded CD22 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 45, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 45.
[0114] In some embodiments, provided herein is a method for treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient's autoimmune disease and / or diagnosing the patient with an autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more chimeric antigen receptors (CARs), wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0115] In some embodiments, provided herein is a method of treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0116] In some embodiments, provided herein is a method for treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient's autoimmune disease and / or diagnosing the patient with an autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0117] In some embodiments, provided herein is a method of treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient's autoimmune disease and / or diagnosing the patient with an autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0118] In some embodiments, provided herein is a method of treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient's autoimmune disease and / or diagnosing the patient with an autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0119] In some embodiments, provided herein is a method of treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient's autoimmune disease and / or diagnosing the patient with an autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0120] In some embodiments, provided herein is a method of treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising assessing the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0121] In some embodiments, the CAR has a scFv sequence of any one of SEQ ID NOs: 19, 29, and 37.
[0122] In some embodiments, the CAR has the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117.
[0123] In some embodiments, the engineered T cells comprise a CD19-specific CAR and a CD20-specific CAR.
[0124] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
[0125] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
[0126] In some embodiments, CD19 CAR T cells and CD20 CAR T cells are administered simultaneously.
[0127] In some embodiments, CD19 CAR+ T cells and CD20 CAR+ T cells are administered sequentially.
[0128] In some embodiments, CD19 CAR+ T cells are administered prior to administration of CD20 CAR+ T cells.
[0129] In some embodiments, CD20 CAR+ T cells are administered prior to administration of CD19 CAR+ T cells.
[0130] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0131] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0132] In some embodiments, engineered T cells are propagated from primary T cells or their progeny, or derived from T cells differentiated from iPSCs or their progeny.
[0133] In some embodiments, the engineered T cells are differentiated cells derived from induced pluripotent stem cells or their progeny.
[0134] In some embodiments, the differentiated cell is a T cell or a natural killer (NK) cell.
[0135] In some embodiments, the engineered T cells are progeny of a primary immune cell, optionally wherein the progeny of the primary immune cell is a T cell or a NK cell.
[0136] In some embodiments, the engineered T cells comprise reduced expression of beta-2-microglobulin (B2M) and / or MHC class II transactivator (CIITA) relative to unaltered or unmodified wild-type or control cells.
[0137] In some embodiments, the engineered T cells do not express B2M and / or CIITA.
[0138] In some embodiments, the engineered T cells comprise reduced expression of TCR-α and / or TCR-β.
[0139] In some embodiments, the engineered T cells do not express TCR-α and / or TCR-β.
[0140] In some embodiments, the one or more tolerogenic factors are selected from the group consisting of CD47, CD24, CD27, CD35, CD46, CD55, CD59, CD200, HLA-C, HLA-E, HLA-E heavy chain, HLA-G, PD-L1, IDO1, CTLA4-Ig, C1 inhibitor, IL-10, IL-35, FasL, CCL21, CCL22, Mfge8, A20 / TNFAIP3, CD39, CR1, HLA-F, IL15-RF, MANF, and Serpinb9.
[0141] In some embodiments, the one or more tolerogenic factors include CD47.
[0142] In some embodiments, the CD19-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0143] In some embodiments, the CD19-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0144] In some embodiments, the CD20-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0145] In some embodiments, the CD20-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0146] In some embodiments, one or more of the first, second, and / or third exogenous polynucleotides or bicistronic polynucleotides are inserted into a first, second, and / or third specific locus of at least one allele of the cell.
[0147] In some embodiments, the first, second, and / or third specific locus is selected from the group consisting of a safe harbor locus, a target locus, an RHD locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus.
[0148] In some embodiments, the safe harbor locus is selected from the group consisting of: a CCR5 locus, a PPP1R12C locus, a CLYBL locus, and a Rosa locus.
[0149] In some embodiments, the target locus is selected from the group consisting of: a CXCR4 locus, an ALB locus, a SHS231 locus, a F3 (CD142) locus, a MICA locus, a MICB locus, a LRP1 (CD91) locus, a HMGB1 locus, an ABO locus, a FUT1 locus, and a KDM5D locus.
[0150] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cells using a gene therapy vector or a transposase system selected from the group consisting of a transposase, a PiggyBac transposon, a Sleeping Beauty (SB11) transposon, a Mos1 transposon, and a Tol2 transposon.
[0151] In some embodiments, the gene therapy vector is a retrovirus or a fusion.
[0152] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cell using CRISPR / Cas gene editing.
[0153] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of Cas9, Cas12a, and Cas12b.
[0154] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of: optionally selected from the group consisting of Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, and GSU0054; optionally selected from the group consisting of Cas9, Csn2, and Cas4; optionally selected from the group consisting of Cas10, Csm2, Cmr5, Cas10, Csx11, and Csx10; optionally Csf1; optionally selected from the group consisting of Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e), and CasY (Cas12d); and optionally selected from the group consisting of Cas13, Cas13a, C2c2, Cas13b, Cas13c, and Cas13d.
[0155] In some embodiments, CRISPR / Cas gene editing is performed ex vivo from a donor subject.
[0156] In some embodiments, a lentiviral vector is used to introduce the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide into the engineered T cell.
[0157] In some embodiments, the engineered T cells evade NK cell-mediated cytotoxicity upon administration to a recipient patient.
[0158] In some embodiments, the engineered T cells are protected from cytolysis by mature NK cells following administration to a recipient patient.
[0159] In some embodiments, the engineered T cells evade macrophage-mediated cytotoxicity, optionally wherein the macrophage-mediated cytotoxicity involves phagocytosis and / or reactive oxygen species.
[0160] In some embodiments, the engineered T cells do not induce an immune response to the cells upon administration to a recipient patient.
[0161] In some embodiments, the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, and a pulmonary condition.
[0162] In some embodiments, administration is selected from the group consisting of intravenous injection, intramuscular injection, intravascular injection, and transplantation.
[0163] In some embodiments, the engineered T cells are administered before, during, or after initiation of a different treatment regimen in the patient.
[0164] In some embodiments, the different treatment regimen is selected from the group consisting of re-administration of the same or different cells, and pre-treatment, concurrent treatment, or subsequent treatment with an additional agent.
[0165] In some embodiments, the different cell is an autologous T or NK cell or a CAR-T cell that expresses a first CAR that is different from a second CAR expressed by the engineered CAR-T cell.
[0166] In some embodiments, the patient is treated with immunodepletion therapy prior to administration of the engineered T cells.
[0167] In some embodiments, immunodepletion therapy comprises administration of fludarabine and / or cyclophosphamide.
[0168] In some embodiments, the patient has received prior antibody therapy.
[0169] In some embodiments, the antibody therapy is rituximab.
[0170] In some embodiments, immunodepletion therapy comprises IV infusion of about 1-50 mg / m 2 Fludarabine is taken for about 1-7 days.
[0171] In some embodiments, immunodepletion therapy comprises IV infusion of about 1, about 5, about 10, about 20, about 30, about 40, or about 50 mg / m 2 of fludarabine for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0172] In some embodiments, immunodepletion therapy comprises IV infusion of about 30 mg / m 2 Fludarabine for about 4 days.
[0173] In some embodiments, immunodepletion therapy comprises IV infusion of about 100-1000 mg / m 2 Cyclophosphamide for about 1-7 days.
[0174] In some embodiments, immunodepletion therapy comprises IV infusion of about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000 mg / m 2 of cyclophosphamide for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0175] In some embodiments, immunodepletion therapy comprises IV infusion of about 500 mg / m 2 of cyclophosphamide for about 2 days.
[0176] In some embodiments, at least about 40 x 10 4 Engineered T cells.
[0177] In some embodiments, at least about 40 x 10 5 Engineered T cells.
[0178] In some embodiments, the engineered T cells persist in the subject for at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0179] In some embodiments, the therapeutic effect of the engineered T cells persists for a duration of at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0180] In some embodiments, wild-type cells or control cells are the starting material.
[0181] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0182] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0183] In some embodiments, the encoded CD19 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 117, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 117, having the following components: a CD8 alpha signal peptide, an FMC63 scFv (VL-Whitlow linker-VH), a CD8 alpha hinge domain, a CD8 alpha transmembrane domain, a 4-1BB costimulatory domain, and a CD3 zeta signaling domain.
[0184] In some embodiments, the encoded CD22 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 45, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 45.
[0185] In some embodiments, provided herein is a use of an engineered T cell population for treating an autoimmune disease in a recipient patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more chimeric antigen receptors (CARs), wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0186] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have the scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0187] In some embodiments, provided herein is a use of an engineered T cell population for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0188] In some embodiments, provided herein is a use of an engineered T cell population for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0189] In some embodiments, provided herein is a use of an engineered T cell population for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0190] In some embodiments, provided herein is a use of an engineered T cell population for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0191] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a recipient patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have the scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0192] In some embodiments, the CAR has a scFv sequence of any one of SEQ ID NOs: 19, 29, and 37.
[0193] In some embodiments, the CAR has the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117.
[0194] In some embodiments, the engineered T cells comprise a CD19-specific CAR and a CD20-specific CAR.
[0195] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
[0196] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
[0197] In some embodiments, CD19 CAR T cells and CD20 CAR T cells are administered simultaneously.
[0198] In some embodiments, CD19 CAR+ T cells and CD20 CAR+ T cells are administered sequentially.
[0199] In some embodiments, CD19 CAR+ T cells are administered prior to administration of CD20 CAR+ T cells.
[0200] In some embodiments, CD20 CAR+ T cells are administered prior to administration of CD19 CAR+ T cells.
[0201] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0202] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0203] In some embodiments, engineered T cells are propagated from primary T cells or their progeny, or derived from T cells differentiated from iPSCs or their progeny.
[0204] In some embodiments, the engineered T cells are differentiated cells derived from induced pluripotent stem cells or their progeny.
[0205] In some embodiments, the differentiated cell is a T cell or a natural killer (NK) cell.
[0206] In some embodiments, the engineered T cells are progeny of a primary immune cell, optionally wherein the progeny of the primary immune cell is a T cell or a NK cell.
[0207] In some embodiments, the engineered T cells comprise reduced expression of beta-2-microglobulin (B2M) and / or MHC class II transactivator (CIITA) relative to unaltered or unmodified wild-type or control cells.
[0208] In some embodiments, the engineered T cells do not express B2M and / or CIITA.
[0209] In some embodiments, the engineered T cells comprise reduced expression of TCR-α and / or TCR-β.
[0210] In some embodiments, the engineered T cells do not express TCR-α and / or TCR-β.
[0211] In some embodiments, the one or more tolerogenic factors are selected from the group consisting of CD47, CD24, CD27, CD35, CD46, CD55, CD59, CD200, HLA-C, HLA-E, HLA-E heavy chain, HLA-G, PD-L1, IDO1, CTLA4-Ig, C1 inhibitor, IL-10, IL-35, FasL, CCL21, CCL22, Mfge8, A20 / TNFAIP3, CD39, CR1, HLA-F, IL15-RF, MANF, and Serpinb9.
[0212] In some embodiments, the one or more tolerogenic factors include CD47.
[0213] In some embodiments, the CD19-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0214] In some embodiments, the CD19-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0215] In some embodiments, the CD20-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0216] In some embodiments, the CD20-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0217] In some embodiments, one or more of the first, second, and / or third exogenous polynucleotides or bicistronic polynucleotides are inserted into a first, second, and / or third specific locus of at least one allele of the cell.
[0218] In some embodiments, the first, second, and / or third specific locus is selected from the group consisting of a safe harbor locus, a target locus, an RHD locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus.
[0219] In some embodiments, the safe harbor locus is selected from the group consisting of: a CCR5 locus, a PPP1R12C locus, a CLYBL locus, and a Rosa locus.
[0220] In some embodiments, the target locus is selected from the group consisting of: a CXCR4 locus, an ALB locus, a SHS231 locus, a F3 (CD142) locus, a MICA locus, a MICB locus, a LRP1 (CD91) locus, a HMGB1 locus, an ABO locus, a FUT1 locus, and a KDM5D locus.
[0221] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cells using a gene therapy vector or a transposase system selected from the group consisting of a transposase, a PiggyBac transposon, a Sleeping Beauty (SB11) transposon, a Mos1 transposon, and a Tol2 transposon.
[0222] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cell using CRISPR / Cas gene editing.
[0223] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of Cas9, Cas12a, and Cas2b.
[0224] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of: optionally selected from the group consisting of Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, and GSU0054; optionally selected from the group consisting of Cas9, Csn2, and Cas4; optionally selected from the group consisting of Cas10, Csm2, Cmr5, Cas10, Csx11, and Csx10; optionally Csf1; optionally selected from the group consisting of Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e), and CasY (Cas12d); and optionally selected from the group consisting of Cas13, Cas13a, C2c2, Cas13b, Cas13c, and Cas13d.
[0225] In some embodiments, CRISPR / Cas gene editing is performed ex vivo from a donor subject.
[0226] In some embodiments, a lentiviral vector is used to introduce the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide into the engineered T cell.
[0227] In some embodiments, the engineered T cells evade NK cell-mediated cytotoxicity upon administration to a recipient patient.
[0228] In some embodiments, the engineered T cells are protected from cytolysis by mature NK cells following administration to a recipient patient.
[0229] In some embodiments, the engineered T cells evade macrophage-mediated cytotoxicity, optionally wherein the macrophage-mediated cytotoxicity involves phagocytosis and / or reactive oxygen species.
[0230] In some embodiments, the engineered T cells do not induce an immune response to the cells upon administration to a recipient patient.
[0231] In some embodiments, the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, and a pulmonary condition.
[0232] In some embodiments, administration is selected from the group consisting of intravenous injection, intramuscular injection, intravascular injection, and transplantation.
[0233] In some embodiments, the engineered T cells are administered before, during, or after initiation of a different treatment regimen in the patient.
[0234] In some embodiments, the different treatment regimen is selected from the group consisting of re-administration of the same or different cells, and pre-treatment, concurrent treatment, or subsequent treatment with an additional agent.
[0235] In some embodiments, the different cell is an autologous T or NK cell or a CAR-T cell that expresses a first CAR that is different from a second CAR expressed by the engineered CAR-T cell.
[0236] In some embodiments, the patient is treated with immunodepletion therapy prior to administration of the engineered T cells.
[0237] In some embodiments, immunodepletion therapy comprises administration of fludarabine and / or cyclophosphamide.
[0238] In some embodiments, the patient has received prior antibody therapy.
[0239] In some embodiments, the antibody therapy is rituximab.
[0240] In some embodiments, immunodepletion therapy comprises IV infusion of about 1-50 mg / m 2 Fludarabine is taken for about 1-7 days.
[0241] In some embodiments, immunodepletion therapy comprises IV infusion of about 1, about 5, about 10, about 20, about 30, about 40, or about 50 mg / m 2 of fludarabine for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0242] In some embodiments, immunodepletion therapy comprises IV infusion of about 30 mg / m 2 Fludarabine for about 4 days.
[0243] In some embodiments, immunodepletion therapy comprises IV infusion of about 100-1000 mg / m 2 Cyclophosphamide for about 1-7 days.
[0244] In some embodiments, immunodepletion therapy comprises IV infusion of about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000 mg / m 2 of cyclophosphamide for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0245] In some embodiments, immunodepletion therapy comprises IV infusion of about 500 mg / m 2 of cyclophosphamide for about 2 days.
[0246] In some embodiments, at least about 40 x 10 4 Engineered T cells.
[0247] In some embodiments, at least about 40 x 10 5 Engineered T cells.
[0248] In some embodiments, the engineered T cells persist in the subject for at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0249] In some embodiments, the therapeutic effect of the engineered T cells persists for a duration of at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0250] In some embodiments, wild-type cells or control cells are the starting material.
[0251] In some embodiments, the unaltered or unmodified wild-type or control cells are starting T cells isolated from a donor.
[0252] In some embodiments, provided herein is a method of treating a patient having an Epstein-Barr virus (EBV) infection, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen (HLA) molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more chimeric antigen receptors (CARs), wherein the one or more CARs comprise an extracellular ligand binding domain specific for CD19, CD20, CD22, BCMA, or an EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0253] In some embodiments, provided herein is a method of treating a patient having EBV infection, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19 or CD22.
[0254] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain.
[0255] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of beta-2-microglobulin (B2M) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0256] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and MHC class II transactivator (CIITA) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0257] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0258] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0259] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain.
[0260] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TCR-α (TRAC) and / or TCR-β (TRB) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0261] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0262] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0263] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0264] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0265] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, a hinge domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain.
[0266] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having multiple sclerosis or diagnosed with multiple sclerosis, comprising assessing the patient for EBV infection and optionally multiple sclerosis and / or diagnosing the patient with EBV infection and optionally multiple sclerosis, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for CD19, CD20, CD22, BCMA or an EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0267] In some embodiments, one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain, or an IgG4 hinge domain.
[0268] In some embodiments, one or more CARs comprises a CD8 alpha hinge domain having the amino acid sequence of SEQ ID NO:9.
[0269] In some embodiments, one or more CARs comprises a CD28 hinge domain having the amino acid sequence of SEQ ID NO: 10 or 113.
[0270] In some embodiments, one or more CARs comprises an IgG4 hinge domain having the amino acid sequence of SEQ ID NO: 11 or 12.
[0271] In some embodiments, one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
[0272] In some embodiments, one or more CARs comprises a CD8α transmembrane domain having the amino acid sequence of SEQ ID NO:14.
[0273] In some embodiments, one or more CARs comprises a CD28 transmembrane domain having the amino acid sequence of SEQ ID NO: 15 or 114.
[0274] In some embodiments, one or more CARs comprise a 4-1BB costimulatory domain, a CD28 costimulatory domain, or a CD3 zeta signaling domain.
[0275] In some embodiments, one or more CARs comprises a 4-1BB costimulatory domain having the amino acid sequence of SEQ ID NO: 16.
[0276] In some embodiments, one or more CARs comprises a CD28 costimulatory domain having the amino acid sequence of SEQ ID NO: 17.
[0277] In some embodiments, one or more CARs comprises a CD3 zeta signaling domain having the amino acid sequence of SEQ ID NO: 18 or 115.
[0278] In some embodiments, one or more CARs comprises an extracellular ligand binding domain comprising a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0279] In some embodiments, one or more CARs have the sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134.
[0280] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD20 CAR having the CDR sequence of SEQ ID NO: 37.
[0281] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an EBV antigen CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172.
[0282] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise a CD19 CAR having a CDR sequence of SEQ ID NO: 117.
[0283] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise a CD22 CAR having a CDR sequence of SEQ ID NO: 45.
[0284] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45.
[0285] In some embodiments, provided herein is a method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0286] In some embodiments, the method further comprises assessing the patient for EBV infection and optionally multiple sclerosis and / or diagnosing the patient with EBV infection and optionally multiple sclerosis prior to administering the engineered T cell population to the patient.
[0287] In some embodiments, diagnosing comprises assessing the patient for EBV infection.
[0288] In some embodiments, diagnosing comprises assessing the patient for multiple sclerosis.
[0289] In some embodiments, the treatment prevents multiple sclerosis.
[0290] In some embodiments, the treatment treats multiple sclerosis.
[0291] In some embodiments, the patient with EBV infection has been diagnosed with multiple sclerosis.
[0292] In some embodiments, the multiple sclerosis is relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, or secondary progressive multiple sclerosis.
[0293] In some embodiments, the patient experiences remission of multiple sclerosis following administration of the engineered T cells.
[0294] In some embodiments, the patient having an EBV infection is receiving treatment for the EBV infection.
[0295] In some embodiments, the patient having an EBV infection has an active EBV infection.
[0296] In some embodiments, the patient having an EBV infection has an inactive EBV infection.
[0297] In some embodiments, the patient has a reduction in EBV infection following administration of the engineered T cells, optionally wherein the reduction in EBV infection is characterized by a reduction in viral load.
[0298] In some embodiments, treatment prevents the EBV infection from transitioning from an inactive EBV infection to an active EBV infection.
[0299] In some embodiments, the method results in B cell depletion.
[0300] In some embodiments, the engineered T cells comprise one or more of a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a BCMA-specific CAR, a GPRC5D-specific CAR, a CD38-specific CAR, a CD70-specific CAR, a CD79b-specific CAR, and an EBV antigen-specific CAR.
[0301] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0302] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0303] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0304] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0305] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0306] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0307] In some embodiments, one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain, or an IgG4 hinge domain.
[0308] In some embodiments, one or more CARs comprises a CD8 alpha hinge domain having the amino acid sequence of SEQ ID NO:9.
[0309] In some embodiments, one or more CARs comprises a CD28 hinge domain having the amino acid sequence of SEQ ID NO: 10 or 113.
[0310] In some embodiments, one or more CARs comprises an IgG4 hinge domain having the amino acid sequence of SEQ ID NO: 11 or 12.
[0311] In some embodiments, one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
[0312] In some embodiments, one or more CARs comprises a CD8α transmembrane domain having the amino acid sequence of SEQ ID NO:14.
[0313] In some embodiments, one or more CARs comprises a CD28 transmembrane domain having the amino acid sequence of SEQ ID NO: 15 or 114.
[0314] In some embodiments, one or more CARs comprise a 4-1BB costimulatory domain, a CD28 costimulatory domain, or a CD3 zeta signaling domain.
[0315] In some embodiments, one or more CARs comprises a 4-1BB costimulatory domain having the amino acid sequence of SEQ ID NO: 16.
[0316] In some embodiments, one or more CARs comprises a CD28 costimulatory domain having the amino acid sequence of SEQ ID NO: 17.
[0317] In some embodiments, one or more CARs comprises a CD3 zeta signaling domain having the amino acid sequence of SEQ ID NO: 18 or 115.
[0318] In some embodiments, one or more CARs comprises an extracellular ligand binding domain comprising a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0319] In some embodiments, one or more CARs have the sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134.
[0320] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0321] In some embodiments, the method further comprises assessing the patient for an autoimmune disease and / or diagnosing the patient with an autoimmune disease.
[0322] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0323] In some embodiments, the encoded CD19 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 117, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 117, having the following components: a CD8 alpha signal peptide, an FMC63 scFv (VL-Whitlow linker-VH), a CD8 alpha hinge domain, a CD8 alpha transmembrane domain, a 4-1BB costimulatory domain, and a CD3 zeta signaling domain.
[0324] In some embodiments, the encoded CD22 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 45, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 45.
[0325] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an EBV antigen-specific CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172, and wherein the autoimmune disease is multiple sclerosis.
[0326] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0327] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0328] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0329] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0330] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0331] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0332] In some embodiments, provided herein is a method of treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0333] In some embodiments, the method further comprises evaluating the patient for an autoimmune disease and / or diagnosing the patient with an autoimmune disease prior to administering the engineered T cell population to the patient.
[0334] In some embodiments, the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, and a pulmonary condition.
[0335] In some embodiments, the patient is suspected of having an EBV infection or has been diagnosed with an EBV infection.
[0336] In some embodiments, the patient is suspected of having or has been diagnosed with multiple sclerosis.
[0337] In some embodiments, the method further comprises administering to the patient a second, third, fourth, fifth, or sixth dose of the engineered T cells.
[0338] In some embodiments, the dose is the same in one or more of the first, second, third, fourth, fifth, and / or sixth doses of engineered T cells.
[0339] In some embodiments, the CAR is different in one or more of the first, second, third, fourth, fifth, and / or sixth doses of engineered T cells.
[0340] In some embodiments, the CAR has a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0341] In some embodiments, the CAR has the sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133, and 134.
[0342] The method of any one of claims 1-78, wherein the engineered T cells comprise a CD19-specific CAR and a CD20-specific CAR.
[0343] In some embodiments, the CD19-specific CAR has a CDR sequence of SEQ ID NO: 117, and the CD22 CAR has a CDR sequence of SEQ ID NO: 45.
[0344] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
[0345] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
[0346] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
[0347] In some embodiments, CD19 CAR T cells and CD20 CAR T cells are administered simultaneously.
[0348] In some embodiments, CD19 CAR+ T cells and CD20 CAR+ T cells are administered sequentially.
[0349] In some embodiments, CD19 CAR+ T cells are administered prior to administration of CD20 CAR+ T cells.
[0350] In some embodiments, CD20 CAR+ T cells are administered prior to administration of CD19 CAR+ T cells.
[0351] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0352] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0353] In some embodiments, the engineered T cells comprise an EBV antigen-specific CAR and a CD20-specific CAR.
[0354] In some embodiments, the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
[0355] In some embodiments, the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
[0356] In some embodiments, the EBV antigen-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
[0357] In some embodiments, EBV antigen CAR T cells and CD20 CAR T cells are administered simultaneously.
[0358] In some embodiments, EBV antigen CAR+ T cells and CD20 CAR+ T cells are administered sequentially.
[0359] In some embodiments, EBV antigen CAR+ T cells are administered prior to administration of CD20 CAR+ T cells.
[0360] In some embodiments, CD20 CAR+ T cells are administered prior to administration of EBV antigen CAR+ T cells.
[0361] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
[0362] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
[0363] In some embodiments, the engineered T cells comprise an EBV antigen-specific CAR and a CD19-specific CAR.
[0364] In some embodiments, the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bicistronic polynucleotide.
[0365] In some embodiments, the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bispecific CAR.
[0366] In some embodiments, the EBV antigen-specific CAR and the CD19-specific CAR are encoded by two separate polynucleotides.
[0367] In some embodiments, EBV antigen CAR T cells and CD19 CAR T cells are administered simultaneously.
[0368] In some embodiments, EBV antigen CAR+ T cells and CD19 CAR+ T cells are administered sequentially.
[0369] In some embodiments, EBV antigen CAR+ T cells are administered prior to administration of CD19 CAR+ T cells.
[0370] In some embodiments, CD19 CAR+ T cells are administered prior to administration of EBV antigen CAR+ T cells.
[0371] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD19 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
[0372] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD19 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
[0373] In some embodiments, the engineered T cells comprise an EBV antigen-specific CAR and a CD22-specific CAR.
[0374] In some embodiments, the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bicistronic polynucleotide.
[0375] In some embodiments, the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bispecific CAR.
[0376] In some embodiments, the EBV antigen-specific CAR and the CD22-specific CAR are encoded by two separate polynucleotides.
[0377] In some embodiments, EBV antigen CAR T cells and CD22 CAR T cells are administered simultaneously.
[0378] In some embodiments, EBV antigen CAR+ T cells and CD22 CAR+ T cells are administered sequentially.
[0379] In some embodiments, EBV antigen CAR+ T cells are administered prior to administration of CD22 CAR+ T cells.
[0380] In some embodiments, CD22 CAR+ T cells are administered prior to administration of EBV antigen CAR+ T cells.
[0381] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD22 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
[0382] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD22 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
[0383] In some embodiments, the engineered T cells are primary T cells, propagated from primary T cells or their progeny, or derived from T cells differentiated from iPSCs or their progeny.
[0384] In some embodiments, the engineered T cells are differentiated cells derived from induced pluripotent stem cells or their progeny.
[0385] In some embodiments, the differentiated cell is a T cell or a natural killer (NK) cell.
[0386] In some embodiments, the engineered T cell is a primary T cell or a progeny of a primary immune cell, optionally wherein the progeny of the primary immune cell is a T cell or a NK cell.
[0387] In some embodiments, the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules relative to unaltered or unmodified wild-type or control cells.
[0388] In some embodiments, the engineered T cells comprise reduced expression of one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
[0389] In some embodiments, the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules and one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
[0390] In some embodiments, the engineered T cells comprise reduced expression of B2M and / or CIITA relative to unaltered or unmodified wild-type or control cells.
[0391] In some embodiments, the engineered T cells do not express B2M and / or CIITA.
[0392] In some embodiments, the engineered T cells comprise reduced expression of TRAC and / or TRB.
[0393] In some embodiments, the engineered T cells do not express TRAC and / or TRB.
[0394] In some embodiments, the engineered T cells comprise reduced expression of TRAC.
[0395] In some embodiments, the engineered T cells do not express TRAC.
[0396] In some embodiments, the engineered T cells comprise reduced expression of TRB.
[0397] In some embodiments, the engineered T cells do not express TRB.
[0398] In some embodiments, the engineered T cells comprise reduced expression of TRAC and TRB.
[0399] In some embodiments, the one or more tolerogenic factors are selected from the group consisting of CD47, CD24, CD27, CD35, CD46, CD55, CD59, CD200, HLA-C, HLA-E, HLA-E heavy chain, HLA-G, PD-L1, IDO1, CTLA4-Ig, C1 inhibitor, IL-10, IL-35, FasL, CCL21, CCL22, Mfge8, A20 / TNFAIP3, CD39, CR1, HLA-F, IL15-RF and MANF, and Serpinb9, optionally wherein the one or more tolerogenic factors include CD47.
[0400] In some embodiments, the CD19-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0401] In some embodiments, the CD19-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0402] In some embodiments, the CD20-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0403] In some embodiments, the CD20-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0404] In some embodiments, one or more of the first, second, and / or third exogenous polynucleotides or bicistronic polynucleotides are inserted into a first, second, and / or third specific locus of at least one allele of the cell.
[0405] In some embodiments, the first, second, and / or third specific locus is selected from the group consisting of a safe harbor locus, a target locus, an RHD locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus.
[0406] In some embodiments, the safe harbor locus is selected from the group consisting of: a CCR5 locus, a PPP1R12C locus, a CLYBL locus, and a Rosa locus.
[0407] In some embodiments, the target locus is selected from the group consisting of: a CXCR4 locus, an ALB locus, a SHS231 locus, a F3 (CD142) locus, a MICA locus, a MICB locus, a LRP1 (CD91) locus, a HMGB1 locus, an ABO locus, a FUT1 locus, and a KDM5D locus.
[0408] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cells using a gene therapy vector or a transposase system selected from the group consisting of a transposase, a PiggyBac transposon, a Sleeping Beauty (SB11) transposon, a Mos1 transposon, and a Tol2 transposon.
[0409] In some embodiments, the gene therapy vector is a retrovirus or a fusion.
[0410] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cell using CRISPR / Cas gene editing.
[0411] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of Cas9, Cas12a, and Cas12b.
[0412] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of:
[0413] (a) optionally selected from the group consisting of Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3 and GSU0054;
[0414] (b) optionally selected from the group consisting of Cas9, Csn2 and Cas4;
[0415] (c) optionally selected from the group consisting of Cas10, Csm2, Cmr5, Cas10, Csx11, and Csx10;
[0416] (d) optionally Csf1;
[0417] (e) is optionally selected from the group consisting of Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e), and CasY (Cas12d); and
[0418] (f) is optionally selected from the group consisting of Cas13, Cas13a, C2c2, Cas13b, Cas13c and Cas13d.
[0419] In some embodiments, CRISPR / Cas gene editing is performed ex vivo from a donor subject.
[0420] In some embodiments, a lentiviral vector is used to introduce the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide into the engineered T cell.
[0421] In some embodiments, the engineered T cells evade NK cell-mediated cytotoxicity upon administration to a patient.
[0422] In some embodiments, the engineered T cells are protected from cytolysis by mature NK cells following administration to a patient.
[0423] In some embodiments, the engineered T cells evade macrophage-mediated cytotoxicity, optionally wherein the macrophage-mediated cytotoxicity involves phagocytosis and / or reactive oxygen species.
[0424] In some embodiments, the engineered T cells do not induce an immune response to the cells upon administration to a patient.
[0425] In some embodiments, administration is selected from the group consisting of intravenous injection, intramuscular injection, intravascular injection, and transplantation.
[0426] In some embodiments, the engineered T cells are administered before, during, or after initiation of a different treatment regimen in the patient.
[0427] In some embodiments, the different treatment regimen is selected from the group consisting of re-administration of the same or different cells, and pre-treatment, concurrent treatment, or subsequent treatment with an additional agent.
[0428] In some embodiments, the different cell is an autologous T or NK cell or a CAR-T cell that expresses a first CAR that is different from a second CAR expressed by the engineered CAR-T cell.
[0429] In some embodiments, the patient is treated with immunodepletion therapy prior to administration of the engineered T cells.
[0430] In some embodiments, immunodepletion therapy comprises administration of fludarabine and / or cyclophosphamide.
[0431] In some embodiments, the patient has received prior antibody therapy.
[0432] In some embodiments, the antibody therapy is rituximab.
[0433] In some embodiments, immunodepletion therapy comprises IV infusion of about 1-50 mg / m 2 Fludarabine is taken for about 1-7 days.
[0434] In some embodiments, immunodepletion therapy comprises IV infusion of about 1, about 5, about 10, about 20, about 30, about 40, or about 50 mg / m2 of fludarabine for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0435] In some embodiments, immunodepletion therapy comprises IV infusion of about 30 mg / m 2 Fludarabine for about 4 days.
[0436] In some embodiments, immunodepletion therapy comprises IV infusion of about 100-1000 mg / m 2 Cyclophosphamide for about 1-7 days.
[0437] In some embodiments, immunodepletion therapy comprises IV infusion of about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000 mg / m 2 of cyclophosphamide for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0438] In some embodiments, immunodepletion therapy comprises IV infusion of about 500 mg / m 2 of cyclophosphamide for about 2 days.
[0439] In some embodiments, at least about 40 x 10 4 Engineered T cells.
[0440] In some embodiments, at least about 40 x 10 5 Engineered T cells.
[0441] In some embodiments, the engineered T cells persist in the subject for at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0442] In some embodiments, the therapeutic effect of the engineered T cells persists for a duration of at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0443] In some embodiments, wild-type cells or control cells are the starting material.
[0444] In some embodiments, provided herein is the use of a population of engineered T cells for treating EBV infection in a patient suspected of having or diagnosed with EBV infection, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen (HLA) molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more chimeric antigen receptors (CARs), wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or an EBV antigen.
[0445] In some embodiments, provided herein is the use of a population of engineered T cells for treating EBV infection in a patient suspected of having or diagnosed with EBV infection, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19 or CD22.
[0446] In some embodiments, provided herein is the use of a population of engineered T cells for treating EBV infection in a patient suspected of having or diagnosed with EBV infection, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or an EBV antigen.
[0447] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0448] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0449] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0450] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0451] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0452] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TCR-α (TRAC) and / or TCR-β (TRB) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0453] In some embodiments, provided herein is the use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0454] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0455] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0456] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0457] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
[0458] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0459] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain specific for a CD19, CD20, CD22, BCMA or EBV antigen, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain.
[0460] In some embodiments, one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain, or an IgG4 hinge domain.
[0461] In some embodiments, one or more CARs comprises a CD8 alpha hinge domain having the amino acid sequence of SEQ ID NO:9.
[0462] In some embodiments, one or more CARs comprises a CD28 hinge domain having the amino acid sequence of SEQ ID NO: 10 or 113.
[0463] In some embodiments, one or more CARs comprises an IgG4 hinge domain having the amino acid sequence of SEQ ID NO: 11 or 12.
[0464] In some embodiments, one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
[0465] In some embodiments, one or more CARs comprises a CD8α transmembrane domain having the amino acid sequence of SEQ ID NO:14.
[0466] In some embodiments, one or more CARs comprises a CD28 transmembrane domain having the amino acid sequence of SEQ ID NO: 15 or 114.
[0467] In some embodiments, one or more CARs comprise a 4-1BB costimulatory domain, a CD28 costimulatory domain, or a CD3 zeta signaling domain.
[0468] In some embodiments, one or more CARs comprises a 4-1BB costimulatory domain having the amino acid sequence of SEQ ID NO: 16.
[0469] In some embodiments, one or more CARs comprises a CD28 costimulatory domain having the amino acid sequence of SEQ ID NO: 17.
[0470] In some embodiments, one or more CARs comprises a CD3 zeta signaling domain having the amino acid sequence of SEQ ID NO: 18 or 115.
[0471] In some embodiments, one or more CARs comprises an extracellular ligand binding domain comprising a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0472] In some embodiments, one or more CARs have the sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134.
[0473] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD20 CAR having the CDR sequence of SEQ ID NO: 37.
[0474] In some embodiments, provided herein is the use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include an EBV antigen CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172.
[0475] In some embodiments, provided herein is a use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117.
[0476] In some embodiments, provided herein is a use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD22 CAR having a CDR sequence of SEQ ID NO: 45.
[0477] In some embodiments, provided herein is a use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45.
[0478] In some embodiments, provided herein is a use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0479] In some embodiments, the use further comprises assessing the patient for EBV infection and optionally multiple sclerosis and / or diagnosing the patient with EBV infection and optionally multiple sclerosis prior to administering the engineered T cell population to the patient.
[0480] In some embodiments, diagnosing comprises assessing the patient for EBV infection.
[0481] In some embodiments, diagnosing comprises assessing the patient for multiple sclerosis.
[0482] In some embodiments, the treatment prevents multiple sclerosis.
[0483] In some embodiments, the treatment treats multiple sclerosis.
[0484] In some embodiments, the patient with EBV infection has been diagnosed with multiple sclerosis.
[0485] In some embodiments, the multiple sclerosis is relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, or secondary progressive multiple sclerosis.
[0486] In some embodiments, the patient experiences remission of multiple sclerosis following administration of the engineered T cells.
[0487] In some embodiments, the patient having an EBV infection is receiving treatment for the EBV infection.
[0488] In some embodiments, the patient having an EBV infection has an active EBV infection.
[0489] In some embodiments, the patient having an EBV infection has an inactive EBV infection.
[0490] In some embodiments, the patient has a reduction in EBV infection following administration of the engineered T cells, optionally wherein the reduction in EBV infection is characterized by a reduction in viral load.
[0491] In some embodiments, treatment prevents the EBV infection from transitioning from an inactive EBV infection to an active EBV infection.
[0492] In some embodiments, the use results in B cell depletion.
[0493] In some embodiments, the engineered T cells comprise one or more of a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a BCMA-specific CAR, a GPRC5D-specific CAR, a CD38-specific CAR, a CD70-specific CAR, a CD79b-specific CAR, and an EBV antigen-specific CAR.
[0494] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0495] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0496] In some embodiments, provided herein is the use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0497] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0498] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0499] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0500] In some embodiments, one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain, or an IgG4 hinge domain.
[0501] In some embodiments, one or more CARs comprises a CD8 alpha hinge domain having the amino acid sequence of SEQ ID NO:9.
[0502] In some embodiments, one or more CARs comprises a CD28 hinge domain having the amino acid sequence of SEQ ID NO: 10 or 113.
[0503] In some embodiments, one or more CARs comprises an IgG4 hinge domain having the amino acid sequence of SEQ ID NO: 11 or 12.
[0504] In some embodiments, one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
[0505] In some embodiments, one or more CARs comprises a CD8α transmembrane domain having the amino acid sequence of SEQ ID NO:14.
[0506] In some embodiments, one or more CARs comprises a CD28 transmembrane domain having the amino acid sequence of SEQ ID NO: 15 or 114.
[0507] In some embodiments, one or more CARs comprise a 4-1BB costimulatory domain, a CD28 costimulatory domain, or a CD3 zeta signaling domain.
[0508] In some embodiments, one or more CARs comprises a 4-1BB costimulatory domain having the amino acid sequence of SEQ ID NO: 16.
[0509] In some embodiments, one or more CARs comprises a CD28 costimulatory domain having the amino acid sequence of SEQ ID NO: 17.
[0510] In some embodiments, one or more CARs comprises a CD3 zeta signaling domain having the amino acid sequence of SEQ ID NO: 18 or 115.
[0511] In some embodiments, one or more CARs comprises an extracellular ligand binding domain comprising a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0512] In some embodiments, one or more CARs have the sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134.
[0513] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0514] In some embodiments, the use further comprises assessing a patient for an autoimmune disease and / or diagnosing a patient with an autoimmune disease.
[0515] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
[0516] In some embodiments, the encoded CD19 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 117, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 117, having the following components: a CD8 alpha signal peptide, an FMC63 scFv (VL-Whitlow linker-VH), a CD8 alpha hinge domain, a CD8 alpha transmembrane domain, a 4-1BB costimulatory domain, and a CD3 zeta signaling domain.
[0517] In some embodiments, the encoded CD22 CAR has the corresponding amino acid sequence set forth in SEQ ID NO: 45, or is at least 80% identical (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical) to the amino acid sequence set forth in SEQ ID NO: 45.
[0518] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA, and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include an EBV antigen-specific CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172, and wherein the autoimmune disease is multiple sclerosis.
[0519] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0520] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have the scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0521] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0522] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have the scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0523] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have the scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0524] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have the scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0525] In some embodiments, provided herein is a use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have the sequence of any one of SEQ ID NOs: 32, 34, 36, and 117, or wherein the one or more CARs have the scFv sequence of any one of SEQ ID NOs: 19, 29, or 37.
[0526] In some embodiments, the use further comprises assessing the patient for an autoimmune disease and / or diagnosing the patient with an autoimmune disease prior to administering the engineered T cell population to the patient.
[0527] In some embodiments, the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, and a pulmonary condition.
[0528] In some embodiments, the patient is suspected of having an EBV infection or has been diagnosed with an EBV infection.
[0529] In some embodiments, the patient is suspected of having or has been diagnosed with multiple sclerosis.
[0530] In some embodiments, the use further comprises administering a second, third, fourth, fifth, or sixth dose of the engineered T cells to the patient.
[0531] In some embodiments, the dose is the same in one or more of the first, second, third, fourth, fifth, and / or sixth doses of engineered T cells.
[0532] In some embodiments, the CAR is different in one or more of the first, second, third, fourth, fifth, and / or sixth doses of engineered T cells.
[0533] In some embodiments, the CAR has a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising the heavy and light chain sequences of any one of SEQ ID NOs: 129-132 or 135-172.
[0534] In some embodiments, the CAR has the sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133, and 134.
[0535] In some embodiments, the engineered T cells comprise a CD19-specific CAR and a CD20-specific CAR.
[0536] In some embodiments, the CD19-specific CAR has a CDR sequence of SEQ ID NO: 117, and the CD22 CAR has a CDR sequence of SEQ ID NO: 45.
[0537] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
[0538] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
[0539] In some embodiments, the CD19-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
[0540] In some embodiments, CD19 CAR T cells and CD20 CAR T cells are administered simultaneously.
[0541] In some embodiments, CD19 CAR+ T cells and CD20 CAR+ T cells are administered sequentially.
[0542] In some embodiments, CD19 CAR+ T cells are administered prior to administration of CD20 CAR+ T cells.
[0543] In some embodiments, CD20 CAR+ T cells are administered prior to administration of CD19 CAR+ T cells.
[0544] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0545] In some embodiments, the number of cells administered in a therapeutically effective amount of CD19 and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
[0546] In some embodiments, the engineered T cells comprise an EBV antigen-specific CAR and a CD20-specific CAR.
[0547] In some embodiments, the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
[0548] In some embodiments, the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
[0549] In some embodiments, the EBV antigen-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
[0550] In some embodiments, EBV antigen CAR T cells and CD20 CAR T cells are administered simultaneously.
[0551] In some embodiments, EBV antigen CAR+ T cells and CD20 CAR+ T cells are administered sequentially.
[0552] In some embodiments, EBV antigen CAR+ T cells are administered prior to administration of CD20 CAR+ T cells.
[0553] In some embodiments, CD20 CAR+ T cells are administered prior to administration of EBV antigen CAR+ T cells.
[0554] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
[0555] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
[0556] In some embodiments, the engineered T cells comprise an EBV antigen-specific CAR and a CD19-specific CAR.
[0557] In some embodiments, the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bicistronic polynucleotide.
[0558] In some embodiments, the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bispecific CAR.
[0559] In some embodiments, the EBV antigen-specific CAR and the CD19-specific CAR are encoded by two separate polynucleotides.
[0560] In some embodiments, EBV antigen CAR T cells and CD19 CAR T cells are administered simultaneously.
[0561] In some embodiments, EBV antigen CAR+ T cells and CD19 CAR+ T cells are administered sequentially.
[0562] In some embodiments, EBV antigen CAR+ T cells are administered prior to administration of CD19 CAR+ T cells.
[0563] In some embodiments, CD19 CAR+ T cells are administered prior to administration of EBV antigen CAR+ T cells.
[0564] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD19 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
[0565] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD19 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
[0566] In some embodiments, the engineered T cells comprise an EBV antigen-specific CAR and a CD22-specific CAR.
[0567] In some embodiments, the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bicistronic polynucleotide.
[0568] In some embodiments, the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bispecific CAR.
[0569] In some embodiments, the EBV antigen-specific CAR and the CD22-specific CAR are encoded by two separate polynucleotides.
[0570] In some embodiments, EBV antigen CAR T cells and CD22 CAR T cells are administered simultaneously.
[0571] In some embodiments, EBV antigen CAR+ T cells and CD22 CAR+ T cells are administered sequentially.
[0572] In some embodiments, EBV antigen CAR+ T cells are administered prior to administration of CD22 CAR+ T cells.
[0573] In some embodiments, CD22 CAR+ T cells are administered prior to administration of EBV antigen CAR+ T cells.
[0574] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD22 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
[0575] In some embodiments, the number of cells administered in a therapeutically effective amount of EBV antigen and / or CD22 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
[0576] In some embodiments, the engineered T cells are primary T cells, propagated from primary T cells or their progeny, or derived from T cells differentiated from iPSCs or their progeny.
[0577] In some embodiments, the engineered T cells are differentiated cells derived from induced pluripotent stem cells or their progeny.
[0578] In some embodiments, the differentiated cell is a T cell or a natural killer (NK) cell.
[0579] In some embodiments, the engineered T cell is a primary T cell, which is a progeny of a primary immune cell, optionally wherein the progeny of the primary immune cell is a T cell or a NK cell.
[0580] In some embodiments, the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules relative to unaltered or unmodified wild-type or control cells.
[0581] In some embodiments, the engineered T cells comprise reduced expression of one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
[0582] In some embodiments, the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules and one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
[0583] In some embodiments, the engineered T cells comprise reduced expression of B2M and / or CIITA relative to unaltered or unmodified wild-type or control cells.
[0584] In some embodiments, the engineered T cells do not express B2M and / or CIITA.
[0585] In some embodiments, the engineered T cells comprise reduced expression of TRAC and / or TRB.
[0586] In some embodiments, the engineered T cells do not express TRAC and / or TRB.
[0587] In some embodiments, the engineered T cells comprise reduced expression of TRAC.
[0588] In some embodiments, the engineered T cells do not express TRAC.
[0589] In some embodiments, the engineered T cells comprise reduced expression of TRB.
[0590] In some embodiments, the engineered T cells do not express TRB.
[0591] In some embodiments, the engineered T cells comprise reduced expression of TRAC and TRB.
[0592] In some embodiments, the one or more tolerogenic factors are selected from the group consisting of CD47, CD24, CD27, CD35, CD46, CD55, CD59, CD200, HLA-C, HLA-E, HLA-E heavy chain, HLA-G, PD-L1, IDO1, CTLA4-Ig, C1 inhibitor, IL-10, IL-35, FasL, CCL21, CCL22, Mfge8, A20 / TNFAIP3, CD39, CR1, HLA-F, IL15-RF, MANF, and Serpinb9, optionally wherein the one or more tolerogenic factors include CD47.
[0593] In some embodiments, the CD19-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0594] In some embodiments, the CD19-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0595] In some embodiments, the CD20-specific CAR and one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
[0596] In some embodiments, the CD20-specific CAR and CD47 are encoded by a single bicistronic polynucleotide.
[0597] In some embodiments, one or more of the first, second, and / or third exogenous polynucleotides or bicistronic polynucleotides are inserted into a first, second, and / or third specific locus of at least one allele of the cell.
[0598] In some embodiments, the first, second, and / or third specific locus is selected from the group consisting of a safe harbor locus, a target locus, an RHD locus, a B2M locus, a CIITA locus, a TRAC locus, and a TRB locus.
[0599] In some embodiments, the safe harbor locus is selected from the group consisting of: a CCR5 locus, a PPP1R12C locus, a CLYBL locus, and a Rosa locus.
[0600] In some embodiments, the target locus is selected from the group consisting of: a CXCR4 locus, an ALB locus, a SHS231 locus, a F3 (CD142) locus, a MICA locus, a MICB locus, a LRP1 (CD91) locus, a HMGB1 locus, an ABO locus, a FUT1 locus, and a KDM5D locus.
[0601] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cells using a gene therapy vector or a transposase system selected from the group consisting of a transposase, a PiggyBac transposon, a Sleeping Beauty (SB11) transposon, a Mos1 transposon, and a Tol2 transposon.
[0602] In some embodiments, the gene therapy vector is a retrovirus or a fusion.
[0603] In some embodiments, the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide is introduced into the engineered T cell using CRISPR / Cas gene editing.
[0604] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of Cas9, Cas12a, and Cas12b.
[0605] In some embodiments, the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of:
[0606] (a) optionally selected from the group consisting of Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3 and GSU0054;
[0607] (b) optionally selected from the group consisting of Cas9, Csn2 and Cas4;
[0608] (c) optionally selected from the group consisting of Cas10, Csm2, Cmr5, Cas10, Csx11, and Csx10;
[0609] (d) optionally Csf1;
[0610] (e) is optionally selected from the group consisting of Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e), and CasY (Cas12d); and
[0611] (f) is optionally selected from the group consisting of Cas13, Cas13a, C2c2, Cas13b, Cas13c and Cas13d.
[0612] In some embodiments, CRISPR / Cas gene editing is performed ex vivo from a donor subject.
[0613] In some embodiments, a lentiviral vector is used to introduce the first, second, and / or third exogenous polynucleotide or bicistronic polynucleotide into the engineered T cell.
[0614] In some embodiments, the engineered T cells evade NK cell-mediated cytotoxicity upon administration to a patient.
[0615] In some embodiments, the engineered T cells are protected from cytolysis by mature NK cells following administration to a patient.
[0616] In some embodiments, the engineered T cells evade macrophage-mediated cytotoxicity, optionally wherein the macrophage-mediated cytotoxicity involves phagocytosis and / or reactive oxygen species.
[0617] In some embodiments, the engineered T cells do not induce an immune response to the cells upon administration to a patient.
[0618] In some embodiments, administration is selected from the group consisting of intravenous injection, intramuscular injection, intravascular injection, and transplantation.
[0619] In some embodiments, the engineered T cells are administered before, during, or after initiation of a different treatment regimen in the patient.
[0620] In some embodiments, the different treatment regimen is selected from the group consisting of re-administration of the same or different cells, and pre-treatment, concurrent treatment, or subsequent treatment with an additional agent.
[0621] In some embodiments, the different cell is an autologous T or NK cell or a CAR-T cell that expresses a first CAR that is different from a second CAR expressed by the engineered CAR-T cell.
[0622] In some embodiments, the patient is treated with immunodepletion therapy prior to administration of the engineered T cells.
[0623] In some embodiments, immunodepletion therapy comprises administration of fludarabine and / or cyclophosphamide.
[0624] In some embodiments, the patient has received prior antibody therapy.
[0625] In some embodiments, the antibody therapy is rituximab.
[0626] In some embodiments, immunodepletion therapy comprises IV infusion of about 1-50 mg / m 2 Fludarabine is taken for about 1-7 days.
[0627] In some embodiments, immunodepletion therapy comprises IV infusion of about 1, about 5, about 10, about 20, about 30, about 40, or about 50 mg / m 2 of fludarabine for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0628] In some embodiments, immunodepletion therapy comprises IV infusion of about 30 mg / m 2 Fludarabine for about 4 days.
[0629] In some embodiments, immunodepletion therapy comprises IV infusion of about 100-1000 mg / m 2 Cyclophosphamide for about 1-7 days.
[0630] In some embodiments, immunodepletion therapy comprises IV infusion of about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000 mg / m 2 of cyclophosphamide for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
[0631] In some embodiments, immunodepletion therapy comprises IV infusion of about 500 mg / m 2 of cyclophosphamide for about 2 days.
[0632] In some embodiments, at least about 40 x 10 4 Engineered T cells.
[0633] In some embodiments, at least about 40 x 10 5 Engineered T cells.
[0634] In some embodiments, the engineered T cells persist in the subject for at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0635] In some embodiments, the therapeutic effect of the engineered T cells persists for a duration of at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
[0636] In some embodiments, wild-type cells or control cells are the starting material.
[0637] This disclosure is related to U.S. Provisional Application No. 112864-5057-PR filed on December 31, 2020, and U.S. Provisional Application No. 18615-30046.00 filed by Morrison and Foerester on January 11, 2021, the contents of which are hereby incorporated by reference in their entirety. Detailed descriptions of engineered and / or low immunogenic cells, methods for their production, and methods for their use can be found in U.S. Provisional Application No. 63 / 065,342, filed on August 13, 2020, WO2016 / 183041, filed on May 9, 2015, WO2018 / 132783, filed on January 14, 2018, WO2020 / 018615, filed on July 17, 2019, WO2020 / 018620, filed on July 17, 2019, and WO2020 / 168317, filed on February 16, 2020, the disclosures of which, including the examples, sequence listings, and figures, are incorporated herein by reference in their entirety. DETAILED DESCRIPTION
[0638] I. Introduction
[0639] Described herein are partially based on the through engineering approaches of the low immune editing platform described in WO2018132783 and PCT / US21 / 65157 (each of which is incorporated herein by reference in its entirety) submitted to 12 / 23 / 2021 or the immune evasive cells (immune evasive cell) of modification, including but not limited to human immune evasive cells. In order to overcome the immune rejection problem of the subject to these primary and / or stem cell-derived transplants, the inventors have developed and described herein low immunogenic cells (e.g., low immunogenicity pluripotent cells, differentiated cells derived from such low immunogenicity pluripotent cells, and primary cells), which represent a feasible source of any transplantable cell type. Such cells are protected from adaptation and / or innate immune rejection after being applied to recipient subjects. Advantageously, regardless of the subject's genetic makeup, cells disclosed herein are not rejected by the immune system of the recipient subject because they are protected from adaptation and innate immune rejection after being applied to recipient subjects. In some embodiments, engineering and / or low immunogenic cells do not express major histocompatibility complex (MHC) class I and class II antigen molecules and / or T cell receptors. In certain embodiments, engineering and / or low immunogenic cells do not express MHC I and II antigen molecules and / or T cell receptors, and overexpress CD47 proteins. In certain embodiments, engineering and / or low immunogenic cells (such as engineering and / or low immunogenic T cells) do not express MHC I and II antigen molecules and / or T cell receptors, overexpress CD47 proteins, and express exogenous CAR.
[0640] In some embodiments, the low immunogenicity cells outlined herein are not subject to innate immune cell rejection. In some cases, low immunogenicity cells are insensitive to NK cell-mediated cracking. In some cases, low immunogenicity cells are insensitive to macrophage phagocytosis. In some embodiments, low immunogenicity cells can be used as the source of generally compatible cells or tissues (for example, universal donor cells or tissues), which are transplanted into recipient subjects and hardly require immunosuppressants. Such low immunogenicity cells retain cell-specific characteristics and properties after transplantation, including, for example, pluripotency, and can be implanted and play a role similarly to corresponding natural cells.
[0641] The technology disclosed herein utilizes the expression of tolerogenic factors in human cells and the regulation (e.g., reduction or elimination) of MHC I molecules, MHC II molecules and / or TCR expression. In some embodiments, the genome editing technology utilizing rare-cutting endonuclease (e.g., CRISPR / Cas, TALEN, zinc finger nuclease, meganuclease and homing endonuclease system) is also used to reduce or eliminate the expression of genes involved in immune response in cells (e.g., by deleting the genomic DNA of genes involved in immune response or by inserting genomic DNA into such genes so that gene expression is affected). In some embodiments, genome editing technology or other gene regulation technologies are used to insert tolerance-inducing (tolerogenic) factors in human cells so that cells and their offspring (including any differentiated cells prepared therefrom) can escape immune recognition after being implanted into recipient subjects. Therefore, cells as described herein show the regulated expression of one or more genes and factors that affect MHC I molecules, MHCII molecules and / or TCR expression, and escape the immune system of recipient subjects.
[0642] Genome editing technology can realize double-strand DNA breaks at desired gene locus points.These controlled double-strand breaks promote homologous recombination at specific gene locus points.This process focuses on identifying and being bonded to the specific sequence of nucleic acid molecules and inducing the endonuclease of double-strand breaks in nucleic acid molecules to target the specific sequence (such as chromosome).Double-strand breaks are repaired by fallible non-homologous end joining (NHEJ) or by homologous recombination (HR).
[0643] Unless otherwise expressly indicated to the contrary, the practice of the various embodiments will employ conventional methods of chemistry, biochemistry, organic chemistry, molecular biology, microbiology, recombinant DNA technology, genetics, immunology, and cell biology, which are within the skill of the art, many of which are described below for illustrative purposes. Such techniques are fully explained in the literature.See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd ed., 2001); Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., 1989); Maniatis et al., Molecular Cloning: A Laboratory Manual (1982); Ausubel et al., Current Protocols in Molecular Biology (John Wiley and Sons, updated July 2008); ShortProtocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Glover, DNACloning: A Practical Approach, Volumes I and II (IRL Press, Oxford, 1985); Anand, Techniques for the Analysis of Complex Genomes, (Academic Press, New York,1992); Transcription and Translation (B. Hames and S. Higgins, eds., 1984); Perbal, A Practical Guide to Molecular Cloning (1984); Harlow and Lane, Antibodies, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998) Current Protocols in Immunology (QE Coligan, A.M. Kruisbeek, DH Margulies, E.M. Shevach and W. Strober, eds., 1991); Annual Review of Immunology; and monographs in journals such as Advances in Immunology.
[0644] II. Definitions
[0645] As described in this disclosure, the following terminology will be employed and defined as described below.
[0646] As used herein, the term "antigen" refers to a molecule capable of stimulating an immune response. Antigens include, but are not limited to, cells, cell extracts, proteins, polypeptides, peptides, polysaccharides, polysaccharide conjugates, peptide and non-peptide mimetics of polysaccharides and other molecules, small molecules, lipids, glycolipids, carbohydrates, viruses and viral extracts, and multicellular organisms such as parasites and allergens. The term antigen broadly includes any type of molecule that is recognized as foreign by the host immune system.
[0647] The term "autoimmune disease" or "autoimmune disorder" or "inflammatory disease" or "inflammatory disorder" refers to any disease or disorder in which a subject produces an immune response against its own tissues and / or cells. Autoimmune disorders can affect almost every organ system of a subject (e.g., a human), including but not limited to diseases of the nervous, gastrointestinal, and endocrine systems, as well as diseases of the skin and other connective tissues, eyes, blood, and blood vessels. Examples of autoimmune diseases include but are not limited to Hashimoto's thyroiditis, systemic lupus erythematosus, Sjögren's syndrome, Graves' disease, scleroderma, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, and diabetes.
[0648] In some embodiments, autoimmune or inflammatory disorders include, but are not limited to, arthritis (rheumatoid arthritis such as acute arthritis, chronic rheumatoid arthritis, gout or gouty arthritis, acute gouty arthritis, acute immune arthritis, chronic inflammatory arthritis, degenerative arthritis, type II collagen-induced arthritis, infectious arthritis, Lyme arthritis, proliferative arthritis, psoriatic arthritis, Still's disease, spondyloarthritis, juvenile-onset rheumatoid arthritis, osteoarthritis, chronic progressive arthritis, chronic aprogrediente), arthritis deformans, primary chronic polyarthritis, reactive arthritis, and ankylosing spondylitis), inflammatory hyperproliferative skin diseases, psoriasis (such as plaque psoriasis, guttate psoriasis, pustular psoriasis, and nail psoriasis), atopy (including atopic diseases such as hay fever and Job's syndrome)), dermatitis (including contact dermatitis, chronic contact dermatitis, exfoliative dermatitis, exfoliative psoriatic dermatitis, allergic dermatitis, allergic contact dermatitis, dermatitis herpetiformis, nummular dermatitis, seborrheic dermatitis, nonspecific dermatitis, primary irritant contact dermatitis, and atopic dermatitis), X-linked hyper-IgM syndrome, allergic intraocular Inflammatory diseases, urticaria (such as chronic allergic urticaria, chronic idiopathic urticaria, chronic autoimmune urticaria), myositis, polymyositis / dermatomyositis, juvenile dermatomyositis, toxic epidermal necrolysis, scleroderma (including systemic scleroderma), sclerosis (such as systemic sclerosis; multiple sclerosis (MS), MS associated with Epstein-Barr virus (EBV) infection, spinal-optic MS, primary progressive MS (PPMS), relapsing-remitting MS (RRMS), progressive relapsing MS, secondary progressive MS (SPMS), progressive systemic sclerosis, atherosclerosis, arteriosclerosis, disseminated sclerosis and ataxia), neuromyelitis optica spectrum disorder (NMO, also known as Devic's disease Disease or DeVick syndrome), inflammatory bowel disease (IBD) (including Crohn's disease); autoimmune-mediated gastrointestinal diseases; colitis, such as ulcerative colitis, colitis ulcers,ulcerosa), microscopic colitis, collagenous colitis, polyposis colitis, necrotizing enterocolitis, and transmural colitis; and autoimmune inflammatory bowel disease), intestinal inflammation, pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, respiratory distress syndrome (including adult or acute respiratory distress syndrome (ARDS)), meningitis, inflammation of the entire or part of the uvea, iritis, choroiditis, autoimmune blood disorders, rheumatoid spondylitis, rheumatoid synovitis, hereditary angioedema, cranial nerve damage as in meningitis, herpes gestationis, pemphigoid gestationis, pruritus scrotum, autoimmune premature ovarian failure, sudden hearing loss due to autoimmune conditions, IgE-mediated diseases such as allergic reactions and allergic and atopic rhinitis, encephalitis such as Rasmussen's encephalitis, encephalitis) and limbic and / or brainstem encephalitis, uveitis (such as anterior uveitis, acute anterior uveitis, granulomatous uveitis, nongranulomatous uveitis, lens antigen uveitis, posterior uveitis, or autoimmune uveitis), glomerulonephritis (GN) with or without nephrotic syndrome (such as chronic or acute glomerulonephritis, primary GN, immune-mediated GN, membranous GN (membranous nephropathy), idiopathic membranous GN or idiopathic membranous nephropathy, membranous or membranoproliferative GN (MPGN) (including type I and type II), and rapidly progressive GN or proliferative nephritis), autoimmune polyglandular endocrine failure, balanitis (including plasma cell localized balanitis), balanoposthitis, erythema annulare centrifugal, erythema dyschromicum perstans, erythema multiforme, granuloma annulare, lichen lustrous, lichen sclerosus atrophicus, lichen simplex chronicus, lichen spinulosus, lichen planus, lamellar ichthyosis, epidermolytic hyperkeratosis, precancerous keratosis, pyoderma gangrenosum, allergic conditions and responses, anaphylaxis, eczema (including allergic or atopic eczema, xerosis, dyshidrotic eczema, and palmoplantar eczema), asthma (such as asthma bronchiale), bronchial asthma,asthma and autoimmune asthma), conditions involving T cell infiltration and chronic inflammatory responses, immune responses to foreign antigens such as fetal ABO blood type during pregnancy, chronic inflammatory lung diseases, autoimmune myocarditis, leukocyte adhesion defects, lupus (including lupus nephritis, lupus encephalitis, pediatric lupus, non-renal lupus, extrarenal lupus, discoid lupus and discoid lupus erythematosus, alopecia, systemic lupus erythematosus (SLE), cutaneous SLE or subacute cutaneous SLE, neonatal lupus syndrome (NLE) and disseminated lupus erythematosus, adult type 1 diabetes mellitus, type 2 diabetes and latent autoimmune diabetes mellitus (or type 1.5 diabetes), juvenile-onset (type 1) diabetes (including insulin-dependent diabetes mellitus (IDDM) in children), adult-onset diabetes mellitus (type 2 diabetes), idiopathic diabetes mellitus, diabetes insipidus, diabetic retinopathy, diabetic nephropathy and diabetic arteropathy tuberculosis, sarcoidosis, granulomatous diseases (including lymphomatoid granulomatosis, Wegener's granulomatosis, or agranulocytosis), vasculitic diseases (including vasculitis, large vessel vasculitis, polymyalgia rheumatica, and giant cell (Takayasu's) arteritis, medium vessel vasculitis, Kawasaki disease, and polyarteritis nodosa / periarteritis nodosa), microscopic polyarteritis, immune vasculitis, CNS vasculitis, cutaneous vasculitis, hypersensitivity vasculitis, necrotizing vasculitis such as systemic necrotizing vasculitis, and ANCA-associated vasculitis (such as Churg-Strauss vasculitis or syndrome (CSS) and ANCA-associated small vessel vasculitis), temporal arteritis, aplastic anemia, autoimmune aplastic anemia, Coombs-positive anemia, Diamond Blackfan anemia, hemolytic anemia, immune hemolytic anemia (including autoimmune hemolytic anemia (AIHA)), pernicious anemia (anemia perniciosa), Addison's disease, pure red cell anemia or aplastic anemia (PRCA); factor VIII deficiency; hemophilia A; autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocytopenia, CNS inflammatory disorders, Alzheimer's disease, Parkinson's disease, multiple organ injury syndrome (such as those secondary to sepsis, trauma, or hemorrhage), antigen-antibody complex-mediated diseases, anti-glomerular basement membrane disease, antiphospholipid antibody syndrome, antiphospholipid syndrome, allergic neuritis, Behçet's disease / syndrome, Castleman's syndrome, Goodpasture'ssyndrome), Raynaud's syndrome, Sjögren's syndrome, Stevens-Johnson syndrome, pemphigoid such as bullous pemphigoid and cutaneous pemphigoid, pemphigus (including pemphigus vulgaris, pemphigus foliaceus, pemphigus mucus-membrane pemphigoid, and pemphigus erythematosus), autoimmune polyendocrinopathy, Reiter's disease or syndrome, thermal injury, preeclampsia, immune complex disorders such as immune complex nephritis, antibody-mediated nephritis, polyneuropathy, chronic neuropathies such as IgM polyneuropathy or IgM-mediated neuropathy, thrombocytopenia (e.g., as developed by patients with myocardial infarction) (including thrombotic thrombocytopenic purpura (TTP), post-transfusion purpura (PTP), heparin-induced platelet hyperplasia (HIPH)), thrombocytopenia (e.g., as developed by patients with myocardial infarction) (including thrombotic thrombocytopenic purpura (TTP), post-transfusion purpura (PTP), heparin-induced platelet hyperplasia (HIPH)), thrombocytopenia (e.g., as developed by patients with myocardial infarction) (including thrombotic thrombocytopenic purpura (TTP), post-transfusion purpura (PTP), heparin-induced platelet hyperplasia (HIPH)), thrombocytopenia (e.g., as developed by patients with myocardial infarction) thrombocytopenia, autoimmune or immune-mediated thrombocytopenia such as idiopathic thrombocytopenic purpura (ITP) (including chronic or acute ITP), acquired thrombocytopenic purpura), scleritis such as idiopathic keratoscleritis, episcleritis, autoimmune diseases of the testicles and ovaries (including autoimmune orchitis and oophoritis), primary hypothyroidism, hypoparathyroidism, autoimmune endocrine diseases (including thyroiditis, autoimmune thyroiditis, Hashimoto's disease disease), chronic thyroiditis (Hashimoto's thyroiditis) or subacute thyroiditis), autoimmune thyroid disease, idiopathic hypothyroidism or Graves' disease), polyglandular syndrome, autoimmune polyglandular syndrome (or polyglandular endocrine disease syndrome), paraneoplastic syndromes (including neurologic paraneoplastic syndromes such as Lambert-Eaton myasthenic syndrome or Eaton-Lambert syndrome), stiff-man or stiff-person syndrome, encephalomyelitis such as allergic encephalomyelitis or hypersensitivity encephalomyelitis and experimental allergic encephalomyelitis (EAE), myasthenia gravis such as thymoma-associated myasthenia gravis, cerebellar degeneration, neuromyotonia, opsoclonus or opsoclonus-myoclonus syndrome (OMS), sensory neuropathy, multifocal motor neuropathy, Sheehan's syndrome syndrome), hepatitis (including autoimmune hepatitis, chronic hepatitis, lupus hepatitis, giant cell hepatitis, chronic active hepatitis or autoimmune chronic active hepatitis), lymphocytic interstitial pneumonia (LIP), bronchiolitis obliterans (non-transplant) and NSIP, Guillain-Barré syndrome, Berger's diseasedisease) (IgA nephropathy), idiopathic IgA nephropathy, linear IgA dermatosis, acute febrile neutrophilic dermatosis, subcorneal pustular dermatosis, transient acantholytic dermatosis, cirrhosis of the liver such as primary biliary cirrhosis and pulmonary cirrhosis, autoimmune bowel syndrome, celiac disease or diarrheal disease, sprue (gluten enteropathy), refractory sprue, idiopathic sprue, cryoglobulinemia, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), coronary artery disease, autoimmune ear diseases such as autoimmune inner ear disease (AIED), autoimmune hearing loss, polychondritis such as refractory or relapsing polychondritis, pulmonary alveolar proteinosis, Cogan's syndrome / nonsyphilitic interstitial keratitis, Bell's palsy palsy), Sweet's disease / syndrome, autoimmune rosacea, herpes zoster-associated pain, amyloidosis, noncancerous lymphocytosis (a primary lymphocytosis, including monoclonal B-cell lymphocytosis (e.g., benign monoclonal gammopathy and monoclonal gammopathy of undetermined significance, MGUS)), peripheral neuropathies, paraneoplastic syndromes, channelopathies such as epilepsy, migraine, cardiac arrhythmias, muscle disorders, deafness, blindness, periodic paralysis, CNS channelopathies, autism, inflammatory myopathies, focal or segmental glomerulosclerosis (FSGS), endocrine eye diseases, uveoretinitis, chorioretinitis, autoimmune liver disease, fibromyalgia, multiple endocrine failure, Schmidt's syndrome syndrome), adrenalitis, gastric atrophy, Alzheimer's disease, demyelinating diseases such as autoimmune demyelinating diseases and chronic inflammatory demyelinating polyneuropathy, Dressler's syndrome, alopecia areata, alopecia totalis, CREST syndrome (calcification, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), autoimmune infertility in men and women (e.g., due to antisperm antibodies), mixed connective tissue disease, Chagas' disease, rheumatic fever, recurrent miscarriage, farmer's lung, erythema multiforme, postcardiotomy syndrome, post myocardial infarction cardiotomy syndrome, Cushing's syndrome, bird farmer's lung, allergic granulomatosis with polyangiitis, benign lymphocytic vasculitis, Alport's syndromesyndrome), alveolitis such as allergic alveolitis and fibrosing alveolitis, interstitial lung disease, transfusion reaction, leprosy, malaria, parasitic diseases such as leishmaniasis, kypanosomiasis, schistosomiasis, ascariasis, aspergillosis, Samter's syndrome, Caplan's syndrome, dengue fever, endocarditis, endomyocardial fibrosis, diffuse interstitial pulmonary fibrosis, interstitial pulmonary fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, endophthalmitis, erythema eminentum, erythroblastosis fetalis, eosinophilic fasciitis, Shulman's syndrome, Felty's syndrome, syndrome), filariasis, cyclitis such as chronic cyclitis, metachronous cyclitis, iridocyclitis (acute or chronic), or Fuch's cyclitis, Henoch-Schonlein purpura, human immunodeficiency virus (HIV) infection, SCID, acquired immune deficiency syndrome (AIDS), echovirus infection, sepsis, endotoxemia, pancreatitis, thyroxicosis, parvovirus infection, rubella virus infection, postvaccination syndrome, congenital rubella infection, Epstein-Barr virus infection, mumps, Evan's syndrome, autoimmune gonadal failure, Sydenham's chorea chorea), poststreptococcal nephritis, thromboangiitis obliterans, thyrotoxicosis, tabes dorsalis, choroiditis, giant cell polymyalgia, chronic hypersensitivity pneumonitis, keratoconjunctivitis sicca, epidemic keratoconjunctivitis, idiopathic nephritic syndrome, minimal change disease, benign familial and ischemia-reperfusion injury, transplant reperfusion, retinal autoimmunity, joint inflammation, bronchitis, chronic obstructive airway / lung disease, silicosis, aphthous stomatitis, aphthous stomatitis, arteriosclerotic disorders, aspermiogenese, autoimmune hemolysis, Boeck's disease, cryoglobulinemia, Dupuytren's contracture, allergic endophthalmitis, allergic enteritis, erythema nodosum leprosum, idiopathic facial palsy, chronic fatigue syndrome, rheumatic fever (febris) rheumatica), Hamman-Rich's disease, sensorineural hearing loss, and paroxysmal hemoglobinuriaparoxysmatica), hypogonadism, Crohn's disease, leukopenia, infectious mononucleosis, transverse myelitis, primary idiopathic myxedema, nephropathy, ophthalmia symphatica, orchitis granulomatosa, pancreatitis, acute polyradiculitis, pyoderma gangrenosum, Quervain's thyroiditis thyreoiditis), acquired splenic atrophy, nonmalignant thymoma, vitiligo, toxic shock syndrome, food poisoning, conditions involving T-cell infiltration, leukocyte adhesion defects, immune responses associated with acute and delayed hypersensitivity reactions mediated by cytokines and T lymphocytes, diseases involving leukocytic diapedesis, multiple organ injury syndrome, antigen-antibody complex-mediated diseases, anti-glomerular basement membrane disease, allergic neuritis, autoimmune polyendocrine disease, oophoritis, primary myxedema, autoimmune atrophic gastritis, sympathetic ophthalmia, rheumatic diseases, mixed connective tissue disease, nephrotic syndrome, insulitis, polyendocrine failure, autoimmune polyglandular syndrome type I, adult-onset idiopathic hypoparathyroidism (AOIH), cardiomyopathies such as dilated cardiomyopathy, acquired Epidermolysis bullosa (EBA), hemochromatosis, myocarditis, nephrotic syndrome, primary sclerosing cholangitis, suppurative or non-suppurative sinusitis, acute or chronic sinusitis, ethmoid sinusitis, frontal sinusitis, maxillary sinusitis or sphenoid sinusitis, eosinophil-related disorders such as eosinophilia, pulmonary infiltrative eosinophilia, eosinophilia-myalgia syndrome, Loffler's syndrome, chronic eosinophilic pneumonia, tropical pulmonary eosinophilia, bronchopulmonary aspergillosis, aspergilloma or granuloma containing eosinophils, allergic reaction, seronegative spondyloarthropathies, polyendocrine autoimmune diseases, sclerosing cholangitis, sclera, episclera, chronic mucocutaneous candidiasis, Bruton's syndrome syndrome), transient hypogammaglobulinemia of infancy, Wiskott-Aldrich syndrome, ataxia-telangiectasia syndrome, vasodilation, autoimmune disorders associated with collagen disease, rheumatic diseases, nervous system diseases, lymphadenitis, hypotensive reactivity, vascular dysfunction, tissue damage, cardiovascular ischemia, hyperalgesia, renal ischemia, cerebral ischemia and diseases associated with vascularization, allergic hypersensitivity disordersdisorder), glomerulonephritis, reperfusion injury, ischemic reperfusion disorder, reperfusion injury of the myocardium or other tissues, lymphomatous tracheobronchitis, inflammatory skin diseases, skin diseases with an acute inflammatory component, multiple organ failure, bullous diseases, renal cortical necrosis, acute purulent meningitis or other central nervous system inflammatory disorders, inflammatory disorders of the eye and orbit, granulocyte transfusion-related syndrome, cytokine-induced toxicity, narcolepsy, acute severe inflammation, chronic refractory inflammation, pyelitis, intimal hyperplasia, peptic ulcer, valvulitis, emphysema, alopecia areata, adipose tissue inflammation / type 2 diabetes, obesity-related adipose tissue inflammation / insulin resistance, endometriosis, and pulmonary hemosiderosis.
[0649] As used herein, "B cell depletion" refers to a decrease in the level of B cells in an animal or human following cell or antibody treatment, compared to the level of B cells before treatment. B cell levels can be measured using well-known assays, such as by obtaining a complete blood count, or by staining for known B cell markers using FACS analysis. B cell depletion can be partial or complete. In one embodiment, the depletion of B cells expressing CD20 is at least 25%. In one embodiment, the depletion of B cells expressing CD19 is at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5% or 100%. In one embodiment, the depletion of B cells expressing CD22 is at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, or 100%. In one embodiment, the depletion of B cells expressing CD19 and CD20 is at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, or 100%. In one embodiment, the depletion of B cells expressing CD19 and CD22 is at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, or 100%. In one embodiment, the depletion of B cells expressing CD20 and CD22 is at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82.5%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, or 100%. In some embodiments, depletion methods include those described in Ercoli, G. et al., Front Immunol. 11:611661 (2020), which is herein incorporated by reference in its entirety.
[0650] The term "chronic infectious disease" refers to a disease caused by an infectious agent, wherein the infection persists. Such diseases may include hepatitis (type A, type B or type C), herpes virus (e.g., VZV, HSV-1, HSV-6, HSV-II, CMV and EBV) and HIV / AIDS. Non-viral examples may include chronic fungal diseases, such as aspergillosis, candidiasis, coccidioidomycosis, and diseases and histoplasmosis associated with cryptococcus (Cryptococcus). Non-limiting examples of chronic bacterial infections may include Chlamydia pneumoniae, Listeria monocytogenes and Mycobacterium tuberculosis. In some embodiments, the disease is human immunodeficiency virus (HIV) infection. In some embodiments, the disease is acquired immunodeficiency syndrome (AIDS).
[0651] As used herein, "clinically effective amount" refers to an amount sufficient to provide a clinical benefit in the treatment and / or management of a disease, disorder, or condition. In some embodiments, a clinically effective amount is an amount that has been shown to produce at least one improved clinical endpoint for the standard of care for a disease, disorder, or condition. In some embodiments, a clinically effective amount is an amount that has been shown, for example, in a clinical trial to provide statistically significant and meaningful effectiveness for treating a disease, disorder, or condition. In some embodiments, a clinically effective amount is also a therapeutically effective amount. In some embodiments, a clinically effective amount is not a therapeutically effective amount.
[0652] In some embodiments, the changes or modifications described herein (including, for example, genetic alterations or modifications) result in reduced expression of the target or selected polynucleotide sequence. In some embodiments, the changes or modifications described herein result in reduced expression of the target or selected polypeptide sequence. In some embodiments, the changes or modifications described herein result in increased expression of the target or selected polynucleotide sequence. In some embodiments, the changes or modifications described herein result in increased expression of the target or selected polypeptide sequence.
[0653] In an additional or alternative embodiment, the present disclosure contemplates changing the target polynucleotide sequence in any manner available to the skilled person, for example, using a TALEN system or a transposase guided by RNA. It should be understood that although examples of methods utilizing CRISPR / Cas (e.g., Cas9 and Cas12a) and TALEN are described in detail herein, the present disclosure is not limited to the use of these methods / systems. Other targeted methods such as B2M that are known to skilled persons for reducing or eliminating expression in target cells may be utilized herein.
[0654] As used herein, the term "comparable" means that two or more subjects, entities, situations, sets of conditions, etc. may not be identical to each other, but are sufficiently similar to allow comparisons to be made therebetween so that conclusions can reasonably be drawn based on the observed differences or similarities. One of ordinary skill in the art will understand, in context, what degree of identity is required between two or more such subjects, entities, situations, sets of conditions, etc. in any given case to be considered comparable. For example, a control cell can be a comparable cell (e.g., the same cell type) that does not contain a relative change.
[0655] The terms "decrease," "reduced," "reduction," and "decrease" are all used herein generally to mean a decrease in a statistically significant amount. However, for the avoidance of doubt, "decrease," "reduced," "reduction," "decrease" means a decrease of at least 10% compared to a reference level, such as at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% decrease (i.e., a level that is absent compared to a reference sample) or any decrease between 10-100%. In some embodiments, cells are engineered to have decreased expression of one or more targets relative to unaltered or unmodified wild-type cells.
[0656] In some embodiments, the engineered and low immunogenic cells are derived from iPSC or its offspring. As used herein, the term "derived from iPSC or its offspring" covers the initial iPSC generated and any subsequent offspring thereof. As used herein, the term "offspring" covers, for example, first-generation offspring, i.e., directly derived from, obtained from, obtainable from, or can be derived from the offspring of initial iPSC by, for example, traditional breeding methods. The term "offspring" also covers other generations, such as the second, third, fourth, fifth, sixth, seventh, or more generations, i.e., derived from, obtained from, obtainable from, or can be derived from the cell generations of the previous generation by, for example, traditional breeding methods. The term "offspring" also covers the modified cells produced due to the modification or change of initial iPSC or its offspring.
[0657] The term "donor subject" refers to an animal, for example, a person from whom cells can be obtained. "Non-human animals" and "non-human mammals" as used interchangeably herein include mammals such as rats, mice, rabbits, sheep, cats, dogs, cattle, pigs and non-human primates. The term "donor subject" also encompasses any vertebrate, including but not limited to mammals, reptiles, amphibians and fish. However, advantageously, the donor subject is a mammal, such as a human or other mammal (such as a domestic mammal, for example, a dog, cat, horse, etc., or a production mammal, for example, a cattle, sheep, pig, etc.). "Donor subject" can also refer to more than one donor, for example, one or more humans or non-human animals or non-human mammals.
[0658] The term "endogenous" refers to a reference molecule or polypeptide that is naturally present in a cell. Similarly, when used in reference to the expression of a coding nucleic acid, the term refers to expression of a coding nucleic acid that is naturally contained within the cell and is not introduced exogenously. Similarly, when used in reference to a promoter sequence, the term refers to a promoter sequence that is naturally contained within the cell and is not introduced exogenously.
[0659] As used herein, the term "engineered cell" refers to a cell that has been altered in at least some way by human intervention, including, for example, by genetic alteration or modification, such that the engineered cell differs from a wild-type cell.
[0660] As used herein, the term "exogenous" in the context of expressed polynucleotides or polypeptides is intended to mean that the referenced molecule or referenced polypeptide is introduced into the cell of interest. The polypeptide can be introduced, for example, by introducing the encoding nucleic acid into the genetic material of the cell (such as by integration into a chromosome) or as non-chromosomal genetic material (such as a plasmid or expression vector). Thus, when used to refer to the expression of a coding nucleic acid, the term refers to the introduction of the coding nucleic acid into the cell in an expressible form.
[0661] An "exogenous" molecule is a molecule, construct, factor, etc. that is not normally present in a cell but that can be introduced into the cell by one or more genetic, biochemical, or other methods. "Normal presence in a cell" is determined relative to the specific developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is only present during embryonic development of a neuron is an exogenous molecule relative to an adult neuronal cell. An exogenous molecule can include, for example, a functional version of a malfunctioning endogenous molecule or a malfunctioning version of a functioning endogenous molecule.
[0662] Among other things, the exogenous molecule or factor can be a small molecule such as one generated by a combinatorial chemical process, or can be a macromolecule such as a protein, a nucleic acid, a carbohydrate, a lipid, a glycoprotein, a lipoprotein, a polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules. Nucleic acids include DNA and RNA and can be single-stranded or double-stranded; can be linear, branched, or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as nucleic acids that form triplexes. See, for example, U.S. Patent Nos. 5,176,996 and 5,422,251. Proteins include, but are not limited to, DNA binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases, and helicases.
[0663] Exogenous molecule or construct can be molecules of the same type as endogenous molecule, for example exogenous protein or nucleic acid.In such cases, exogenous molecule is introduced into the cell with a concentration higher than the endogenous molecule in the cell.In some cases, exogenous nucleic acid can comprise an infectious viral genome, be introduced into the plasmid or episome in the cell or the chromosome that does not exist usually in the cell.Being used for exogenous molecule is introduced into the method in the cell well known by persons skilled in the art and includes but not limited to lipid-mediated transfer (that is, liposome, comprises neutral and cationic lipid), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate coprecipitation, DEAE-dextran-mediated transfer and viral vector-mediated transfer.
[0664] As used herein, "fusion" includes gene therapy vectors comprising a retroviral vector pseudotyped with an engineered fusogenic agent comprising a G protein modified to include a targeting moiety and an F protein blinded to no longer recognize its cognate receptor. In some embodiments, the fusogenic protein complex is from a paramyxovirus, optionally wherein the paramyxovirus is Nipah virus. In some embodiments, the retroviral vector is a lentiviral vector.
[0665] For purposes of this disclosure, a "gene" includes a DNA region that encodes a gene product, as well as all DNA regions that regulate the production of a gene product, whether or not such regulatory sequences are adjacent to the coding and / or transcribed sequence. Thus, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, origins of replication, matrix attachment sites, and / or locus control regions.
[0666] "Gene expression" refers to the conversion of the information contained in a gene into a gene product. A gene product can be a direct transcription product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozymes, structural RNA, or any other type of RNA) or a protein produced by translation of mRNA. Gene products also include RNA modified by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristoylation, and / or glycosylation.
[0667] As used herein, term " genetic modification " and grammatical equivalents thereof can refer to one or more changes of nucleic acid (such as nucleic acid in organism genome).For example, genetic modification can refer to the change, addition and / or disappearance of gene or gene part or other nucleotide sequence.The cell of genetic modification can also refer to the cell with the gene or gene part added, disappeared and / or changed.The cell of genetic modification can also refer to the cell with the nucleotide sequence that is not a gene or gene part added.Genetic modification includes, for example, transient knock-in or knock-down mechanism, and causes the permanent knock-in, knock-down or knock-out mechanism of target gene or gene part or nucleotide sequence.Genetic modification includes, for example, transient knock-in, and causes the permanent knock-in mechanism of nucleotide sequence.Genetic modification also includes, for example, transcription reduced or increased, mRNA stability reduced or increased, translation reduced or increased and protein stability reduced or increased.
[0668] As used herein, the terms "implanting," "administering," "introducing," "implanting," and "transplanting," and grammatical variants thereof, are used interchangeably in the context of placing cells (e.g., cells described herein) into a subject by a method or approach that results in the localization or at least partial localization of the introduced cells at a desired site or systemic introduction (e.g., into the circulation). The cells can be implanted directly into the desired site, or administered by any suitable route that results in delivery to the desired site of the subject where at least a portion of the implanted cells or cellular components remain viable. The lifespan of the cells after administration to the subject can be as short as a few hours (e.g., twenty-four hours) to several days, or even up to several years. In some embodiments, the cells can also be administered (e.g., injected) to a location other than the desired site, such as in the brain or subcutaneously, for example in capsule form, to maintain the implanted cells at the implantation site and to avoid migration of the implanted cells.
[0669] The "HLA" or "human leukocyte antigen" or "HLA molecule" or "human leukocyte antigen molecule" complex is a gene complex that encodes the MHC proteins in the human body. These cell surface proteins that make up the HLA complex are responsible for regulating the immune response to antigens. There are two types of MHC in the human body, class I and class II molecules, "HLA-I" and "HLA-II," or "HLA-I molecule" and "HLA-II molecule." HLA-I includes three proteins, HLA-A, HLA-B, and HLA-C, which present peptides from the inside of the cell, and the antigens presented by the HLA-I complex attract killer T cells (also called CD8+ T cells or cytotoxic T cells). The HLA-I protein is associated with beta-2 microglobulin (B2M). HLA-II includes five proteins, HLA-DP, HLA-DM, HLA-DOB, HLA-DQ, and HLA-DR, which present antigens from the outside of the cell to T lymphocytes. This stimulates CD4+ cells (also known as helper T cells). It should be understood that the use of "MHC" or "HLA" is not meant to be limiting, as it depends on whether the gene is from human (HLA) or mouse (MHC). Therefore, when it comes to mammalian cells, these terms are used interchangeably herein.
[0670] As used herein to characterize cells, the term "low immunogenicity" generally means that such cells are less susceptible to the innate or adaptive immune rejection of the subject by which such cells are transplanted, for example, cells are less susceptible to allogeneic rejection by the subject by which such cells are transplanted. For example, relative to cells of the same cell type not comprising modification, such low immunogenic cells may be about 2.5%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99% or more less susceptible to the innate or adaptive immune rejection of the subject by which such cells are transplanted. In some embodiments, genome editing technology is used to regulate the expression of MHC I and MHC II genes, thereby promoting the generation of low immunogenic cells. In some embodiments, low immunogenic cells escape immune rejection in the allogeneic receptors of MHC mismatch. In some cases, when administered (for example, transplanting or implanting) to the allogeneic receptors of MHC mismatch, the differentiated cells produced by the low immunogenic stem cells outlined herein escape immune rejection. In some embodiments, the low immunogenic cells are protected from T cell-mediated adaptive immune rejection and / or innate immune cell rejection. Detailed descriptions of low immunogenic cells, methods for producing them, and methods for using them are provided in WO2016183041, filed May 9, 2015; WO2018132783, filed January 14, 2018; WO2018176390, filed March 20, 2018; WO2020018615, filed July 17, 2019; WO2020018620, filed July 17, 2019; and WO20200186391, filed March 20, 2020. PCT / US2020 / 44635, filed on July 31, 2020; WO2021022223, filed on July 31, 2020; WO2021041316, filed on August 24, 2020; WO2021222285, filed on April 27, 2021; and WO2021222285, filed on April 27, 2021, the disclosures of which, including the embodiments, sequence listing, and figures, are incorporated herein by reference in their entirety.
[0671] The low immunogenicity of a cell can be determined by evaluating the immunogenicity of the cell (such as the ability of the cell to trigger adaptive and innate immune responses or to avoid triggering such adaptive and innate immune responses). This immune response can be measured using a determination approved by those skilled in the art. In some embodiments, immune response determination measures the impact of low immunogenic cells on T cell proliferation, T cell activation, T cell killing, donor-specific antibody generation, NK cell proliferation, NK cell activation and macrophage activity. In some cases, low immunogenic cells and their derivatives experience a reduction in T cell and / or NK cell killing after being administered to a subject. In some cases, compared with unmodified or wild-type cells, cells and their derivatives show reduced macrophage phagocytosis. In some embodiments, compared with corresponding unmodified wild-type cells, low immunogenic cells trigger a reduced or weakened immune response in recipient subjects. In some embodiments, low immunogenic cells are non-immunogenic or can not trigger an immune response in recipient subjects.
[0672] The term percentage " identity " in the context of two or more nucleic acids or peptide sequences refers to that two or more sequences or subsequences have the specified percentage of identical Nucleotide or amino acid residue when comparing and comparing to obtain maximum corresponding relationship, as used a kind of or measured by range estimation in following sequence comparison algorithm (for example, BLASTP and BLASTN or the available other algorithms of technical personnel).According to application, percentage " identity " can be present in the region of compared sequences, for example, is present in functional domain, or is present in the total length of two sequences to be compared.For sequence comparison, usually a sequence serves as the reference sequence compared with test sequence.When using sequence comparison algorithm, test sequence and reference sequence are input in computer, specify subsequence coordinates (if necessary), and specify sequence algorithm program parameters.Then sequence comparison algorithm calculates the percentage sequence identity of test sequence relative to reference sequence based on the program parameters specified.
[0673] Optimal alignment of sequences for comparison can be achieved, for example, by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally, Ausubel et al., infra).
[0674] An example of an algorithm suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
[0675] As used herein, "immune signaling factor" in some cases refers to a molecule, protein, peptide, etc. that activates an immune signaling pathway.
[0676] As used herein, "immunosuppressive factors" or "immunomodulatory factors" or "tolerogenic factors" include hypoimmunity factors, complement inhibitors, and other factors that regulate or affect the ability of cells to be recognized by the immune system of the host or recipient subject after administration, transplantation or implantation. These may be combined with additional genetic modifications.
[0677] The terms "increased," "increase," "enhance," or "activate" are all used herein to generally mean an increase by a statistically significant amount; for the avoidance of any doubt, the terms "increased," "increase," "enhance," or "activate" mean an increase of at least 10% compared to a reference level, such as at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including a 100% increase or any increase between 10%-100%, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, or at least about 10-fold, or any increase between 2-fold and 10-fold, or more, compared to a reference level. In some embodiments, the reference level, also referred to as the basal level, is 0.
[0678] In some embodiments, the change is an indel. As used herein, "indel" refers to a mutation caused by insertion, deletion, or a combination thereof. As will be understood by those skilled in the art, unless the length of the indel is a multiple of three, the indel in the coding region of the genomic sequence will result in a frameshift mutation. In some embodiments, the change is a point mutation. As used herein, "point mutation" refers to the substitution of one of the substituted nucleotides. The gene editing (e.g., CRISPR / Cas) system disclosed herein can be used to induce indels or point mutations of any length in a target polynucleotide sequence.
[0679] As used herein, " knocking down " refers to that the expression of target mRNA or corresponding target protein is reduced. Usually relative to the level that exists after administration or expression of non-control molecules (for example, non-targeted control shRNA, siRNA or miRNA) that do not mediate RNA expression level reduction to report and strike low. In some embodiments, the knocking down of target gene is realized by conditional or inducible shRNA, conditional or inducible siRNA, conditional or inducible miRNA or conditional or inducible CRISPR interference (CRISPRi). In some embodiments, the knocking down of target gene is realized by protein-based methods (such as conditional or inducible degradation determinant (degron) method). In some embodiments, the knocking down of target gene is realized by genetic modification (including shRNA, siRNA, miRNA) or using gene editing system (such as CRISPR / Cas).
[0680] Generally, knocking out is assessed by using quantitative polymerase chain reaction (qPCR) amplification to measure mRNA levels or by measuring protein levels with western blot or enzyme-linked immunosorbent assay (ELISA). Analyzing protein levels provides an assessment of mRNA cutting and translation inhibition. Other techniques for measuring knocking out include RNA solution hybridization, nuclease protection, Northern hybridization, monitoring gene expression with microarray, antibody binding, radioimmunoassay, and fluorescence activated cell analysis. Based on the details described herein, those skilled in the art will readily understand how to use the gene editing system (e.g., CRISPR / Cas) disclosed herein to knock out a target polynucleotide sequence or a portion thereof.
[0681] " knock-in " or " knock-in " herein means the genetic modification caused by inserting a DNA sequence into the chromosome locus of a host cell. This causes the initiation or level increase of the expression of knock-in genes, gene parts or nucleic acid sequences inserted into products, such as the increase of RNA transcript levels and / or coded protein levels. As will be appreciated by those skilled in the art, this can be achieved in several ways, including inserting or adding one or more extra copies of a gene or part thereof into a host cell, or changing the regulatory components of an endogenous gene to increase protein expression, or inserting a specific nucleic acid sequence desired to be expressed. This can be achieved by modifying promoters, adding different promoters, adding enhancers, adding other regulatory elements or modifying other gene expression sequences.
[0682] As used herein, "knock out" or "knock-out" includes deleting all or part of a target polynucleotide sequence in a manner that interferes with the translation or function of the target polynucleotide sequence. For example, the target polynucleotide sequence can be changed by inducing insertions or deletions ("indels") in the target polynucleotide sequence (including in a functional domain (e.g., a DNA binding domain) of the target polynucleotide sequence), thereby achieving knockout. Based on the details described herein, those skilled in the art will readily understand how to use the gene editing system (e.g., CRISPR / Cas) disclosed herein to knock out a target polynucleotide sequence or a portion thereof.
[0683] In some embodiments, genetic modification or change cause the knockout of target polynucleotide sequence or its part or strike low.Knockout target polynucleotide sequence or its part using gene editing system (such as CRISPR / Cas) disclosed herein can be used for multiple applications.For example, for research purposes, the target polynucleotide sequence in knockout cell can be performed in vitro.For in vitro purpose, the target polynucleotide sequence in knockout cell can be used for treating or preventing the disease related to the expression of target polynucleotide sequence (for example, by knocking out the mutant allele in in vitro cell and these cells comprising the mutant allele of knockout are introduced into subject) or for changing the genotype or phenotype of cell.
[0684] "Regulation" of gene expression refers to a change in the level of gene expression. Regulation of expression can include, but is not limited to, gene activation and gene repression. Regulation can also be complete, i.e., wherein gene expression is completely inactivated or activated to wild-type levels or higher; or it can be partial, wherein gene expression is partially reduced or partially activated to a fraction of wild-type levels.
[0685] In additional or alternative aspects, the present disclosure contemplates changing the target polynucleotide sequence in any manner available to the skilled person, for example, using a nuclease system, such as a TAL effector nuclease (TALEN) or zinc finger nuclease (ZFN) system. It should be understood that although examples of methods utilizing CRISPR / Cas (e.g., Cas9 and Cas12a) and TALEN are described in detail herein, the present disclosure is not limited to the use of these methods / systems. Other targeting methods known to the skilled person for reducing or eliminating expression in target cells can be utilized herein. The methods provided herein can be used to change the target polynucleotide sequence in a cell. The present disclosure contemplates changing the target polynucleotide sequence in a cell for any purpose. In some embodiments, the target polynucleotide sequence in a cell is changed to produce a mutant cell. As used herein, a "mutant cell" refers to a cell having a resulting genotype that is different from its original genotype. In some cases, a "mutant cell" exhibits a mutant phenotype, for example, when a gene expression system (e.g., CRISPR / Cas system) of the present disclosure is used to change a gene that functions normally. In other cases, "mutant cells" exhibit a wild-type phenotype, such as when a gene expression system (e.g., CRISPR / Cas system) of the present disclosure is used to correct a mutant genotype. In some embodiments, the target polynucleotide sequence in a cell is altered to correct or repair a genetic mutation (e.g., to restore the normal phenotype of the cell). In some embodiments, the target polynucleotide sequence in a cell is altered to induce a genetic mutation (e.g., to disrupt the function of a gene or genomic element).
[0686] As used herein, the term "native cell" refers to a cell that has not been otherwise modified (eg, engineered). In some embodiments, a native cell is a naturally occurring wild-type or control cell.
[0687] The terms "operatively linked" or "operably linked" are used interchangeably with respect to the juxtaposition of two or more components, such as sequence elements, wherein the components are arranged so that both components function normally and allow the possibility that at least one component can mediate a function imposed on at least one other component. For example, a transcriptional regulatory sequence, such as a promoter, is operatively linked to a coding sequence if it controls the level of transcription of the coding sequence in response to the presence or absence of one or more transcriptional regulatory factors. A transcriptional regulatory sequence is typically operatively linked to a coding sequence in cis, but need not be directly adjacent to it. For example, an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even if they are not contiguous.
[0688] As used herein, "pluripotent stem cells" have the potential to differentiate into any one of the three germ layers: endoderm (e.g., gastric junction, gastrointestinal tract, lungs, etc.), mesoderm (e.g., muscle, bone, blood, urogenital tissue, etc.), or ectoderm (e.g., epidermal tissue and nervous system tissue). As used herein, the term "pluripotent stem cell" also encompasses "induced pluripotent stem cells" or "iPSCs," or a class of pluripotent stem cells derived from non-pluripotent cells. In some embodiments, pluripotent stem cells are produced or generated by cells that are not pluripotent cells. In other words, pluripotent stem cells can be the direct or indirect offspring of non-pluripotent cells. The example of parental cell includes somatic cells that have been reprogrammed to induce pluripotency, undifferentiated phenotypes in various ways. Such "iPS" or "iPSC" cells can be produced by inducing the expression of certain regulatory genes or by the exogenous application of certain proteins. Methods for inducing iPS cells are known in the art and are further described below. (See, e.g., Zhou et al., Stem Cells 27(11):2667-74 (2009); Huangfu et al., Nature Biotechnol. 26(7):795 (2008); Woltjen et al., Nature 458(7239):766-770 (2009); and Zhou et al., Cell Stem Cell 8:381-384 (2009); each of which is incorporated herein by reference in its entirety.) The generation of induced pluripotent stem cells (iPSCs) is outlined below. As used herein, "hiPSCs" are human induced pluripotent stem cells. In some embodiments, as used herein, "pluripotent stem cells" also encompass mesenchymal stem cells (MSCs) and / or embryonic stem cells (ESCs).
[0689] As used herein, "promoter", "promoter sequence" or "promoter region" refers to a DNA regulatory region / sequence that is capable of binding RNA polymerase and participating in initiating transcription of downstream coding or non-coding sequences. In some instances, the promoter sequence includes a transcription start site and extends upstream to include the minimum number of bases or elements necessary to initiate transcription at a detectable level above background. In some embodiments, the promoter sequence includes a transcription start site and a protein binding domain responsible for RNA polymerase binding. Eukaryotic promoters will often, but not always, contain a "TATA" box and a "CAT" box.
[0690] In some embodiments, engineered and low immunogenic cells are bred from primary T cells or their offspring. As used herein, the term "bred from primary T cells or their offspring" encompasses initial primary T cells and any subsequent offspring thereof separated from a donor subject. As used herein, the term "offspring" encompasses, for example, first generation offspring, i.e., directly derived from, obtained from, obtainable from, or can be derived from the offspring of initial primary T cells by, for example, traditional propagation methods. The term "offspring" also encompasses other generations, such as second, third, fourth, fifth, sixth, seventh, or more generations, i.e., derived from, obtained from, obtainable from, or can be derived from the cell generations of the previous generation by, for example, traditional propagation methods. The term "offspring" also encompasses cells modified due to the modification or change of initial primary T cells or their offspring.
[0691] The term "recipient patient" refers to an animal, for example, a human to whom treatment (including prophylactic treatment) with the cells described herein is provided. For treatment of those infections, conditions, or disease states that are specific to a particular animal, such as a human patient, the term patient refers to that particular animal. The term "recipient patient" also encompasses any vertebrate, including but not limited to mammals, reptiles, amphibians, and fish. However, advantageously, the recipient patient is a mammal, such as a human, or other mammal, such as a domestic mammal, for example, a dog, cat, horse, etc., or a production mammal, for example, a cow, sheep, pig, etc.
[0692] As used herein, the terms "regulatory sequence," "regulatory element," and "control element" are interchangeable and refer to polynucleotide sequences upstream (5' non-coding sequences), internal, or downstream (3' non-translated sequences) of a polynucleotide target to be expressed. Regulatory sequences influence, for example, but not limited to, the timing of transcription, the amount or level of transcription, RNA processing or stability, and / or translation of associated structural nucleotide sequences. Regulatory sequences may include activator binding sequences, enhancers, introns, polyadenylation recognition sequences, promoters, repressor binding sequences, stem-loop structures, translation initiation sequences, translation leader sequences, transcription termination sequences, translation termination sequences, primer binding sites, and the like. It is recognized that because the exact boundaries of regulatory sequences have not been completely defined in most cases, nucleotide sequences of different lengths may have the same regulatory or promoter activity.
[0693] As used herein, a "safe harbor locus" refers to a locus that allows expression of a transgenic or exogenous gene in a manner that enables newly inserted genetic elements to function predictably, and that does not cause changes in the host genome in a manner that is risky to the host cell. Exemplary "safe harbor" loci include, but are not limited to, the CCR5 gene, PPP1R12C (also known as AAVS1) gene, CLYBL gene, and / or Rosa gene (e.g., ROSA26).
[0694] As used herein, "target locus" refers to a locus that allows expression of a transgenic or exogenous gene. Exemplary "target locus" includes, but is not limited to, CXCR4 gene, albumin gene, SHS231 locus, F3 gene (also known as CD142), MICA gene, MICB gene, LRP1 gene (also known as CD91), HMGB1 gene, ABO gene, RHD gene, FUT1 gene and / or KDM5D gene (also known as HY). The exogenous polynucleotide encoding the exogenous gene can be inserted into the CDS region of B2M, CIITA, TRAC, TRBC, CCR5, F3 (i.e., CD142), MICA, MICB, LRP1, HMGB1, ABO, RHD, FUT1, KDM5D (i.e., HY), PDGFRa, OLIG2 and / or GFAP. The exogenous polynucleotide encoding the exogenous gene can be inserted into intron 1 or 2 of PPP1R12C (i.e., AAVS1) or CCR5. The exogenous polynucleotide encoding the exogenous gene can be inserted into exon 1, 2, or 3 of CCR5. The exogenous polynucleotide encoding the exogenous gene can be inserted into intron 2 of CLYBL. The exogenous polynucleotide encoding the exogenous gene can be inserted into a 500 bp window in Ch-4:58,976,613 (i.e., SHS231). The exogenous polynucleotide encoding the exogenous gene can be inserted into any suitable region of the safe harbor or target locus mentioned above that allows expression of the exogenous gene, including, for example, introns, exons, or coding sequence regions in the safe harbor or target locus.
[0695] As used herein, "target" can refer to a gene, portion of a gene, portion of a genome, or protein that is subject to regulatable reduced expression by the methods described herein.
[0696] As used herein, a "therapeutically effective amount" refers to an amount sufficient to provide a clinical benefit in the treatment and / or management of a disease, disorder, or condition. In some embodiments, a therapeutically effective amount is an amount sufficient to ameliorate, alleviate, stabilize, reverse, slow, attenuate, or delay the progression of a disease, disorder, or condition, or a symptom or side effect of the disease, disorder, or condition. In some embodiments, a therapeutically effective amount is also a clinically effective amount. In other embodiments, a therapeutically effective amount is not a clinically effective amount.
[0697] As used herein, the terms "treating" and "treatment" include administering a therapeutically or clinically effective amount of a cell as described herein to a subject such that at least one symptom of the subject's disease is alleviated or the disease is improved, e.g., a beneficial or desired therapeutic or clinical outcome. For the purposes of this technology, beneficial or desired therapeutic or clinical outcomes include, but are not limited to, alleviation of one or more symptoms, alleviation of the extent of the disease, a stable (i.e., non-worsening) disease state, a delay or slowing of disease progression, an improvement or alleviation of the disease state, and remission (whether partial or complete), whether detectable or undetectable. Treatment can refer to prolonged survival compared to expected survival if not receiving treatment. Thus, those skilled in the art recognize that treatment can improve the disease condition, but may not be a complete cure for the disease. In some embodiments, following treatment of a condition, disease, or disorder, one or more symptoms of the condition, disease, or disorder are alleviated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.
[0698] For purposes of this technology, beneficial or desired therapeutic or clinical results of disease treatment include, but are not limited to, alleviation of one or more symptoms, reduction in extent of disease, stable (i.e., not worsening) disease state, delay or slowing of disease progression, improvement or palliation of the disease state, and remission (whether partial or complete), whether detectable or undetectable.
[0699] "Vector" or "construct" is capable of transferring a gene sequence to a target cell. Generally, "vector construct," "expression vector," and "gene transfer vector" refer to any nucleic acid construct that can direct the expression of a gene of interest and that can transfer a gene sequence to a target cell. Thus, the term includes cloning and expression vehicles and integration vectors. Methods for introducing a vector or construct into a cell are well known to those skilled in the art and include, but are not limited to, lipid-mediated transfer (i.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate coprecipitation, DEAE-dextran-mediated transfer, and / or viral vector-mediated transfer.
[0700] In some embodiments, cells are engineered to have reduced or increased expression of one or more targets relative to unaltered or unmodified wild-type cells. In some embodiments, cells are engineered to have constitutive reduced or increased expression of one or more targets relative to unaltered or unmodified wild-type cells. In some embodiments, cells are engineered to have regulatable reduced or increased expression of one or more targets relative to unaltered or unmodified wild-type cells. In some embodiments, the cells comprise increased expression of CD47 relative to wild-type cells or control cells of the same cell type. In the context of cells, "wild type" or "wt" or "control" means any naturally occurring cell. Examples of wild-type or control cells include naturally occurring primary cells and T cells. However, for example, in the context of engineered cells, as used herein, "wild type" or "control" may also mean engineered cells that may contain nucleic acid changes that result in reduced expression of one or more MHC class I molecules and / or class II molecules and / or T cell receptors, but have not undergone a gene editing program that results in overexpression of CD47 protein. For example, as used herein, "wild type" or "control" means an engineered cell comprising reduced or knocked-out B2M, CIITA and / or TRAC expression. In addition, as used herein, "wild type" or "control" means an engineered cell comprising reduced or knocked-out B2M, CIITA, TRAC and / or TRBC expression. As used herein, "wild type" or "control" also means an engineered cell that may contain nucleic acid changes that cause overexpression of CD47 protein, but has not undergone a gene editing program that causes reduced expression of one or more MHC class I molecules and / or class II molecules and / or T cell receptors. In the context of iPSC or its progeny, "wild type" or "control" also means an iPSC or its progeny that may contain nucleic acid changes that cause pluripotency, but has not undergone a gene editing program disclosed herein that achieves reduced expression of one or more MHC class I molecules and / or class II molecules and / or T cell receptors and / or overexpression of CD47 protein. For example, as used herein, "wild type" or "control" means an iPSC or its progeny comprising reduced or knocked-out B2M, CIITA and / or TRAC expression. In addition, as used herein, "wild type" or "control" means an iPSC or its progeny comprising reduced or knocked-out B2M, CIITA, TRAC and / or TRBC expression. In the context of primary T cells or their progeny, "wild type" or "control" also means primary T cells or their progeny, which may contain nucleic acid changes that result in reduced expression of one or more MHC class I molecules and / or class II molecules and / or T cell receptors, but have not undergone a gene editing program that results in overexpression of CD47 protein.For example, as used herein, "wild type" or "control" means primary T cells or their descendants comprising B2M, CIITA and / or TRAC expressed for reduction or knockout. In addition, as used herein, "wild type" or "control" means primary T cells or their descendants comprising B2M, CIITA, TRAC and / or TRBC expressed for reduction or knockout. In addition, in the context of primary T cells or their descendants, "wild type" or "control" also means primary T cells or their descendants, which may contain nucleic acid changes that cause overexpression of CD47 protein, but have not undergone gene editing programs that cause reduction in expression of one or more MHC class I molecules and / or class II molecules and / or T cell receptors. In some embodiments, cells are engineered to have expression of one or more targets that are regulatable relative to cells of the same cell type that do not comprise modification. In some embodiments, wild-type cells or control cells are starting materials. In some embodiments, starting materials are otherwise modified or engineered to have expression of one or more genes that have been changed to generate engineered cells.
[0701] It should be noted that the claims may be drafted to exclude any optional elements. Therefore, this statement is intended to serve as an antecedent basis for the use of exclusive terms such as "only," "only," or the use of a "negative" limitation when referencing claim elements. As will be apparent to those skilled in the art after reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features that are easily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of this disclosure. Any enumerated method can be performed in the order of the events enumerated or in any other order that is logically possible. Although any methods and materials similar or equivalent to those described herein can also be used to practice or test this disclosure, representative illustrative methods and materials are now described.
[0702] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. Where a range of values is provided, it is understood that each intervening value between the upper and lower limits of the range (unless the context clearly indicates otherwise, up to one-tenth of the unit of the lower limit) and any other stated or intervening values within the stated range are encompassed within the present disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the present disclosure, as are any explicitly excluded limits within the stated ranges. Where the stated range includes one or both of the limits, ranges excluding one or both of those included limits are also encompassed within the present disclosure. Certain ranges are presented herein with values beginning with the term "about". The term "about" is used herein to provide literal support for the exact number that follows, as well as for numbers that are close to or approximately the number that follows the term. When determining whether a number is close to or approximately a specifically recited number, the close or approximate unrecited number may be a number that provides a substantial equivalent to the specifically recited number in the context presented. The term about is used herein to mean plus or minus ten percent (10%) of a value. For example, "about 100" means any number between 90 and 110.
[0703] All publications, patents and patent applications cited in this specification are incorporated herein by reference, to the extent that each individual publication, patent or patent application is specifically and individually indicated to be incorporated by reference. In addition, each publication, patent or patent application cited is incorporated herein by reference to disclose and describe the subject matter relevant to the publication cited. Reference to any publication is for its disclosure before the filing date and should not be construed as admitting that the technology described herein is not entitled to precede such publication due to prior art. In addition, the publication date provided may be different from the actual publication date, which may need to be confirmed independently.
[0704] Before further describing the present technology, it should be understood that the present technology is not limited to the specific embodiments described and, as such, may, of course, vary. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be limiting, as the scope of the present disclosure will be limited only by the appended claims. It should also be understood that the headings used herein are not limiting and are intended only to guide the reader, but the subject matter is generally applicable to the technology disclosed herein.
[0705] III. Specific Implementation Methods
[0706] A. Low immunogenic cells
[0707] In some embodiments, the present disclosure relates to pluripotent stem cells (e.g., pluripotent stem cells and induced pluripotent stem cells (iPSC)), differentiated cells (such as, but not limited to, T cells and NK cells) and primary cells (such as, but not limited to, primary T cells and primary NK cells) derived from such pluripotent stem cells. In some embodiments, pluripotent stem cells, differentiated cells (such as, but not limited to, T cells and NK cells) and primary cells (such as, but not limited to, primary T cells and primary NK cells) derived therefrom are engineered to achieve reduced expression or lack of expression of one or more MHC class I and / or MHC class II human leukocyte antigen molecules, and in some cases, to achieve reduced expression or lack of expression of T cell receptor (TCR) complexes. In some embodiments, in addition to reduced expression or lack of expression of one or more MHC class I and / or MHC class II human leukocyte antigen molecules, low immune (HIP) T cells and primary T cells overexpress CD47 and chimeric antigen receptor (CAR), and have reduced expression or lack of expression of T cell receptor (TCR) complexes. In some embodiments, the CAR comprises an antigen binding domain that binds to any one of the following: CD19, CD22, CD20, BCMA, EBV antigen, CD27, CD30, EBNA1, EBNA3A, BRLF1, BALF4, EBNA3C, LMP1, LMP2, LMP2A, LMP2B, BZLF1, BMLF1, gp350, and gH / gL. In some embodiments, the CAR is a CD19-specific CAR. In some embodiments, the CAR is a CD20-specific CAR. In some cases, the CAR is a BCMA-specific CAR. In some embodiments, the CAR is an EBV antigen-specific CAR. In some embodiments, the CAR is a CD27-specific CAR. In some embodiments, the CAR is a CD30-specific CAR. In some embodiments, the CAR is an EBNA1-specific CAR. In some embodiments, the CAR is an EBNA3A-specific CAR. In some embodiments, the CAR is a BRLF1-specific CAR. In some embodiments, the CAR is a BALF4-specific CAR. In some embodiments, the CAR is an EBNA3C-specific CAR. In some embodiments, the CAR is a LMP1-specific CAR. In some embodiments, the CAR is a LMP2-specific CAR. In some embodiments, the CAR is a LMP2A-specific CAR. In some embodiments, the CAR is a LMP2B-specific CAR. In some embodiments, the CAR is a BZLF1-specific CAR. In some embodiments, the CAR is a BMLF1-specific CAR. In some embodiments, the CAR is a gp350-specific CAR. In some embodiments, the CAR is a gH / gL-specific CAR.In some embodiments, CAR is a bispecific CAR. In some embodiments, the bispecific CAR is a CD19 / CD20 bispecific CAR. In some embodiments, the bispecific CAR is a CD19 / CD22 bispecific CAR. In some embodiments, the bispecific CAR is an EBV antigen / CD20 bispecific CAR. In some embodiments, the bispecific CAR is an EBV antigen / CD19 bispecific CAR. In some embodiments, the bispecific CAR is an EBV antigen / CD22 bispecific CAR. In some embodiments, the cell expresses a CD19-specific CAR and a different CAR, such as, but not limited to, a CD20-specific CAR, a BCMA-specific CAR, an EBV antigen-specific CAR, a CD27-specific CAR, a CD30-specific CAR, an EBNA1-specific CAR, an EBNA3A-specific CAR, a BRLF1-specific CAR, a BALF4-specific CAR, an EBNA3C-specific CAR, an LMP1-specific CAR, an LMP2-specific CAR, an LMP2A-specific CAR, an LMP2B-specific CAR, a BZLF1-specific CAR, a BMLF1-specific CAR, a gp350-specific CAR, and a gH / gL-specific CAR. In some embodiments, the cells express a CD20-specific CAR and a different CAR, such as, but not limited to, a CD19-specific CAR, a BCMA-specific CAR, an EBV antigen-specific CAR, a CD27-specific CAR, a CD30-specific CAR, an EBNA1-specific CAR, an EBNA3A-specific CAR, a BRLF1-specific CAR, a BALF4-specific CAR, an EBNA3C-specific CAR, an LMP1-specific CAR, an LMP2-specific CAR, an LMP2A-specific CAR, an LMP2B-specific CAR, a BZLF1-specific CAR, a BMLF1-specific CAR, a gp350-specific CAR, and a gH / gL-specific CAR. In some embodiments, the cells express an EBV antigen-specific CAR and a different CAR, such as, but not limited to, a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a BCMA-specific CAR, an EBV antigen-specific CAR, a CD27-specific CAR, a CD30-specific CAR, an EBNA1-specific CAR, an EBNA3A-specific CAR, a BRLF1-specific CAR, a BALF4-specific CAR, an EBNA3C-specific CAR, an LMP1-specific CAR, an LMP2-specific CAR, an LMP2A-specific CAR, an LMP2B-specific CAR, a BZLF1-specific CAR, a BMLF1-specific CAR, a gp350-specific CAR, and a gH / gL-specific CAR.In some embodiments, the cells express CD22-specific CAR and different CARs, such as, but not limited to, CD19-specific CAR, BCMA-specific CAR, EBV antigen-specific CAR, CD27-specific CAR, CD30-specific CAR, EBNA1-specific CAR, EBNA3A-specific CAR, BRLF1-specific CAR, BALF4-specific CAR, EBNA3C-specific CAR, LMP1-specific CAR, LMP2-specific CAR, LMP2A-specific CAR, LMP2B-specific CAR, BZLF1-specific CAR, BMLF1-specific CAR, gp350-specific CAR, and gH / gL-specific CAR. In some embodiments, the cells express BCMA-specific CAR and different CARs, such as, but not limited to, CD20-specific CAR and CD19-specific CAR. In some embodiments, the cells express BCMA-specific CAR and different CARs, such as, but not limited to, CD22-specific CAR and CD19-specific CAR. In some embodiments, the cell expression BCMA specific CAR and different CAR, such as but not limited to CD20 specific CAR, CD19 specific CAR, CD22 specific CAR, EBV antigen specific CAR, CD27 specific CAR, CD30 specific CAR, EBNA1 specific CAR, EBNA3A specific CAR, BRLF1 specific CAR, BALF4 specific CAR, EBNA3C specific CAR, LMP1 specific CAR, LMP2 specific CAR, LMP2A specific CAR, LMP2B specific CAR, BZLF1 specific CAR, BMLF1 specific CAR, gp350 specific CAR and gH / gL specific CAR. In some embodiments, compared with wild type or control cells (including unmodified or unmodified wild type cells or control cells), cell is modified or engineered. In some embodiments, wild type cells or control cells are starting materials. In some embodiments, starting materials are otherwise modified or engineered to have the expression of one or more genes changed to generate engineered cells.
[0708] In some embodiments, engineering and / or low immunity (HIP) T cells and primary T cells overexpress CD47 and chimeric antigen receptor (CAR), and include the genome modification of B2M genes. In some embodiments, engineering and / or low immunity (HIP) T cells and primary T cells overexpress CD47, and include the genome modification of CIITA genes. In some embodiments, engineering and / or low immunity (HIP) T cells and primary T cells overexpress CD47 and CAR, and include the genome modification of TRAC genes. In some embodiments, engineering and / or low immunity (HIP) T cells and primary T cells overexpress CD47 and CAR, and include the genome modification of TRAC genes. In some embodiments, engineering and / or low immunity (HIP) T cells and primary T cells overexpress CD47 and CAR, and include the genome modification of TRB genes. In some embodiments, engineering and / or low immunity (HIP) T cells and primary T cells overexpress CD47 and CAR, and include one or more genome modifications selected from the group consisting of B2M, CIITA, TRAC and TRB genes. In some embodiments, engineered and / or low immune (HIP) T cells and primary T cells overexpress CD47 and CAR and include genomic modifications of the B2M, CIITA, TRAC, and TRB genes. In some embodiments, the cells are B2M that also express CAR. - / - 、CIITA - / - 、TRAC - / - , CD47tg cells. In some embodiments, engineered and / or low immune (HIP) T cells are produced by differentiation of induced pluripotent stem cells (such as engineered and / or low immunogenicity induced pluripotent stem cells). In some embodiments, compared to wild-type or control cells (including unaltered or unmodified wild-type cells or control cells), cells are modified or engineered. In some embodiments, wild-type cells or control cells are starting materials. In some embodiments, starting materials are otherwise modified or engineered to have the expression of one or more genes that have been altered to generate engineered cells.
[0709] In some embodiments, engineered and / or hypoimmune (HIP) T cells and primary T cells are B2M cells that also express a CAR. - / - 、CIITA - / - 、TRB - / - , CD47tg cells. In some embodiments, the cells are B2M cells that also express CAR - / - 、CIITA - / - 、TRAC - / - 、TRB - / - , CD47tg cells. In certain embodiments, the cells are B2M cells that also express CAR 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失, CD47tg cells. In certain embodiments, the cells are B2M cells that also express CAR 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRB 插入缺失 / 插入缺失 , CD47tg cells. In certain embodiments, the cells are B2M cells that also express CAR 插入缺失 / 插入缺失 、CIITA 插入缺失 / 插入缺失 、TRAC 插入缺失 / 插入缺失 、TRB 插入缺失 / 插入缺失 , CD47tg cells. In some embodiments, the engineered or modified cells are pluripotent stem cells, induced pluripotent stem cells, NK cells differentiated from such pluripotent stem cells and induced pluripotent stem cells, T cells differentiated from such pluripotent stem cells and induced pluripotent stem cells, or primary T cells. Non-limiting examples of primary T cells include CD3+T cells, CD4+T cells, CD8+T cells, unsensitized T cells, regulatory T (Treg) cells, non-regulatory T cells, Th1 cells, Th2 cells, Th9 cells, Th17 cells, T follicular helper (Tfh) cells, cytotoxic T lymphocytes (CTL), effector T (Teff) cells, central memory T (Tcm) cells, effector memory T (Tem) cells, effector memory T cells expressing CD45RA (TEMRA cells), tissue-resident memory (Trm) cells, virtual memory T cells, innate memory T cells, memory stem cells (Tsc), γδT cells, and any other subtype of T cells. In some embodiments, primary T cells are selected from the group including cytotoxic T cells, helper T cells, memory T cells, regulatory T cells, tumor infiltrating lymphocytes and combinations thereof. Non-limiting examples of NK cells and primary NK cells include immature NK cells and mature NK cells. In some embodiments, compared with wild type or control cells (including unmodified or unmodified wild type cells or control cells), cells are modified or engineered. In some embodiments, wild type cells or control cells are starting materials. In some embodiments, starting materials are otherwise modified or engineered to have the expression of one or more genes changed to generate engineered cells.
[0710] In some embodiments, primary T cells are from the primary T cell bank of one or more donor subjects, and the donor subject is different from the recipient subject (for example, the patient to whom the cell is administered). Primary T cells can be obtained from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, 100 or more donor subjects and are brought together. Primary T cells can be obtained from 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 20 or more, 50 or more or 100 or more donor subjects and are brought together. In some embodiments, primary T cells are harvested from one or more individuals, and in some cases, primary T cells or primary T cell banks are cultured in vitro. In some embodiments, primary T cells or primary T cell banks are engineered to express CD47 exogenously and are cultured in vitro.
[0711] In certain embodiments, primary T cells or primary T cell banks are engineered to express chimeric antigen receptor (CAR).CAR can be any one known to persons skilled in the art.Available CAR includes those selected from the group consisting of CD19, CD20, CD22, BCMA, EBV antigens, CD27, CD30, EBNA1, EBNA3A, BRLF1, BALF4, EBNA3C, LMP1, LMP2, LMP2A, LMP2B, BZLF1, BMLF1, gp350 and gH / gL. In some cases, CAR is identical or equivalent to those used in the CAR-T cell therapy approved by the FDA (such as, but not limited to, those used in tisagenlecleucel and axicabtagene ciloleucel) or other CARs being studied in clinical trials.
[0712] In some embodiments, primary T cells or primary T cell banks are engineered to show reduced endogenous T cell receptor expression compared to unmodified primary T cells. In certain embodiments, primary T cells or primary T cell banks are engineered to show reduced CTLA-4, PD-1 or both CTLA-4 and PD-1 expression compared to unmodified primary T cells. Methods for genetically modifying cells including T cells are described in detail in, for example, WO2020 / 018620 and WO2016 / 183041, the disclosure of which is incorporated herein by reference as a whole, including tables, appendices, sequence tables, and accompanying drawings.
[0713] In some embodiments, the CAR-T cell comprises a CAR selected from the group consisting of: (a) a first generation CAR comprising an antigen binding domain, a transmembrane domain, and a signaling domain; (b) a second generation CAR comprising an antigen binding domain, a transmembrane domain, and at least two signaling domains; (c) a third generation CAR comprising an antigen binding domain, a transmembrane domain, and at least three signaling domains; (d) a fourth generation CAR comprising an antigen binding domain, a transmembrane domain, three or four signaling domains, and a domain that induces cytokine gene expression upon successful signaling by the CAR.
[0714] In some embodiments, a CAR-T comprises a CAR comprising an antigen binding domain, a transmembrane domain, and one or more signaling domains. In some embodiments, the CAR further comprises a linker. In some embodiments, the CAR comprises a CD19 antigen binding domain. In some embodiments, the CAR comprises an EBV antigen binding domain. In some embodiments, the CAR comprises a CD27 binding domain. In some embodiments, the CAR comprises a CD30 binding domain. In some embodiments, the CAR comprises an EBNA1 binding domain. In some embodiments, the CAR comprises an EBNA3A binding domain. In some embodiments, the CAR comprises a BRLF1 binding domain. In some embodiments, the CAR comprises a BALF4 binding domain. In some embodiments, the CAR comprises an EBNA3C binding domain. In some embodiments, the CAR comprises an LMP1 binding domain. In some embodiments, the CAR comprises an LMP2 binding domain. In some embodiments, the CAR comprises an LMP2A binding domain. In some embodiments, the CAR comprises an LMP2B binding domain. In some embodiments, the CAR comprises a BZ LF1 binding domain. In some embodiments, the CAR comprises a BMLF1 binding domain. In some embodiments, CAR comprises a gp350 binding domain. In some embodiments, CAR comprises a gH / gL binding domain. In some embodiments, CAR comprises a CD28 or CD8α transmembrane domain. In some embodiments, CAR comprises a CD8α signal peptide. In some embodiments, CAR comprises a Whitlow linker GSTSGSGKPGS GEGSTKG (SEQ ID NO: 15). In some embodiments, the antigen binding domain of CAR is selected from the group including but not limited to the following: (a) antigen binding domains targeting tumor cell characteristic antigens; (b) antigen binding domains targeting T cell characteristic antigens; (c) antigen binding domains targeting autoimmune diseases / disorders and / or inflammatory diseases / disorders characteristic antigens; (d) antigen binding domains targeting aging cell characteristic antigens; (e) antigen binding domains targeting infectious disease characteristic antigens; and (f) antigen binding domains that bind to cell surface antigens of cells.
[0715] In some embodiments, CAR further comprises one or more linkers. The form of scFv is typically two variable domains connected by a flexible peptide sequence or "linker", in the direction of VH-linker-VL or VL-linker-VH. According to the instructions, any suitable linker known to those skilled in the art can be used for CAR. Examples of suitable linkers include, but are not limited to, GS-based linker sequences and Whitlow linkers GSTSGSGKPGSGEGSTKG (SEQ ID NO: 15). In some embodiments, the linker is a GS or gly-ser linker. An exemplary gly-ser polypeptide linker comprises the amino acid sequence Ser (Gly4Ser) n , and (Gly4Ser) n and / or (Gly4Ser3) n In some embodiments, n=1. In some embodiments, n=2. In some embodiments, n=3, i.e., Ser(Gly4Ser)3. In some embodiments, n=4, i.e., Ser(Gly4Ser)4. In some embodiments, n=5. In some embodiments, n=6. In some embodiments, n=7. In some embodiments, n=8. In some embodiments, n=9. In some embodiments, n=10. Another exemplary gly-ser polypeptide linker comprises the amino acid sequence Ser(Gly4Ser) n In some embodiments, n=1. In some embodiments, n=2. In some embodiments, n=3. In another embodiment, n=4. In some embodiments, n=5. In some embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly4Ser)n. In some embodiments, n=1. In some embodiments, n=2. In some embodiments, n=3. In some embodiments, n=4. In some embodiments, n=5. In some embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly3Ser)n. n In some embodiments, n=1. In some embodiments, n=2. In some embodiments, n=3. In some embodiments, n=4. In another embodiment, n=5. In yet another embodiment, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly4Ser3) n In some embodiments, n=1. In some embodiments, n=2. In some embodiments, n=3. In some embodiments, n=4. In some embodiments, n=5. In some embodiments, n=6. Another exemplary gly-ser polypeptide linker comprises (Gly3Ser) nIn some embodiments, n = 1. In some embodiments, n = 2. In some embodiments, n = 3. In some embodiments, n = 4. In another embodiment, n = 5. In yet another embodiment, n = 6.
[0716] In some embodiments, the antigen binding domain is selected from the group consisting of an antibody, an antigen binding portion or fragment thereof, a scFv, and a Fab. In some embodiments, the antigen binding domain binds to CD19, CD20, CD22, BCMA, an EBV antigen, CD27, CD30, EBNA1, EBNA3A, BRLF1, BALF4, EBNA3C, LMP1, LMP2, LMP2A, LMP2B, BZLF1, BMLF1, gp350, or gH / gL. In some embodiments, the antigen binding domain is an anti-CD19 scFv, such as, but not limited to, FMC63. In some embodiments, the antigen binding domain is an anti-CD20 scFv. In some embodiments, the antigen binding domain is an anti-CD22 scFv. In some embodiments, the antigen binding domain is an anti-BCMA scFv. In some embodiments, the antigen binding domain is an anti-EBV antigen scFv. In some embodiments, the antigen binding domain is an anti-CD27 scFv. In some embodiments, the antigen-binding domain is an anti-CD30 scFv. In some embodiments, the antigen-binding domain is an anti-EBNA1 scFv. In some embodiments, the antigen-binding domain is an anti-EBNA3A scFv. In some embodiments, the antigen-binding domain is an anti-BRLF1 scFv. In some embodiments, the antigen-binding domain is an anti-BALF4 scFv. In some embodiments, the antigen-binding domain is an anti-EBNA3C scFv. In some embodiments, the antigen-binding domain is an anti-LMP1 scFv. In some embodiments, the antigen-binding domain is an anti-LMP2 scFv. In some embodiments, the antigen-binding domain is an anti-LMP2A scFv. In some embodiments, the antigen-binding domain is an anti-LMP2B scFv. In some embodiments, the antigen-binding domain is an anti-BZLF1 scFv. In some embodiments, the antigen-binding domain is an anti-BMLF1 scFv. In some embodiments, the antigen-binding domain is an anti-gp350 scFv. In some embodiments, the antigen binding domain is an anti-gH / gL scFv.
[0717] In some embodiments, the transmembrane domain includes a transmembrane domain selected from the group comprising the transmembrane regions of TCRα, TCRβ, TCRζ, CD3ε, CD3γ, CD3δ, CD3ζ, CD4, CD5, CD8α, CD8β, CD9, CD16, CD28, CD45, CD22, CD33, CD34, CD37, CD40, CD40L / CD154, CD45, CD64, CD80, CD86, OX40 / CD134, 4-1BB / CD137, CD154, FcεRIγ, VEGFR2, FAS, FGFR2B, and functional variants thereof.
[0718] In some embodiments, the signaling domain of CAR includes a costimulatory domain. For example, the signaling domain may contain a costimulatory domain. Alternatively, the signaling domain may contain one or more costimulatory domains. In certain embodiments, the signaling domain includes one costimulatory domain. In other embodiments, the signaling domain includes multiple costimulatory domains. In some cases, when CAR comprises two or more costimulatory domains, the two costimulatory domains are not the same. In some embodiments, the costimulatory domain includes two different costimulatory domains. In some embodiments, the one costimulatory domain enhances cytokine production during T cell activation, CAR-T cell proliferation and / or CAR-T cell persistence. In some embodiments, the multiple costimulatory domains enhance cytokine production during T cell activation, CAR-T cell proliferation and / or CAR-T cell persistence.
[0719] As described herein, the fourth generation CAR may contain an antigen binding domain, a transmembrane domain, three or four signaling domains and a domain that induces cytokine gene expression after successful signal transduction of CAR. In some cases, the cytokine gene is an endogenous or exogenous cytokine gene of a low immunogenic cell. In some cases, the cytokine gene encodes a proinflammatory cytokine. In some embodiments, the proinflammatory cytokine is selected from the group including IL-1, IL-2, IL-9, IL-12, IL-18, TNF, IFN-γ and its functional fragment. In some embodiments, the domain that induces cytokine gene expression after successful signal transduction of CAR comprises a transcription factor or its functional domain or fragment.
[0720] In some embodiments, CAR includes CD3 zeta (CD3 ζ) domain or activation motif (ITAM) based on immunoreceptor tyrosine or its functional variant. In some embodiments, CAR includes (i) CD3 ζ domain or activation motif (ITAM) based on immunoreceptor tyrosine or its functional variant;And (ii) CD28 domain or 4-1BB domain or its functional variant. In other embodiments, CAR includes (i) CD3 ζ domain or activation motif (ITAM) based on immunoreceptor tyrosine or its functional variant;(ii) CD28 domain or its functional variant;And (iii) 4-1BB domain or CD134 domain or its functional variant. In certain embodiments, CAR includes (i) CD3 ζ domain or activation motif (ITAM) based on immunoreceptor tyrosine or its functional variant;(ii) CD28 domain or its functional variant;(iii) 4-1BB domain or CD134 domain or its functional variant;And (iv) cytokine or costimulatory ligand transgene. In some embodiments, the CAR comprises (i) an anti-CD19 scFv; (ii) a CD8α hinge and transmembrane domain or a functional variant thereof; (iii) a 4-1BB co-stimulatory domain or a functional variant thereof; and (iv) a CD3ζ signaling domain or a functional variant thereof.
[0721] Methods for introducing CAR constructs or producing CAR-T cells are well known to those skilled in the art. Detailed descriptions can be found in, for example, Vormittag et al., Curr Op...
Claims
1. A method for treating a patient with Epstein-Barr virus (EBV) infection, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen (HLA) molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more chimeric antigen receptors (CARs), wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or an EBV antigen.
2. A method for treating a patient with EBV infection, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19 or CD22.
3. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
4. A method for treating multiple sclerosis in a patient suspected of having multiple sclerosis or who has been diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of beta-2-microglobulin (B2M) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens.
5. A method for treating multiple sclerosis in a patient suspected of having multiple sclerosis or who has been diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and MHC class II transactivator (CIITA) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens.
6. A method for treating multiple sclerosis in a patient suspected of having multiple sclerosis or who has been diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and MHC class II transactivator (CIITA) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens.
7. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens.
8. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
9. A method for treating multiple sclerosis in a patient suspected of having multiple sclerosis or who has been diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TCR-α (TRAC) and / or TCR-β (TRB) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
10. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
11. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
12. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens.
13. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens.
14. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
15. A method for treating multiple sclerosis in a patient suspected of having multiple sclerosis or who has been diagnosed with multiple sclerosis, comprising assessing the patient for EBV infection and optionally multiple sclerosis and / or diagnosing the patient with EBV infection and optionally multiple sclerosis, and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or an EBV antigen.
16. The method of any one of claims 1-15, wherein the one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain, or an IgG4 hinge domain.
17. The method of claim 15, wherein the one or more CARs comprise a CD8 alpha hinge domain having the amino acid sequence of SEQ ID NO:
9.
18. The method of claim 15, wherein the one or more CARs comprise a CD28 hinge domain having an amino acid sequence of SEQ ID NO: 10 or 113.
19. The method of claim 15, wherein the one or more CARs comprise an IgG4 hinge domain having the amino acid sequence of SEQ ID NO: 11 or 12.
20. The method of any one of claims 1-19, wherein the one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
21. The method of claim 20, wherein the one or more CARs comprise a CD8α transmembrane domain having an amino acid sequence of SEQ ID NO:
14.
22. The method of claim 20, wherein the one or more CARs comprise a CD28 transmembrane domain having an amino acid sequence of SEQ ID NO: 15 or 114.
23. The method of any one of claims 1-22, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain, a CD28 co-stimulatory domain, or a CD3ζ signaling domain.
24. The method of claim 23, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain having the amino acid sequence of SEQ ID NO:
16.
25. The method of claim 23, wherein the one or more CARs comprise a CD28 co-stimulatory domain having the amino acid sequence of SEQ ID NO:
17.
26. The method of claim 23, wherein the one or more CARs comprise a CD3 zeta signaling domain having an amino acid sequence of SEQ ID NO: 18 or 115.
27. The method of any one of claims 1-26, wherein the one or more CARs comprise an extracellular ligand binding domain comprising an scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has an scFv sequence comprising a heavy chain and light chain sequence of any one of SEQ ID NOs: 129-132 or 135-172.
28. The method of any one of claims 1-27, wherein the one or more CARs have a sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134.
29. A method of treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis and administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD20 CAR having a CDR sequence of SEQ ID NO:
37.
30. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an EBV antigen CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172.
31. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise a CD19 CAR having a CDR sequence of SEQ ID NO:
117.
32. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise a CD22 CAR having a CDR sequence of SEQ ID NO:
45.
33. A method for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA, TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO:
45.
34. A method for treating multiple sclerosis in a patient suspected of having or having been diagnosed with multiple sclerosis, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133, or 134, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising a heavy chain and light chain sequence of any one of SEQ ID NOs: 129-132 or 135-172.
35. The method of any one of claims 1-34, further comprising assessing the patient for EBV infection and optionally multiple sclerosis and / or diagnosing the patient with EBV infection and optionally multiple sclerosis prior to administering the engineered T cell population to the patient.
36. The method of claim 35, wherein the diagnosis comprises assessing the patient for EBV infection.
37. The method of claim 35 or 36, wherein the diagnosis comprises assessing the patient for multiple sclerosis.
38. The method of any one of claims 1-37, wherein the treatment prevents multiple sclerosis.
39. The method of any one of claims 1-37, wherein the treatment treats multiple sclerosis.
40. The method of any one of claims 1-39, wherein the patient suffering from the EBV infection has been diagnosed with multiple sclerosis.
41. The method of any one of claims 1-40, wherein the multiple sclerosis is relapsing-remitting multiple sclerosis, progressive-relapsing multiple sclerosis, primary progressive multiple sclerosis, or secondary progressive multiple sclerosis.
42. The method of any one of claims 1-41, wherein the patient experiences remission of multiple sclerosis following administration of the engineered T cells.
43. The method of any one of claims 1-42, wherein the patient suffering from the EBV infection is receiving treatment for the EBV infection.
44. The method of any one of claims 1-43, wherein the patient suffering from the EBV infection has an active EBV infection.
45. The method of any one of claims 1-43, wherein the patient suffering from the EBV infection has an inactive EBV infection.
46. The method of any one of claims 1-45, wherein the patient experiences a reduction in EBV infection following administration of the engineered T cells, optionally wherein the reduction in EBV infection is characterized by a reduction in viral load.
47. The method of any one of claims 1-46, wherein the treatment prevents the transition of EBV infection from an inactive to an active EBV infection.
48. The method of any one of claims 1-47, wherein the method results in B cell depletion.
49. A method according to any one of claims 1-48, wherein the engineered T cells comprise one or more of a CD19-specific CAR, a CD20-specific CAR, a CD22-specific CAR, a BCMA-specific CAR, a GPRC5D-specific CAR, a CD38-specific CAR, a CD70-specific CAR, a CD79b-specific CAR, and an EBV antigen-specific CAR.
50. A method for treating an autoimmune disease in a patient suspected of having or having been diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
51. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
52. A method for treating an autoimmune disease in a patient suspected of having or having been diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
53. A method for treating an autoimmune disease in a patient suspected of having or having been diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
54. A method for treating an autoimmune disease in a patient suspected of having or having been diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
55. A method for treating an autoimmune disease in a patient suspected of having or having been diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
56. The method of any one of claims 50-55, wherein the one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain, or an IgG4 hinge domain.
57. The method of claim 56, wherein the one or more CARs comprise a CD8 alpha hinge domain having the amino acid sequence of SEQ ID NO:
9.
58. The method of claim 56, wherein the one or more CARs comprise a CD28 hinge domain having an amino acid sequence of SEQ ID NO: 10 or 113.
59. The method of claim 56, wherein the one or more CARs comprise an IgG4 hinge domain having an amino acid sequence of SEQ ID NO: 11 or 12.
60. The method of any one of claims 50-59, wherein the one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
61. The method of claim 60, wherein the one or more CARs comprise a CD8α transmembrane domain having an amino acid sequence of SEQ ID NO:
14.
62. The method of claim 60, wherein the one or more CARs comprise a CD28 transmembrane domain having an amino acid sequence of SEQ ID NO: 15 or 114.
63. The method of any one of claims 50-62, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain, a CD28 co-stimulatory domain, or a CD3ζ signaling domain.
64. The method of claim 63, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain having an amino acid sequence of SEQ ID NO:
16.
65. The method of claim 63, wherein the one or more CARs comprise a CD28 co-stimulatory domain having the amino acid sequence of SEQ ID NO:
17.
66. The method of claim 63, wherein the one or more CARs comprise a CD3 zeta signaling domain having an amino acid sequence of SEQ ID NO: 18 or 115.
67. The method of any one of claims 50-66, wherein the one or more CARs comprise an extracellular ligand binding domain comprising an scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has an scFv sequence comprising a heavy chain and light chain sequence of any one of SEQ ID NOs: 129-132 or 135-172.
68. The method of any one of claims 50-67, wherein the one or more CARs have a sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133 or 134.
69. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
70. The method of claim 69, further comprising assessing the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease.
71. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
72. The method of any one of claims 69-71, wherein the encoded CD19CAR has a corresponding amino acid sequence listed in SEQ ID NO: 117, or has at least 80% identity (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity) to the amino acid sequence listed in SEQ ID NO: 117, having the following components: CD8α signal peptide, FMC63 scFv (VL-Whitlow linker-VH), CD8α hinge domain, CD8α transmembrane domain, 4-1BB co-stimulatory domain and CD3ζ signaling domain.
73. The method of any one of claims 69-72, wherein the encoded CD22 CAR has a corresponding amino acid sequence listed in SEQ ID NO: 45 or has at least 80% identity (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity) to the amino acid sequence listed in SEQ ID NO:
45.
74. A method for treating an autoimmune disease in a patient suspected of having or having been diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an EBV antigen-specific CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172, and wherein the autoimmune disease is multiple sclerosis.
75. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
76. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
77. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
78. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
79. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
80. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
81. A method for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, comprising administering to the patient a population of engineered T cells, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
82. The method of any one of claims 74-81, further comprising assessing the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease prior to administering the engineered T cell population to the patient.
83. The method of any one of claims 74-82, wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, and a pulmonary condition.
84. The method of any one of claims 74-83, wherein the patient is suspected of having or has been diagnosed with an EBV infection.
85. The method of any one of claims 74-84, wherein the patient is suspected of having or has been diagnosed with multiple sclerosis.
86. The method of any one of claims 1-85, further comprising administering to the patient a second, third, fourth, fifth, or sixth dose of the engineered T cells.
87. The method of claim 86, wherein the CAR is the same in one or more of the first, second, third, fourth, fifth and / or sixth doses of engineered T cells.
88. The method of claim 86, wherein the CAR is different in one or more of the first, second, third, fourth, fifth and / or sixth doses of engineered T cells.
89. The method of any one of claims 1-88, wherein the CAR has a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72, or 118, or wherein the CAR has a scFv sequence comprising a heavy chain and light chain sequence of any one of SEQ ID NOs: 129-132 or 135-172.
90. The method of any one of claims 1-89, wherein the CAR has a sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133, and 134.
91. The method of any one of claims 1-90, wherein the engineered T cells comprise a CD19-specific CAR and a CD20-specific CAR.
92. The method of claim 91, wherein the CD19-specific CAR has a CDR sequence of SEQ ID NO: 117, and the CD22 CAR has a CDR sequence of SEQ ID NO:
45.
93. The method of claim 92, wherein the CD19-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
94. The method of claim 92, wherein the CD19-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
95. The method of claim 92, wherein the CD19-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
96. The method of any one of claims 91-95, wherein the CD19 CAR T cells and CD20 CAR T cells are administered simultaneously.
97. The method of any one of claims 91-95, wherein the CD19 CAR+ T cells and CD20 CAR+ T cells are administered sequentially.
98. The method of claim 97, wherein the CD19 CAR+ T cells are administered prior to administration of the CD20 CAR+ T cells.
99. The method of claim 97, wherein the CD20CAR+T cells are administered prior to administration of the CD19CAR+T cells.
100. The method of any one of claims 91-99, wherein the number of cells administered in a therapeutically effective amount of the CD19 and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
101. The method of any one of claims 91-100, wherein the number of cells administered in a therapeutically effective amount of the CD19 and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
102. The method of any one of claims 1-101, wherein the engineered T cells comprise an EBV antigen-specific CAR and a CD20-specific CAR.
103. The method of claim 102, wherein the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
104. The method of claim 102, wherein the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
105. The method of claim 102, wherein the EBV antigen-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
106. The method of any one of claims 102-106, wherein the EBV antigen CAR T cells and CD20 CAR T cells are administered simultaneously.
107. The method according to any one of claims 102-106, wherein the EBV antigen CAR+T cells and CD20CAR+T cells are administered sequentially.
108. The method of claim 107, wherein the EBV antigen CAR+T cells are administered before the CD20CAR+T cells.
109. The method of claim 107, wherein the CD20 CAR+ T cells are administered before the EBV antigen CAR+ T cells.
110. The method of any one of claims 102-109, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
111. The method of any one of claims 102-109, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
112. A method according to any one of claims 1-111, wherein the engineered T cells comprise an EBV antigen-specific CAR and a CD19-specific CAR.
113. The method of claim 112, wherein the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bicistronic polynucleotide.
114. The method of claim 113, wherein the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bispecific CAR.
115. The method of claim 113, wherein the EBV antigen-specific CAR and the CD19-specific CAR are encoded by two separate polynucleotides.
116. A method according to any one of claims 113-115, wherein the EBV antigen CAR T cells and CD19 CAR T cells are administered simultaneously.
117. The method according to any one of claims 113-115, wherein the EBV antigen CAR+T cells and CD19CAR+T cells are administered sequentially.
118. The method of claim 117, wherein the EBV antigen CAR+T cells are administered before the CD19CAR+T cells.
119. The method of claim 117, wherein the CD19 CAR+T cells are administered before the EBV antigen CAR+T cells.
120. The method of any one of claims 113-119, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD19 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
121. The method of any one of claims 113-119, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD19 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
122. A method according to any one of claims 1-121, wherein the engineered T cells comprise an EBV antigen-specific CAR and a CD22-specific CAR.
123. The method of claim 122, wherein the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bicistronic polynucleotide.
124. The method of claim 122, wherein the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bispecific CAR.
125. The method of claim 122, wherein the EBV antigen-specific CAR and the CD22-specific CAR are encoded by two separate polynucleotides.
126. A method according to any one of claims 122-125, wherein the EBV antigen CAR T cells and CD22 CAR T cells are administered simultaneously.
127. The method according to any one of claims 122-125, wherein the EBV antigen CAR+T cells and CD22CAR+T cells are administered sequentially.
128. The method of claim 127, wherein the EBV antigen CAR+T cells are administered before the CD22CAR+T cells.
129. The method of claim 127, wherein the CD22 CAR+T cells are administered before the EBV antigen CAR+T cells.
130. The method of any one of claims 122-129, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD22 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
131. The method of any one of claims 122-129, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD22 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
132. The method of any one of claims 1-131, wherein the engineered T cells are primary T cells, propagated from primary T cells or their progeny, or derived from T cells differentiated from iPSCs or their progeny.
133. The method of any one of claims 1-132, wherein the engineered T cells are differentiated cells derived from induced pluripotent stem cells or their progeny.
134. The method of claim 133, wherein the differentiated cells are T cells or natural killer (NK) cells.
135. The method of any one of claims 1-134, wherein the engineered T cell is a primary T cell or a progeny of a primary immune cell, optionally wherein the progeny of a primary immune cell is a T cell or a NK cell.
136. The method of any one of claims 1-135, wherein the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules relative to unaltered or unmodified wild-type or control cells.
137. The method of any one of claims 1-136, wherein the engineered T cells comprise reduced expression of one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
138. The method of any one of claims 1-137, wherein the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules and one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
139. The method of any one of claims 1-138, wherein the engineered T cells comprise reduced expression of B2M and / or CIITA relative to unaltered or unmodified wild-type or control cells.
140. The method of claim 139, wherein the engineered T cells do not express B2M and / or CIITA.
141. The method of any one of claims 1-140, wherein the engineered T cells comprise reduced expression of TRAC and / or TRB.
142. The method of claim 141, wherein the engineered T cells do not express TRAC and / or TRB.
143. The method of any one of claims 1-142, wherein the engineered T cells comprise reduced expression of TRAC.
144. The method of claim 143, wherein the engineered T cells do not express TRAC.
145. The method of any one of claims 1-144, wherein the engineered T cells comprise reduced expression of TRB.
146. The method of claim 145, wherein the engineered T cells do not express TRB.
147. The method of any one of claims 1-146, wherein the engineered T cells comprise reduced expression of TRAC and TRB.
148. The method of any one of claims 1-147, wherein the one or more tolerogenic factors are selected from the group consisting of CD47, CD24, CD27, CD35, CD46, CD55, CD59, CD200, HLA-C, HLA-E, HLA-E heavy chain, HLA-G, PD-L1, IDO1, CTLA4-Ig, C1 inhibitor, IL-10, IL-35, FasL, CCL21, CCL22, Mfge8 and A20 / TNFAIP3, CD39, CR1, HLA-F, IL15-RF, MANF, Serpinb9, optionally wherein the one or more tolerogenic factors include CD47.
149. The method of any one of claims 1-148, wherein the CD19-specific CAR and the one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
150. The method of any one of claims 1-148, wherein the CD19-specific CAR and the CD47 are encoded by a single bicistronic polynucleotide.
151. The method of any one of claims 1-148, wherein the CD20-specific CAR and the one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
152. The method of any one of claims 1-148, wherein the CD20-specific CAR and the CD47 are encoded by a single bicistronic polynucleotide.
153. The method of any one of claims 1-152, wherein one or more of the first, second and / or third exogenous polynucleotides or the bicistronic polynucleotides are inserted into a first, second and / or third specific locus of at least one allele of the cell.
154. The method of claim 153, wherein the first, second and / or third specific loci are selected from the group consisting of a safe harbor locus, a target locus, an RHD locus, a B2M locus, a CIITA locus, a TRAC locus and a TRB locus.
155. The method of claim 154, wherein the safe harbor locus is selected from the group consisting of: a CCR5 locus, a PPP1R12C locus, a CLYBL locus, and a Rosa locus.
156. The method of claim 154, wherein the target locus is selected from the group consisting of a CXCR4 locus, an ALB locus, a SHS231 locus, a F3 (CD142) locus, a MICA locus, a MICB locus, a LRP1 (CD91) locus, a HMGB1 locus, an ABO locus, a FUT1 locus, and a KDM5D locus.
157. The method of any one of claims 1-156, wherein the first, second and / or third exogenous polynucleotide or the bicistronic polynucleotide is introduced into the engineered T cells using a gene therapy vector or a transposase system selected from the group consisting of a transposase, a PiggyBac transposon, a Sleeping Beauty (SB11) transposon, a Mos1 transposon and a Tol2 transposon.
158. The method of claim 157, wherein the gene therapy vector is a retrovirus or a fusion.
159. The method of any one of claims 1-158, wherein the first, second and / or third exogenous polynucleotide or the bicistronic polynucleotide is introduced into the engineered T cell using CRISPR / Cas gene editing.
160. The method of claim 159, wherein the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of Cas9, Cas12a, and Cas12b.
161. The method or dosage regimen of claim 160, wherein the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of: a. optionally selected from the group consisting of Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3 and GSU0054; b. optionally selected from the group consisting of Cas9, Csn2 and Cas4; c. optionally selected from the group consisting of Cas10, Csm2, Cmr5, Cas10, Csx11 and Csx10; d. Optionally Csf1; e. optionally selected from the group consisting of Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e) and CasY (Cas12d); and f. Optionally selected from the group consisting of Cas13, Cas13a, C2c2, Cas13b, Cas13c and Cas13d.
162. The method of any one of claims 159-161, wherein the CRISPR / Cas gene editing is performed ex vivo from a donor subject.
163. The method of any one of claims 159-162, wherein the first, second and / or third exogenous polynucleotide or the bicistronic polynucleotide is introduced into the engineered T cell using a lentiviral vector.
164. The method of any one of claims 1-163, wherein the engineered T cells evade NK cell-mediated cytotoxicity upon administration to the patient.
165. The method of any one of claims 1-164, wherein the engineered T cells are protected from cell lysis by mature NK cells upon administration to the patient.
166. The method of any one of claims 1-165, wherein the engineered T cells evade macrophage-mediated cytotoxicity, optionally wherein the macrophage-mediated cytotoxicity involves phagocytosis and / or reactive oxygen species.
167. The method of any one of claims 1-166, wherein the engineered T cells do not induce an immune response against the cells upon administration to the patient.
168. The method of any one of claims 1-167, wherein the administration is selected from the group consisting of intravenous injection, intramuscular injection, intravascular injection, and transplantation.
169. The method of any one of claims 1-168, wherein the engineered T cells are administered before, during, or after initiation of a different treatment regimen for the patient.
170. The method of claim 169, wherein the different treatment regimen is selected from the group consisting of re-administration of the same or different cells, and pre-treatment, concurrent treatment, or subsequent treatment with an additional agent.
171. The method of claim 170, wherein the different cells are autologous T or NK cells or CAR-T cells that express a first CAR that is different from a second CAR expressed by the engineered CAR-T cells.
172. The method of any one of claims 1-171, wherein the patient is treated with immunodepletion therapy prior to administration of the engineered T cells.
173. The method of claim 172, wherein the immunodepleting therapy comprises administration of fludarabine and / or cyclophosphamide.
174. The method of any one of claims 1-173, wherein the patient has received prior antibody therapy.
175. The method of claim 174, wherein the antibody therapy is rituximab.
176. The method of claim 173, wherein the immunodepletion therapy comprises IV infusion of about 1-50 mg / m 2 Fludarabine for about 1-7 days.
177. The method of claim 176, wherein the immunodepletion therapy comprises IV infusion of about 1, about 5, about 10, about 20, about 30, about 40, or about 50 mg / m 2 of fludarabine for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
178. The method of claim 176 or 177, wherein the immunodepletion therapy comprises IV infusion of about 30 mg / m 2 Fludarabine for about 4 days.
179. The method of claim 173, wherein the immunodepletion therapy comprises IV infusion of about 100-1000 mg / m 2 Cyclophosphamide for about 1-7 days.
180. The method of claim 179, wherein the immunodepletion therapy comprises IV infusion of about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000 mg / m 2 of cyclophosphamide for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
181. The method of claim 179 or 180, wherein the immunodepletion therapy comprises IV infusion of about 500 mg / m 2 of cyclophosphamide for about 2 days.
182. The method of any one of claims 1-181, wherein at least about 40 x 10 4 Engineered T cells.
183. The method of any one of claims 1-182, wherein at least about 40 x 10 5 Engineered T cells.
184. The method of any one of claims 1-183, wherein the engineered T cells persist in the subject for at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or longer.
185. The method of any one of claims 1-184, wherein the therapeutic effect of the engineered T cells persists for a duration of at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, or longer.
186. The method of any one of claims 1-185, wherein the wild-type cells or the control cells are the starting material.
187. Use of a population of engineered T cells for treating EBV infection in patients suspected of having or diagnosed with EBV infection, wherein the engineered T cells comprise reduced expression of one or more major histocompatibility complex (MHC) class I and / or class II human leukocyte antigen (HLA) molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more chimeric antigen receptors (CARs), wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or an EBV antigen.
188. Use of an engineered T cell population for treating EBV infection in patients suspected of having EBV infection or diagnosed with EBV infection, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19 or CD22.
189. Use of a population of engineered T cells for treating EBV infection in patients suspected of having or diagnosed with EBV infection, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or an EBV antigen.
190. Use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
191. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
192. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
193. Use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
194. Use of a population of engineered T cells for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
195. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TCR-α (TRAC) and / or TCR-β (TRB) relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
196. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
197. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
198. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
199. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA or EBV antigens.
200. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, reduced expression of TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
201. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
202. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
203. The use according to any one of claims 187-202, wherein the one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain or an IgG4 hinge domain.
204. The use according to claim 203, wherein the one or more CARs comprise a CD8α hinge domain having an amino acid sequence of SEQ ID NO:
9.
205. The use according to claim 303, wherein the one or more CARs comprise a CD28 hinge domain having an amino acid sequence of SEQ ID NO: 10 or 113.
206. The use according to claim 203, wherein the one or more CARs comprise an IgG4 hinge domain having an amino acid sequence of SEQ ID NO: 11 or 12.
207. The use according to any one of claims 187-206, wherein the one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
208. The use according to claim 207, wherein the one or more CARs comprise a CD8α transmembrane domain having an amino acid sequence of SEQ ID NO:
14.
209. The use according to claim 207, wherein the one or more CARs comprise a CD28 transmembrane domain having an amino acid sequence of SEQ ID NO: 15 or 114.
210. The use of any one of claims 187-206, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain, a CD28 co-stimulatory domain, or a CD3ζ signaling domain.
211. The use of claim 210, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain having an amino acid sequence of SEQ ID NO:
16.
212. The use according to claim 210, wherein the one or more CARs comprise a CD28 co-stimulatory domain having an amino acid sequence of SEQ ID NO:
17.
213. The use according to claim 210, wherein the one or more CARs comprise a CD3ζ signaling domain having an amino acid sequence of SEQ ID NO: 18 or 115.
214. The use according to any one of claims 187-213, wherein the one or more CARs comprise an extracellular ligand binding domain, the extracellular ligand binding domain comprises an scFv sequence of any one of SEQ ID NO: 19, 29, 37, 45, 54, 85, 63, 72 or 118, or wherein the CAR has an scFv sequence comprising heavy chain and light chain sequences of any one of SEQ ID NO: 129-132 or 135-172.
215. The use according to any one of claims 187-214, wherein the one or more CARs have a sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133 or 134.
216. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD20 CAR having a CDR sequence of SEQ ID NO:
37.
217. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include an EBV antigen CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172.
218. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO:
117.
219. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD22 CAR having a CDR sequence of SEQ ID NO:
45.
220. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC and / or TRB relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO:
45.
221. Use of an engineered T cell population for treating multiple sclerosis in a patient suspected of having or diagnosed with multiple sclerosis, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133 or 134, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72 or 118, or wherein the CAR has a scFv sequence comprising a heavy chain and light chain sequence of any one of SEQ ID NOs: 129-132 or 135-172.
222. The use according to any one of claims 187-221, further comprising assessing the patient for EBV infection and optionally multiple sclerosis and / or diagnosing the patient with EBV infection and optionally multiple sclerosis before administering the engineered T cell population to the patient.
223. The use according to claim 222, wherein the diagnosis comprises assessing the patient for EBV infection.
224. The use according to claim 222 or 223, wherein the diagnosis comprises assessing the patient for multiple sclerosis.
225. The use according to any one of claims 187-224, wherein the treatment prevents multiple sclerosis.
226. The use according to any one of claims 187-224, wherein the treatment treats multiple sclerosis.
227. The use according to any one of claims 187-226, wherein the patient suffering from the EBV infection has been diagnosed with multiple sclerosis.
228. The use according to any one of claims 187-227, wherein the multiple sclerosis is relapsing-remitting multiple sclerosis, progressive-relapsing multiple sclerosis, primary progressive multiple sclerosis or secondary progressive multiple sclerosis.
229. The use according to any one of claims 187-228, wherein the patient experiences remission of multiple sclerosis after administration of the engineered T cells.
230. The use according to any one of claims 187-229, wherein the patient suffering from the EBV infection is receiving treatment for the EBV infection.
231. The use according to any one of claims 187-230, wherein the patient suffering from the EBV infection has an active EBV infection.
232. The use according to any one of claims 187-231, wherein the patient suffering from the EBV infection has an inactive EBV infection.
233. The use according to any one of claims 187-232, wherein the patient experiences a reduction in EBV infection following administration of the engineered T cells, optionally wherein the reduction in EBV infection is characterized by a reduction in viral load.
234. The use according to any one of claims 187-232, wherein the treatment prevents the transition of EBV infection from inactive to active EBV infection.
235. The use according to any one of claims 187-234, wherein the use results in B cell depletion.
236. The use according to any one of claims 187-235, wherein the engineered T cells comprise one or more of CD19-specific CAR, CD20-specific CAR, CD22-specific CAR, BCMA-specific CAR, GPRC5D-specific CAR, CD38-specific CAR, CD70-specific CAR, CD79b-specific CAR and EBV antigen-specific CAR.
237. Use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
238. Use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
239. The use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
240. Use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
241. The use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
242. The use of a population of engineered T cells for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19, CD20, CD22, BCMA, or EBV antigens, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
243. The use according to any one of claims 237-242, wherein the one or more CARs comprise a CD8α hinge domain, a CD28 hinge domain, or an IgG4 hinge domain.
244. The use according to claim 243, wherein the one or more CARs comprise a CD8α hinge domain having an amino acid sequence of SEQ ID NO:
9.
245. The use according to claim 243, wherein the one or more CARs comprise a CD28 hinge domain having an amino acid sequence of SEQ ID NO: 10 or 113.
246. The use according to claim 243, wherein the one or more CARs comprise an IgG4 hinge domain having an amino acid sequence of SEQ ID NO: 11 or 12.
247. The use according to any one of claims 237-246, wherein the one or more CARs comprise a CD8α transmembrane domain or a CD28 transmembrane domain.
248. The use according to claim 247, wherein the one or more CARs comprise a CD8α transmembrane domain having an amino acid sequence of SEQ ID NO:
14.
249. The use according to claim 247, wherein the one or more CARs comprise a CD28 transmembrane domain having an amino acid sequence of SEQ ID NO: 15 or 114.
250. The use of any one of claims 237-249, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain, a CD28 co-stimulatory domain, or a CD3ζ signaling domain.
251. The use of claim 250, wherein the one or more CARs comprise a 4-1BB co-stimulatory domain having an amino acid sequence of SEQ ID NO:
16.
252. The use of claim 250, wherein the one or more CARs comprise a CD28 co-stimulatory domain having an amino acid sequence of SEQ ID NO:
17.
253. The use according to claim 250, wherein the one or more CARs comprise a CD3ζ signaling domain having an amino acid sequence of SEQ ID NO: 18 or 115.
254. The use according to any one of claims 237-253, wherein the one or more CARs comprise an extracellular ligand binding domain, the extracellular ligand binding domain comprises an scFv sequence of any one of SEQ ID NO: 19, 29, 37, 45, 54, 85, 63, 72 or 118, or wherein the CAR has an scFv sequence comprising heavy chain and light chain sequences of any one of SEQ ID NO: 129-132 or 135-172.
255. The use according to any one of claims 237-254, wherein the one or more CARs have a sequence of any one of SEQ ID NO: 32, 34, 36, 117, 91, 92, 92, 128, 133 or 134.
256. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
257. The use according to claim 256, further comprising assessing the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease.
258. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include a CD19 CAR having a CDR sequence of SEQ ID NO: 117 and a CD22 CAR having a CDR sequence of SEQ ID NO: 45, and wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
259. The use according to any one of claims 256-258, wherein the encoded CD19 CAR has the corresponding amino acid sequence listed in SEQ ID NO: 117 or has at least 80% identity (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity) to the amino acid sequence listed in SEQ ID NO: 117, and has the following components: CD8α signal peptide, FMC63 scFv (VL-Whitlow linker-VH), CD8α hinge domain, CD8α transmembrane domain, 4-1BB co-stimulatory domain and CD3ζ signaling domain.
260. The use according to any one of claims 256-259, wherein the encoded CD22 CAR has the corresponding amino acid sequence listed in SEQ ID NO: 45 or has at least 80% identity (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity) to the amino acid sequence listed in SEQ ID NO:
45.
261. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M, CIITA and TRAC relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs include an EBV antigen-specific CAR having a CDR sequence of SEQ ID NO: 133 or 134 and / or a CDR sequence of a VH / VL sequence from SEQ ID NO: 129-132 or 135-172, and wherein the autoimmune disease is multiple sclerosis.
262. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise an exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
263. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
264. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
265. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding a tolerogenic factor, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
266. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
267. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of B2M and CIITA relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
268. Use of an engineered T cell population for treating an autoimmune disease in a patient suspected of having or diagnosed with an autoimmune disease, wherein the engineered T cells comprise reduced expression of one or more MHC class I and / or class II HLA molecules relative to unaltered or unmodified wild-type or control cells, a first exogenous polynucleotide encoding CD47, and a second exogenous polynucleotide encoding one or more CARs, wherein the one or more CARs have a sequence of any one of SEQ ID NOs: 32, 34, 36 and 117, or wherein the one or more CARs have a scFv sequence of any one of SEQ ID NOs: 19, 29 or 37.
269. The use according to any one of claims 237-268, further comprising evaluating the patient for the autoimmune disease and / or diagnosing the patient with the autoimmune disease before administering the engineered T cell population to the patient.
270. The use according to any one of claims 237-269, wherein the autoimmune disease is selected from the group consisting of lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome and a pulmonary condition.
271. The use according to any one of claims 237-270, wherein the patient is suspected of having an EBV infection or has been diagnosed as having an EBV infection.
272. The use according to any one of claims 237-271, wherein the patient is suspected of having or has been diagnosed with multiple sclerosis.
273. The use of any one of claims 237-246, further comprising administering a second, third, fourth, fifth or sixth dose of the engineered T cells to the patient.
274. The use of claim 273, wherein the CAR is the same in one or more of the first, second, third, fourth, fifth and / or sixth doses of engineered T cells.
275. The use of claim 273, wherein the CAR is different in one or more of the first, second, third, fourth, fifth and / or sixth doses of engineered T cells.
276. The use of any one of claims 187-275, wherein the CAR has a scFv sequence of any one of SEQ ID NOs: 19, 29, 37, 45, 54, 85, 63, 72 or 118, or wherein the CAR has a scFv sequence comprising a heavy chain and light chain sequence of any one of SEQ ID NOs: 129-132 or 135-172.
277. The use according to any one of claims 187-276, wherein the CAR has a sequence of any one of SEQ ID NOs: 32, 34, 36, 117, 91, 92, 92, 128, 133 and 134.
278. The use according to any one of claims 187-277, wherein the engineered T cells comprise a CD19-specific CAR and a CD20-specific CAR.
279. The use according to claim 278, wherein the CD19-specific CAR has a CDR sequence of SEQ ID NO: 117, and the CD22 CAR has a CDR sequence of SEQ ID NO:
45.
280. The use according to claim 278, wherein the CD19-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
281. The use according to claim 278, wherein the CD19-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
282. The use according to claim 278, wherein the CD19-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
283. The use according to any one of claims 278-282, wherein the CD19 CAR T cells and CD20 CAR T cells are administered simultaneously.
284. The use according to any one of claims 278-282, wherein the CD19 CAR+T cells and CD20CAR+T cells are administered sequentially.
285. The use according to claim 284, wherein the CD19CAR+T cells are administered before the CD20CAR+T cells.
286. The use according to claim 284, wherein the CD20CAR+T cells are administered before the CD19CAR+T cells.
287. The use according to any one of claims 278-286, wherein the number of cells administered in a therapeutically effective amount of the CD19 and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
288. The use of any one of claims 278-286, wherein the number of cells administered in a therapeutically effective amount of the CD19 and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of CD19 CAR T cells or CD20 CAR T cells alone.
289. The use according to any one of claims 187-288, wherein the engineered T cells comprise an EBV antigen-specific CAR and a CD20-specific CAR.
290. The use according to claim 289, wherein the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bicistronic polynucleotide.
291. The use according to claim 289, wherein the EBV antigen-specific CAR and the CD20-specific CAR are encoded by a single bispecific CAR.
292. The use according to claim 289, wherein the EBV antigen-specific CAR and the CD20-specific CAR are encoded by two separate polynucleotides.
293. The use according to any one of claims 289-292, wherein the EBV antigen CAR T cells and CD20 CAR T cells are administered simultaneously.
294. The use according to any one of claims 289-292, wherein the EBV antigen CAR+T cells and CD20CAR+T cells are administered sequentially.
295. The use according to claim 294, wherein the EBV antigen CAR+T cells are administered before the CD20CAR+T cells.
296. The use according to claim 294, wherein the CD20 CAR+T cells are administered before the EBV antigen CAR+T cells are administered.
297. The use according to any one of claims 289-296, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD20 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
298. The use according to any one of claims 289-296, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD20 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD20 CAR T cells alone.
299. The use according to any one of claims 187-298, wherein the engineered T cells comprise EBV antigen-specific CAR and CD19-specific CAR.
300. The use according to claim 299, wherein the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bicistronic polynucleotide.
301. The use according to claim 299, wherein the EBV antigen-specific CAR and the CD19-specific CAR are encoded by a single bispecific CAR.
302. The use according to claim 299, wherein the EBV antigen-specific CAR and the CD19-specific CAR are encoded by two separate polynucleotides.
303. The use according to any one of claims 299-302, wherein the EBV antigen CAR T cells and CD19 CAR T cells are administered simultaneously.
304. The use according to any one of claims 299-302, wherein the EBV antigen CAR+T cells and CD19CAR+T cells are administered sequentially.
305. The use according to claim 304, wherein the EBV antigen CAR+T cells are administered before the CD19CAR+T cells.
306. The use according to claim 304, wherein the CD19 CAR+T cells are administered before the EBV antigen CAR+T cells are administered.
307. The use according to any one of claims 299-306, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD19 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
308. The use according to any one of claims 299-306, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD19 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD19 CAR T cells alone.
309. The use according to any one of claims 187-308, wherein the engineered T cells comprise an EBV antigen-specific CAR and a CD22-specific CAR.
310. The use according to claim 309, wherein the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bicistronic polynucleotide.
311. The use according to claim 309, wherein the EBV antigen-specific CAR and the CD22-specific CAR are encoded by a single bispecific CAR.
312. The use according to claim 309, wherein the EBV antigen-specific CAR and the CD22-specific CAR are encoded by two separate polynucleotides.
313. The use according to any one of claims 309-312, wherein the EBV antigen CAR T cells and CD22 CAR T cells are administered simultaneously.
314. The use according to any one of claims 309-312, wherein the EBV antigen CAR+T cells and CD22CAR+T cells are administered sequentially.
315. The use according to claim 314, wherein the EBV antigen CAR+T cells are administered before the CD22CAR+T cells.
316. The use according to claim 314, wherein the CD22 CAR+T cells are administered before the EBV antigen CAR+T cells are administered.
317. The use according to any one of claims 309-316, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD22 CAR T cells is greater than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
318. The use according to any one of claims 309-316, wherein the number of cells administered in a therapeutically effective amount of the EBV antigen and / or CD22 CAR T cells is less than the number of cells administered in a therapeutically effective amount of EBV antigen CAR T cells or CD22 CAR T cells alone.
319. The use according to any one of claims 187-318, wherein the engineered T cells are primary T cells, propagated from primary T cells or their progeny, or derived from T cells differentiated from iPSCs or their progeny.
320. The use according to any one of claims 187-318, wherein the engineered T cells are differentiated cells derived from induced pluripotent stem cells or their progeny.
321. The use according to claim 320, wherein the differentiated cells are T cells or natural killer (NK) cells.
322. The use according to any one of claims 187-321, wherein the engineered T cell is a primary T cell, which is a descendant of a primary immune cell, optionally wherein the descendant of a primary immune cell is a T cell or a NK cell.
323. The use of any one of claims 187-322, wherein the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules relative to unaltered or unmodified wild-type or control cells.
324. The use of any one of claims 187-323, wherein the engineered T cells comprise reduced expression of one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
325. The use according to any one of claims 187-324, wherein the engineered T cells comprise reduced expression of one or more MHC HLA class I molecules and one or more MHC HLA class II molecules relative to unaltered or unmodified wild-type or control cells.
326. The use of any one of claims 187-325, wherein the engineered T cells comprise reduced expression of B2M and / or CIITA relative to unaltered or unmodified wild-type or control cells.
327. The use according to claim 326, wherein the engineered T cells do not express B2M and / or CIITA.
328. The use of any one of claims 187-327, wherein the engineered T cells comprise reduced expression of TRAC and / or TRB.
329. The use according to claim 328, wherein the engineered T cells do not express TRAC and / or TRB.
330. The use of any one of claims 187-329, wherein the engineered T cells comprise reduced expression of TRAC.
331. The use of claim 330, wherein the engineered T cells do not express TRAC.
332. The use of any one of claims 187-331, wherein the engineered T cells comprise reduced expression of TRB.
333. The use of claim 332, wherein the engineered T cells do not express TRB.
334. The use of any one of claims 187-333, wherein the engineered T cells comprise reduced expression of TRAC and TRB.
335. The use according to any one of claims 187-334, wherein the one or more tolerogenic factors are selected from the group consisting of: CD47, CD24, CD27, CD35, CD46, CD55, CD59, CD200, HLA-C, HLA-E, HLA-E heavy chain, HLA-G, PD-L1, IDO1, CTLA4-Ig, C1 inhibitor, IL-10, IL-35, FasL, CCL21, CCL22, Mfge8, A20 / TNFAIP3, CD39, CR1, HLA-F, IL15-RF, MANF and Serpinb9, optionally wherein the one or more tolerogenic factors include CD47.
336. The use according to any one of claims 187-335, wherein the CD19-specific CAR and the one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
337. The use according to any one of claims 187-335, wherein the CD19-specific CAR and the CD47 are encoded by a single bicistronic polynucleotide.
338. The use according to any one of claims 187-335, wherein the CD20-specific CAR and the one or more tolerogenic factors are encoded by a single bicistronic polynucleotide.
339. The use according to any one of claims 187-335, wherein the CD20-specific CAR and the CD47 are encoded by a single bicistronic polynucleotide.
340. The use according to any one of claims 187-339, wherein one or more of the first, second and / or third exogenous polynucleotides or the bicistronic polynucleotides are inserted into a first, second and / or third specific locus of at least one allele of the cell.
341. The use according to claim 340, wherein the first, second and / or third specific loci are selected from the group consisting of: a safe harbor locus, a target locus, a RHD locus, a B2M locus, a CIITA locus, a TRAC locus and a TRB locus.
342. The use according to claim 341, wherein the safe harbor locus is selected from the group consisting of: CCR5 locus, PPP1R12C locus, CLYBL locus and Rosa locus.
343. The use according to claim 341, wherein the target locus is selected from the group consisting of: CXCR4 locus, ALB locus, SHS231 locus, F3 (CD142) locus, MICA locus, MICB locus, LRP1 (CD91) locus, HMGB1 locus, ABO locus, FUT1 locus and KDM5D locus.
344. The use according to any one of claims 187-343, wherein the first, second and / or third exogenous polynucleotide or the bicistronic polynucleotide is introduced into the engineered T cell using a gene therapy vector or a transposase system selected from the group consisting of a transposase, a PiggyBac transposon, a Sleeping Beauty (SB11) transposon, a Mos1 transposon and a Tol2 transposon.
345. The use according to claim 344, wherein the gene therapy vector is a retrovirus or a fusion.
346. The use of any one of claims 187-345, wherein the first, second and / or third exogenous polynucleotide or the bicistronic polynucleotide is introduced into the engineered T cell using CRISPR / Cas gene editing.
347. The use according to claim 346, wherein the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of Cas9, Cas12a and Cas12b.
348. The use or dosage regimen of claim 347, wherein the CRISPR / Cas system comprises a Cas effector protein selected from the group consisting of: a. optionally selected from the group consisting of Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3 and GSU0054; b. optionally selected from the group consisting of Cas9, Csn2 and Cas4; c. optionally selected from the group consisting of Cas10, Csm2, Cmr5, Cas10, Csx11 and Csx10; d. Optionally Csf1; e. optionally selected from the group consisting of Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e) and CasY (Cas12d); and f. Optionally selected from the group consisting of Cas13, Cas13a, C2c2, Cas13b, Cas13c and Cas13d.
349. The use of any one of claims 346-348, wherein the CRISPR / Cas gene editing is performed ex vivo from a donor subject.
350. The use according to any one of claims 346-349, wherein the first, second and / or third exogenous polynucleotide or the bicistronic polynucleotide is introduced into the engineered T cell using a lentiviral vector.
351. The use of any one of claims 187-350, wherein the engineered T cells evade NK cell-mediated cytotoxicity upon administration to the patient.
352. The use according to any one of claims 187-351, wherein the engineered T cells are protected from cell lysis by mature NK cells after administration to the patient.
353. The use of any one of claims 187-352, wherein the engineered T cells evade macrophage-mediated cytotoxicity, optionally wherein the macrophage-mediated cytotoxicity involves phagocytosis and / or reactive oxygen species.
354. The use according to any one of claims 187-353, wherein the engineered T cells do not induce an immune response against the cells upon administration to the patient.
355. The use according to any one of claims 187-354, wherein the administration is selected from the group consisting of intravenous injection, intramuscular injection, intravascular injection and transplantation.
356. The use of any one of claims 187-355, wherein the engineered T cells are administered before, during or after initiation of a different treatment regimen for the patient.
357. The use of claim 356, wherein the different treatment regimen is selected from the group consisting of re-administration of the same or different cells, and pre-treatment, concurrent treatment, or subsequent treatment with an additional agent.
358. The use according to claim 357, wherein the different cells are autologous T or NK cells or CAR-T cells, which express a first CAR different from the second CAR expressed by the engineered CAR-T cells.
359. The use of any one of claims 187-358, wherein the patient is treated with immunodepletion therapy prior to administration of the engineered T cells.
360. The use according to claim 359, wherein the immunodepletion therapy comprises administration of fludarabine and / or cyclophosphamide.
361. The use according to any one of claims 187-360, wherein the patient has received prior antibody therapy.
362. The use according to claim 361, wherein the antibody therapy is rituximab.
363. The use according to claim 360, wherein the immunodepletion therapy comprises IV infusion of about 1-50 mg / m 2 Fludarabine for about 1-7 days.
364. The use according to claim 363, wherein the immunodepletion therapy comprises IV infusion of about 1, about 5, about 10, about 20, about 30, about 40 or about 50 mg / m 2 of fludarabine for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
365. The use according to claim 363 or 364, wherein the immunodepletion therapy comprises IV infusion of about 30 mg / m 2 Fludarabine for about 4 days.
366. The use according to claim 360, wherein the immunodepletion therapy comprises IV infusion of about 100-1000 mg / m 2 Cyclophosphamide for about 1-7 days.
367. The use according to claim 366, wherein the immunodepletion therapy comprises IV infusion of about 100, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1000 mg / m 2 of cyclophosphamide for about 1, about 2, about 3, about 4, about 5, about 6, or about 7 days.
368. The use according to claim 366 or 367, wherein the immunodepletion therapy comprises IV infusion of about 500 mg / m 2 of cyclophosphamide for about 2 days.
369. The use according to any one of claims 187-368, wherein at least about 40 x 10 4 Engineered T cells.
370. The use of any one of claims 187-369, wherein at least about 40 x 10 5 Engineered T cells.
371. The use of any one of claims 187-370, wherein the engineered T cells persist in the subject for at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or longer.
372. The use according to any one of claims 187-371, wherein the therapeutic effect of the engineered T cells lasts for a duration of at least 4 weeks, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or longer.
373. The use according to any one of claims 187-372, wherein the wild-type cells or the control cells are the starting material.
374. The method of any one of claims 1-186 or the use of any one of claims 187-373, wherein the population of engineered T cells comprises engineered T cells comprising one or more modifications, wherein the modifications (i) reduce the expression of one or more MHC class I molecules and / or one or more MHC class II molecules, and / or (ii) increase the expression of one or more tolerogenic factors, wherein the reduced expression of (i) and the increased expression of (ii) are relative to comparable T cells that do not comprise the modifications.
375. An engineered T cell comprising one or more modifications that (i) reduce the expression of one or more MHC class I molecules and / or one or more MHC class II molecules, and / or (ii) increase the expression of one or more tolerogenic factors, wherein the reduced expression of (i) and the increased expression of (ii) are relative to a comparable T cell that does not comprise the modifications.
376. A method comprising administering to a patient an engineered cell population, wherein the engineered cell population comprises engineered cells comprising one or more modifications that (i) disrupt one or more MHC class I molecules and / or one or more MHC class II molecules, and / or (ii) increase expression of one or more tolerogenic factors, wherein the increased expression of (ii) is relative to comparable cells that do not comprise the modifications.
377. The method of claim 376, wherein the method is a method of treating a patient suspected of having an autoimmune disease or who has been diagnosed with an autoimmune disease.
378. The method of claim 377, wherein the autoimmune disease is selected from the group consisting of Epstein-Barr virus (EBV), multiple sclerosis, lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-person syndrome, or a pulmonary condition.
379. The method of any one of claims 376-378, wherein the engineered cell is a T cell or a NK cell, optionally wherein the T cell is a cytotoxic T cell, a helper T cell, a memory T cell, a central memory T cell, an effector memory T cell, an effector memory RA T cell, a regulatory T cell, or a tissue infiltrating lymphocyte.
380. The method of any one of claims 376-379, wherein the engineered cell is a primary cell or a differentiated cell.
381. The method of any one of claims 376-380, wherein disrupting the one or more modifications of the one or more MHC class I molecules and / or one or more MHC class II molecules reduces expression of the one or more MHC class I molecules and / or one or more MHC class II molecules.
382. The method of any one of claims 376-381, wherein the one or more tolerogenic factors are selected from the group consisting of A20 / TNFAIP3, C1 inhibitor, CCL21, CCL22, CD16, CD16 Fc receptor, CD24, CD27, CD35, CD39, CD46, CD47, CD52, CD55, CD59, CD200, CR1, CTLA4-Ig, DUX4, FasL, H2-M3, HLA-C, HLA-E, HLA-E heavy chain, HLA-F, HLA-G, IDO1, IL-10, IL15-RF, IL-35, MANF, Mfge8, PD-L1, Serpinb9, and any combination thereof.
383. The method of any one of claims 376-382, wherein the engineered cells further comprise exogenous polynucleotides encoding one or more chimeric antigen receptors (CARs), chimeric autoantibody receptors (CAARs), or chimeric B-cell autoantibody receptors (BARs).
384. The method of claim 383, wherein the one or more CARs comprise an extracellular ligand binding domain specific for CD19, CD22, CD20, BCMA, EBV antigens, CD27, CD30, CD19 and CD20, CD19 and CD22, CD19 and CD27, EBNA1, EBNA3A, BRLF1, BALF4, EBNA3C, LMP1, LMP2, LMP2A, LMP2B, BZLF1, BMLF1, gp350, gH / gL, EBNA1 and LMP1, EBNA1 and LMP2A, EBNA1 and LMP1 and LMP2A, LMP and BARF1 and EBNA1, CD19 and EBV antigens, CD20 and EBV antigens, or CD22 and EBV antigens.
385. The method of claim 383 or 384, wherein the one or more CAARs include an antigen selected from the group consisting of: pancreatic beta cell antigen, synovial joint antigen, myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein, MuSK, keratinocyte adhesion protein desmoglein 3 (Dsg3), Ro-RNP complex, La antigen, myeloperoxidase, proteinase 3, cardiolipin, citrullinated proteins, carbamylated proteins, and the α3 chain of basement membrane collagen.
386. The method of any one of claims 383-385, wherein the one or more BARs comprise a FVIII antigen.
387. The method of claim 383 or 384, wherein the autoimmune disease is EBV and wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
388. The method of claim 383 or 384, wherein the autoimmune disease is EBV and wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for CD19 or CD22.
389. The method of claim 383 or 384, wherein the autoimmune disease is multiple sclerosis and wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
390. The method of claim 383 or 384, wherein the autoimmune disease is multiple sclerosis and wherein the one or more CARs comprise an extracellular ligand binding domain, a hinge domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain specific for a CD19, CD20, CD22, BCMA, or EBV antigen.
391. The method of any one of claims 376-390, further comprising assessing the patient for EBV, multiple sclerosis, lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition, or diagnosing the patient with EBV, multiple sclerosis, lupus, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis, vasculitis, Crohn's disease, myasthenia gravis, stiff-man syndrome, or a pulmonary condition.
392. The method of any one of claims 376-391, wherein the engineered cells further comprise one or more modifications that disrupt TCR-α (TRAC) and / or TCR-β (TRB).
393. The method of claim 392, wherein the one or more modifications that disrupt TCR-α (TRAC) and / or TCR-β (TRB) reduce the expression of TCR-α (TRAC) and / or TCR-β (TRB).
394. The method of any one of claims 376-393, further comprising administering a second therapeutic agent to the patient.
395. The method of claim 394, wherein the second therapeutic agent is an anti-BLyS therapy.
396. An engineered cell comprising one or more modifications that (i) disrupt one or more MHC class I molecules and / or one or more MHC class II molecules, and / or (ii) increase expression of one or more tolerogenic factors, wherein the increased expression of (ii) is relative to a comparable cell not comprising the modification.
397. The engineered cell of claim 396, wherein the engineered cell is a T cell or a NK cell, optionally wherein the T cell is a cytotoxic T cell, a helper T cell, a memory T cell, a central memory T cell, an effector memory T cell, an effector memory RA T cell, a regulatory T cell, or a tissue infiltrating lymphocyte.
398. The engineered cell of claim 396 or claim 397, wherein the engineered cell is a primary cell or a differentiated cell.
399. The engineered cell of any one of claims 396-398, wherein the one or more modifications that destroy the one or more MHC class I molecules and / or one or more MHC class II molecules reduce the expression of the one or more MHC class I molecules and / or one or more MHC class II molecules.
400. The engineered cell of any one of claims 396-399, wherein the one or more tolerogenic factors are selected from the group consisting of A20 / TNFAIP3, C1 inhibitor, CCL21, CCL22, CD16, CD16 Fc receptor, CD24, CD27, CD35, CD39, CD46, CD47, CD52, CD55, CD59, CD200, CR1, CTLA4-Ig, DUX4, FasL, H2-M3, HLA-C, HLA-E, HLA-E heavy chain, HLA-F, HLA-G, IDO1, IL-10, IL15-RF, IL-35, MANF, Mfge8, PD-L1, Serpinb9, and any combination thereof.
401. An engineered cell according to any one of claims 396-400, wherein the engineered cell further comprises an exogenous polynucleotide encoding one or more chimeric antigen receptors (CARs), chimeric autoantibody receptors (CAARs), or chimeric B-cell autoantibody receptors (BARs).
402. The engineered cell of claim 401, wherein the one or more CARs comprise an extracellular ligand binding domain specific for CD19, CD22, CD20, BCMA, EBV antigens, CD27, CD30, CD19 and CD20, CD19 and CD22, CD19 and CD27, EBNA1, EBNA3A, BRLF1, BALF4, EBNA3C, LMP1, LMP2, LMP2A, LMP2B, BZLF1, BMLF1, gp350, gH / gL, EBNA1 and LMP1, EBNA1 and LMP2A, EBNA1 and LMP1 and LMP2A, LMP and BARF1 and EBNA1, CD19 and EBV antigens, CD20 and EBV antigens, or CD22 and EBV antigens.
403. An engineered cell according to claim 401 or 402, wherein the one or more CAARs include an antigen selected from the group consisting of: pancreatic beta cell antigen, synovial joint antigen, myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein, MuSK, keratinocyte adhesion protein desmoglein 3 (Dsg3), Ro-RNP complex, La antigen, myeloperoxidase, proteinase 3, cardiolipin, citrullinated protein, carbamylated protein and α3 chain of basement membrane collagen.
404. The engineered cell of any one of claims 401-403, wherein the one or more BARs comprise a FVIII antigen.
405. The engineered cell of any one of claims 396-404, wherein the engineered cell further comprises one or more modifications that disrupt TCR-α (TRAC) and / or TCR-β (TRB).
406. The engineered cell of claim 405, wherein the one or more modifications that disrupt TCR-α (TRAC) and / or TCR-β (TRB) reduce expression of TCR-α (TRAC) and / or TCR-β (TRB).
